Pharma & Biotech Sector Financials, Performance and Ratios
-
Sector Score
38.4 /100
Rank 14 out of 27 Sectors -
Advance/Decline
181/491
-
No. of Companies672
-
Avg. Market Cap8,977
-
Price to Earning Ratio11.91
-
Price to Earning Growth Ratio1.04
-
Price to Book Ratio19.86
-
Return on Equity12.60
-
Return on Capital Employed-
-
Return on Assets7.07
-
Dividend yield 1 year %0.62 %
-
Net Profit Growth Annual YoY %-75.21 %
-
Net Profit Growth Qtr YoY %-653.15 %
-
Net Profit Growth Qtr QoQ %-299.45 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Pharma & Biotech Sector Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Pharma & Biotech Peer comparison
Compare all stocks in Pharma & Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
449,454.4
|
254.4
|
L
 4.2%
H
243.5
254.5
|
L
 1.8%
H
243.1
254.5
|
L
 14.4%
H
215.4
261.6
|
L
 21.7%
H
190.8
261.6
|
L
 33.5%
H
184.6
261.6
|
L
 87.0%
H
134.6
261.6
|
L
 116.5%
H
105.6
261.6
|
L
 301.8%
H
55.1
261.6
|
| Adc Therapeutics SA |
|
171.7
|
1.4
|
L
 5.5%
H
1.2
1.4
|
L
 3.9%
H
1.2
1.4
|
L
 35%
H
1
1.4
|
L
 -69.2%
H
0.8
4.5
|
L
 -55.6%
H
0.8
5.0
|
L
 -10.6%
H
0.4
6.0
|
L
 -94.1%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
5,760.7
|
18.0
|
L
 4.9%
H
17.2
18.1
|
L
 6.0%
H
16.6
18.1
|
L
 11.0%
H
15.7
18.1
|
L
 37.8%
H
11.8
18.1
|
L
 118.4%
H
7.7
18.1
|
L
 495.4%
H
3.0
18.1
|
L
 318.6%
H
1.2
18.1
|
L
 -41.9%
H
1.2
31.9
|
| Annovis Bio Inc |
|
74.0
|
1.7
|
L
 -3.3%
H
1.7
1.8
|
L
 -10.8%
H
1.7
2.0
|
L
 -2.8%
H
1.6
2.2
|
L
 -2.3%
H
1.6
2.5
|
L
 -36.5%
H
1.5
5.5
|
L
 -87.4%
H
1.1
22.5
|
L
 -98.3%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
1,841.2
|
4.9
|
L
 0.8%
H
4.9
5
|
L
 1.4%
H
4.7
5
|
L
 -0.6%
H
4.6
5.9
|
L
 -15.3%
H
4.6
6.3
|
L
 -23.5%
H
4.6
8.7
|
L
 -41.5%
H
4.0
11.5
|
L
 -82.1%
H
4.0
30.0
|
L
 -78.4%
H
4.0
34.8
|
| Bristol-Myers Squibb |
|
123,565.7
|
60.5
|
L
 3.1%
H
58.6
60.6
|
L
 4.4%
H
56.8
60.6
|
L
 8.2%
H
53.4
60.6
|
L
 2.6%
H
53.4
60.8
|
L
 28.3%
H
42.5
62.9
|
L
 -2.3%
H
39.4
65.4
|
L
 -10.1%
H
39.4
81.4
|
L
 -20.4%
H
39.4
81.4
|
| Bellring Brands Inc |
|
1,394.2
|
12.0
|
L
 -0.8%
H
12.0
12.5
|
L
 -1.3%
H
12.0
12.8
|
L
 35.8%
H
8.8
14.3
|
L
 -26.1%
H
7.8
18.4
|
L
 -79.1%
H
7.8
59.1
|
L
 -67.0%
H
7.8
80.7
|
L
 -62.2%
H
7.8
80.7
|
L
H
7.8
80.7
|
| Emergent Biosolutions Inc |
|
396.8
|
7.7
|
L
 -2.5%
H
7.6
7.9
|
L
 -6.0%
H
7.4
8.2
|
L
 -0.8%
H
7.4
8.6
|
L
 -10.8%
H
7.4
9.7
|
L
 10.0%
H
5.6
14.1
|
L
 6.7%
H
1.4
15.1
|
L
 -87.7%
H
1.4
68.0
|
L
 -73.9%
H
1.4
137.6
|
| Elanco Animal Health Inc |
|
12,960.7
|
26.0
|
L
 1.6%
H
25.2
26.3
|
L
 5.4%
H
24.1
26.3
|
L
 7.1%
H
23.1
26.3
|
L
 12.2%
H
19.4
26.3
|
L
 78.8%
H
13.4
27.7
|
L
 119.2%
H
8.0
27.7
|
L
 -24.3%
H
7.9
37.5
|
L
H
7.9
37.6
|
| GSK PLC (ADR) |
|
105,687.6
|
52.8
|
L
 2.6%
H
51.4
52.9
|
L
 0.6%
H
51.1
53.1
|
L
 1.1%
H
50.4
54.3
|
L
 -7.6%
H
48.6
58.4
|
L
 37.9%
H
35.5
61.7
|
L
 52.8%
H
31.7
61.7
|
L
 30.1%
H
28.5
61.7
|
L
 18.0%
H
28.5
61.7
|
| IQVIA |
|
35,130.8
|
210.5
|
L
 1.8%
H
208.0
211.9
|
L
 0.7%
H
202.8
212.4
|
L
 17.5%
H
162.2
212.4
|
L
 22.4%
H
154.5
212.4
|
L
 32.7%
H
154.5
247.0
|
L
 -4.8%
H
134.6
261.7
|
L
 -15.0%
H
134.6
285.6
|
L
 193.7%
H
70.1
285.6
|
| Johnson & Johnson |
|
601,732.0
|
250.0
|
L
 1.2%
H
246.3
253.5
|
L
 -3.5%
H
246.1
261.3
|
L
 6.3%
H
227.5
269.4
|
L
 6.6%
H
220.4
269.4
|
L
 51.7%
H
162.3
269.4
|
L
 56.4%
H
140.7
269.4
|
L
 48.7%
H
140.7
269.4
|
L
 103.2%
H
109.2
269.4
|
| Eli Lilly |
|
1,042,597.3
|
1,169.2
|
L
 1.1%
H
1141.2
1189.1
|
L
 -3.9%
H
1134.4
1213.0
|
L
 4.2%
H
1079.2
1249.5
|
L
 29.3%
H
850.5
1249.5
|
L
 48.0%
H
623.8
1249.5
|
L
 160.1%
H
443.3
1249.5
|
L
 403.0%
H
220.2
1249.5
|
L
 1357.5%
H
64.2
1249.5
|
| Merck & Company |
|
315,223.7
|
127.6
|
L
 3.3%
H
124
128.9
|
L
 2.1%
H
120.2
128.9
|
L
 10.8%
H
111.6
130.3
|
L
 10.5%
H
107.9
130.3
|
L
 54.8%
H
76.7
130.3
|
L
 18.9%
H
73.3
134.6
|
L
 63.6%
H
70.9
134.6
|
L
 124.3%
H
50.4
134.6
|
| Nuvation Bio Inc (Class A) |
|
1,963.9
|
5.6
|
L
 -4.4%
H
5.6
5.9
|
L
 -7.7%
H
5.6
6.1
|
L
 10.2%
H
5.1
6.6
|
L
 17.3%
H
4.1
6.6
|
L
 152.9%
H
2.2
9.8
|
L
 231.8%
H
1.0
9.8
|
L
 -33.0%
H
1.0
10.5
|
L
H
1.0
15.2
|
| Novo Nordisk (ADR) |
|
227,738.8
|
51.5
|
L
 1.8%
H
50.6
51.8
|
L
 5.3%
H
48.3
51.8
|
L
 18.2%
H
42.5
51.8
|
L
 25.8%
H
38.0
51.8
|
L
 -23.2%
H
35.1
71.8
|
L
 -35.7%
H
35.1
148.2
|
L
 16.1%
H
35.1
148.2
|
L
 86.7%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
291,422.9
|
152.7
|
L
 1.3%
H
150.2
153.2
|
L
 -1.2%
H
149.7
155
|
L
 1.2%
H
146.6
160.6
|
L
 2%
H
142.3
160.6
|
L
 29.0%
H
112.3
170.5
|
L
 54.5%
H
92.2
170.5
|
L
 66.6%
H
74.1
170.5
|
L
 111.7%
H
59.2
170.5
|
| Organon & Co. |
|
3,542.6
|
13.5
|
L
H
13.5
13.5
|
L
H
13.5
13.5
|
L
 0.5%
H
13.4
13.6
|
L
 44.6%
H
8.5
13.6
|
L
 40.1%
H
5.7
13.6
|
L
 -34.3%
H
5.7
24.1
|
L
 -53.3%
H
5.7
39.5
|
L
H
5.7
39.5
|
| Prestige Consumer Healthcare Inc |
|
2,397.0
|
50.6
|
L
 4.6%
H
48.7
50.8
|
L
 4.4%
H
47.0
50.8
|
L
 6.5%
H
45.2
50.8
|
L
 -11.3%
H
42.6
60.3
|
L
 -32.7%
H
42.6
77.5
|
L
 -14.2%
H
42.6
90.0
|
L
 -1.7%
H
42.6
90.0
|
L
 -8.8%
H
26.3
90.0
|
| Pfizer |
|
143,284.0
|
25.1
|
L
 1.3%
H
24.9
25.4
|
L
 3.7%
H
24.1
25.4
|
L
 -3.5%
H
23.6
26.3
|
L
 -7.6%
H
23.6
27.8
|
L
 2.2%
H
23.1
28.7
|
L
 -30.8%
H
20.9
37.8
|
L
 -37.7%
H
20.9
61.7
|
L
 -27.8%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,544.2
|
11.2
|
L
 10.0%
H
10.3
11.2
|
L
 7.2%
H
9.8
11.2
|
L
 4.6%
H
9.4
11.6
|
L
 -2.3%
H
9.4
12.6
|
L
 -58.8%
H
9.2
28.4
|
L
 -67.2%
H
9.2
40.3
|
L
 -75.6%
H
9.2
50.9
|
L
 -88.2%
H
9.2
99.1
|
| Arcus Biosciences Inc |
|
3,350.6
|
26.6
|
L
 -4.9%
H
26.5
27.8
|
L
 -11.1%
H
26.5
29.8
|
L
 13.1%
H
23.6
31.7
|
L
 12.9%
H
20.3
31.7
|
L
 187.7%
H
8.8
31.7
|
L
 21.6%
H
6.5
31.7
|
L
 -9.6%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
10,575.4
|
12.7
|
L
 -0.6%
H
12.7
12.9
|
L
 -8.6%
H
12.7
13.7
|
L
 -4.5%
H
12.7
15.7
|
L
 -2.8%
H
12.2
15.7
|
L
 -13.1%
H
12.2
15.7
|
L
 2.6%
H
12.2
74.9
|
L
 -12.4%
H
9.6
74.9
|
L
 18.4%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
53,427.3
|
16.7
|
L
 1.7%
H
16.5
16.8
|
L
 0.7%
H
16.2
16.8
|
L
 6.8%
H
15.3
17.1
|
L
 -5.9%
H
14.8
18.0
|
L
 13.7%
H
13.0
18.9
|
L
 8.8%
H
12.6
18.9
|
L
 -1.6%
H
12.3
18.9
|
L
 -19.1%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
37,517.8
|
32.2
|
L
 2.1%
H
31.5
32.4
|
L
 -2.7%
H
31.3
33.4
|
L
 -2.1%
H
30.8
35.5
|
L
 3.1%
H
30.0
37.0
|
L
 101.3%
H
15.0
37.3
|
L
 292.4%
H
8.0
37.3
|
L
 274.2%
H
6.8
37.3
|
L
 -40.6%
H
6.1
55.8
|
| Usana Health Sciences Inc |
|
418.2
|
22.7
|
L
 1.6%
H
22.2
23.1
|
L
 2.8%
H
21.1
23.1
|
L
 19.2%
H
18.3
23.1
|
L
 18.8%
H
16.9
23.1
|
L
 -27.7%
H
16.6
38.3
|
L
 -62.8%
H
16.6
69.6
|
L
 -77.3%
H
16.6
104.0
|
L
 -63.7%
H
16.6
138.0
|
| Zoetis (Class A) |
|
32,242.8
|
76.9
|
L
 3.2%
H
75.4
77.4
|
L
 2.4%
H
73.4
77.4
|
L
 -3.1%
H
71.5
80.0
|
L
 -35.4%
H
71.5
123.3
|
L
 -49.3%
H
71.5
160.5
|
L
 -55.3%
H
71.5
201.9
|
L
 -61.5%
H
71.5
249.3
|
L
 54.8%
H
46.9
249.3
|
| Biohaven Ltd |
|
2,133.4
|
14.2
|
L
 -4.6%
H
14.0
14.7
|
L
 -15.6%
H
14.0
16.4
|
L
 17.2%
H
13.0
17.3
|
L
 41.6%
H
8.2
17.3
|
L
 6.1%
H
7.5
18.6
|
L
 -41.1%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Haleon PLC (ADR) |
|
44,522.4
|
10.1
|
L
 3.7%
H
9.8
10.1
|
L
 4.1%
H
9.6
10.1
|
L
 11.2%
H
8.8
10.1
|
L
 5.4%
H
8.7
10.1
|
L
 4.3%
H
8.7
11.3
|
L
 20.4%
H
7.7
11.4
|
L
H
5.6
11.4
|
L
H
5.6
11.4
|
| Whitehawk Therapeutics Inc |
|
192.4
|
3.9
|
L
 1.0%
H
3.6
4.0
|
L
 0.8%
H
3.6
4.1
|
L
 -6.7%
H
3.6
4.9
|
L
 -8.0%
H
3.6
5.5
|
L
 99.5%
H
1.6
5.5
|
L
 -32.2%
H
1.2
7.2
|
L
 -87.4%
H
1.2
40.2
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,881.1
|
6.2
|
L
 -8.6%
H
6.1
6.7
|
L
 -15.5%
H
6.1
7.3
|
L
 21.0%
H
5.2
8.4
|
L
 60.8%
H
3.8
8.4
|
L
 51.7%
H
2.7
8.4
|
L
 -14.0%
H
1.9
8.4
|
L
 -63.6%
H
1.9
22.6
|
L
H
1.9
71.9
|
| Abeona Therapeutics Inc |
|
400.1
|
7.0
|
L
 -3.7%
H
6.8
7.4
|
L
 -1.4%
H
6.7
7.4
|
L
 24.3%
H
5.5
7.4
|
L
 30.5%
H
5.1
7.4
|
L
 12.1%
H
4
7.5
|
L
 80.9%
H
2.9
9.0
|
L
 -78.1%
H
2.2
38.5
|
L
 -88.4%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
5,008.3
|
83.0
|
L
 -4.2%
H
82.6
86.9
|
L
 -5.9%
H
82.5
88.3
|
L
 22.6%
H
67.9
97.8
|
L
 23.8%
H
53.6
97.8
|
L
 461.1%
H
12.8
97.8
|
L
 242.6%
H
2.2
97.8
|
L
 138.6%
H
2.2
97.8
|
L
 -87.1%
H
2.2
699.8
|
| Acumen Pharma Inc |
|
156.7
|
2.2
|
L
 -2.3%
H
2.1
2.2
|
L
 -19.6%
H
2.1
2.8
|
L
 -5.2%
H
2.1
2.8
|
L
 -19.3%
H
2.1
3.0
|
L
 57.3%
H
1.2
3.6
|
L
 -65.4%
H
0.9
11.3
|
L
 -87.8%
H
0.9
20.3
|
L
H
0.9
27.0
|
| Absci Corp |
|
1,394.2
|
8.2
|
L
 -15.7%
H
8.1
9.6
|
L
 -28.3%
H
8.1
11.4
|
L
 17.6%
H
6.9
12.1
|
L
 154.8%
H
3.3
12.1
|
L
 200.4%
H
2.2
12.1
|
L
 311.5%
H
1.1
12.1
|
L
H
1.1
31.5
|
L
H
1.1
31.5
|
| Arbutus Biopharma Corp |
|
936.3
|
4.7
|
L
 4.0%
H
4.6
4.8
|
L
 -7.8%
H
4.5
5.2
|
L
 8.0%
H
4.3
5.4
|
L
 1.3%
H
4.0
5.4
|
L
 51.4%
H
3.1
5.4
|
L
 112.6%
H
1.7
5.4
|
L
 78.2%
H
1.7
6.5
|
L
 12.6%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
31.5
|
1.2
|
L
 -5.5%
H
1.2
1.4
|
L
 -16.6%
H
1.2
1.6
|
L
 -6.2%
H
1.2
2.2
|
L
 -1.6%
H
1
2.2
|
L
 -65.6%
H
0.9
3.6
|
L
 -71.2%
H
0.4
6.9
|
L
 -97.6%
H
0.4
116.9
|
L
 -99.7%
H
0.4
378
|
| Acadia Pharma Inc |
|
4,388.8
|
25.6
|
L
 -1.1%
H
25.5
26.2
|
L
 -3.0%
H
25.0
26.5
|
L
 22.4%
H
20.9
27.3
|
L
 20.6%
H
20.3
27.3
|
L
 13.7%
H
19.7
28.4
|
L
 -20.4%
H
13.4
33.9
|
L
 9.1%
H
12.2
33.9
|
L
 -22.3%
H
12.2
58.7
|
| Adicet Bio Inc |
|
76.8
|
8.2
|
L
 -5.3%
H
7.9
8.7
|
L
 -8.1%
H
7.9
9.2
|
L
 5.9%
H
7.8
9.4
|
L
 2.1%
H
7.0
9.5
|
L
 -34.1%
H
6.0
17.4
|
L
 -83.3%
H
6.0
60.3
|
L
 -93.4%
H
6.0
349.9
|
L
H
6.0
349.9
|
| Achieve Life Sciences Inc |
|
611.8
|
6.0
|
L
 -5.9%
H
5.8
6.4
|
L
 -6.9%
H
5.8
6.4
|
L
 7.4%
H
4.8
7.1
|
L
 23.9%
H
3.9
7.1
|
L
 121.6%
H
2.4
7.1
|
L
 12.0%
H
1.8
7.1
|
L
 -20.8%
H
1.8
10.3
|
L
 -99.7%
H
1.8
2178
|
| AC Immune SA |
|
221.9
|
2.2
|
L
 -7.6%
H
2.2
2.4
|
L
 -16.2%
H
2.2
2.6
|
L
 -8.0%
H
2.1
2.7
|
L
 -29.0%
H
2.1
3.2
|
L
 5.8%
H
2.0
4
|
L
 -28.3%
H
1.4
5.1
|
L
 -70.5%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
748.6
|
5.4
|
L
 -4.3%
H
5.3
5.6
|
L
 -6.1%
H
5.3
5.8
|
L
 23.5%
H
4.3
5.9
|
L
 34.7%
H
4.0
5.9
|
L
 239.2%
H
1.5
5.9
|
L
 -51.1%
H
0.6
11.1
|
L
 -63.0%
H
0.6
20.0
|
L
 -73.6%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
74.9
|
1.8
|
L
 -8.9%
H
1.7
1.9
|
L
 -14.6%
H
1.7
2.2
|
L
 17.5%
H
1.5
2.2
|
L
 4.8%
H
1.4
2.2
|
L
 34.6%
H
1.2
3.6
|
L
 -85.9%
H
1.1
13.5
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
22.9
|
1.4
|
L
 -6.3%
H
1.3
1.4
|
L
 -0.7%
H
1.3
1.5
|
L
 46.7%
H
0.9
1.5
|
L
 66.7%
H
0.7
1.5
|
L
 214.0%
H
0.4
1.6
|
L
 11.6%
H
0.4
1.6
|
L
 -94.6%
H
0.4
26.2
|
L
 -97.8%
H
0.4
115
|
| Grace Therapeutics Inc |
|
39.2
|
2.4
|
L
 -0.8%
H
2.3
2.5
|
L
 -1.2%
H
2.3
2.5
|
L
 8.6%
H
2.1
2.6
|
L
 -46.3%
H
1.8
5.1
|
L
 -27.8%
H
1.8
5.2
|
L
 -3.6%
H
1.7
5.2
|
L
 -89.9%
H
1.7
27.1
|
L
 -96.7%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
6.8
|
1.6
|
L
 -9.1%
H
1.5
1.8
|
L
 8.9%
H
1.4
1.9
|
L
 3.3%
H
1.3
1.9
|
L
 -36.1%
H
1.3
2.7
|
L
 -81.6%
H
1.3
10.0
|
L
 -96.3%
H
1.3
176.4
|
L
 -98.7%
H
1.3
176.4
|
L
H
1.3
176.4
|
| Adial Pharma Inc |
|
6.1
|
2.8
|
L
 2.6%
H
2.7
2.8
|
L
 -0.4%
H
2.6
2.9
|
L
 9.8%
H
2.3
3.0
|
L
 72.2%
H
1.3
5.2
|
L
 -72.4%
H
1.3
18.9
|
L
 -98.4%
H
1.3
221.9
|
L
 -99.8%
H
1.3
3175
|
L
H
1.3
5900
|
| Adma Biologics Inc |
|
2,041.9
|
8.8
|
L
 1.5%
H
8.7
8.9
|
L
 -5.0%
H
8.6
9.3
|
L
 2.7%
H
8.2
9.3
|
L
 -18.0%
H
7.5
11.4
|
L
 -50.2%
H
7.2
20.5
|
L
 146.8%
H
3.1
25.7
|
L
 475.8%
H
1.0
25.7
|
L
 29.7%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
3,537.0
|
22.1
|
L
 -3.5%
H
21.5
23.2
|
L
 -74.7%
H
21.5
88.5
|
L
 -67.9%
H
21.5
91.2
|
L
 -60.8%
H
21.5
91.2
|
L
 -49.0%
H
21.5
91.2
|
L
 -22.9%
H
9.1
91.2
|
L
 -85.0%
H
9.1
160
|
L
H
9.1
285
|
| Agenus Inc |
|
208.2
|
5
|
L
 -0.2%
H
4.7
5.3
|
L
 54.3%
H
3.1
8.7
|
L
 67.8%
H
2.9
8.7
|
L
 7.8%
H
2.9
8.7
|
L
 -21.4%
H
2.7
8.7
|
L
 -85.8%
H
1.4
196
|
L
 -95.3%
H
1.4
196
|
L
 -94.6%
H
1.4
196
|
| Agios Pharma Inc |
|
2,302.7
|
38.7
|
L
 -2.9%
H
38.3
39.7
|
L
 -9.5%
H
38.3
42.9
|
L
 21.6%
H
31.8
44.1
|
L
 10.9%
H
24.3
44.1
|
L
 -3.2%
H
22.2
46
|
L
 42.2%
H
19.8
62.6
|
L
 -30.9%
H
16.8
62.6
|
L
 -7.2%
H
16.8
99.8
|
| Aeglea BioTherapeutics Inc |
|
381.1
|
94.1
|
L
 -7.8%
H
93.4
103.3
|
L
 -4.7%
H
92.7
105.1
|
L
 12.8%
H
81.7
105.1
|
L
 35.0%
H
64.7
105.1
|
L
 481.0%
H
14.5
105.1
|
L
 573.2%
H
8.4
105.1
|
L
 -44.4%
H
2.7
212.5
|
L
 -16.7%
H
2.7
300
|
| Akebia Therapeutics Inc |
|
375.6
|
1.4
|
L
 1.5%
H
1.3
1.4
|
L
 -2.1%
H
1.3
1.4
|
L
 42.9%
H
1.0
1.5
|
L
 3.7%
H
0.8
1.5
|
L
 -64.1%
H
0.8
4.0
|
L
 32.1%
H
0.8
4.1
|
L
 -54.8%
H
0.2
4.1
|
L
 -83.6%
H
0.2
20.3
|
| Avalon GloboCare Corp |
|
4.1
|
0.3
|
L
 14.8%
H
0.3
0.3
|
L
 10.7%
H
0.2
0.3
|
L
H
0.2
0.4
|
L
 -26.2%
H
0.2
0.5
|
L
 -87.2%
H
0.2
4.7
|
L
 -74.6%
H
0.2
11.7
|
L
 -96.4%
H
0.2
11.9
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
103.8
|
1.7
|
L
 -10.4%
H
1.6
1.9
|
L
 -25.2%
H
1.6
2.3
|
L
 -3.4%
H
1.6
2.5
|
L
 -4.4%
H
1.5
2.5
|
L
 -66.7%
H
1.1
6.2
|
L
 -78.1%
H
1.1
8.4
|
L
 -81.9%
H
1.1
12.0
|
L
 -71.6%
H
1.1
16.7
|
| Alector Inc |
|
163.2
|
1.5
|
L
 -2%
H
1.4
1.5
|
L
 -10.4%
H
1.4
1.7
|
L
 -4.6%
H
1.4
2.1
|
L
 -42.4%
H
1.4
2.7
|
L
 -5.8%
H
1.1
3.4
|
L
 -77.3%
H
0.9
9.1
|
L
 -95.6%
H
0.9
35.1
|
L
H
0.9
43.3
|
| Aligos Therapeutics Inc |
|
35.6
|
5.8
|
L
 -0.4%
H
5.6
6.1
|
L
 -15.1%
H
5.6
6.9
|
L
 15.2%
H
5.1
7.1
|
L
 -24.9%
H
4.8
7.4
|
L
 -33.8%
H
4.8
13.7
|
L
 -77.7%
H
3.8
46.3
|
L
 -98.5%
H
3.8
449.3
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
8,657.1
|
51.9
|
L
 -0.1%
H
51.6
53.5
|
L
 -3.4%
H
50.5
53.5
|
L
 17.8%
H
44.0
55.7
|
L
 53.9%
H
32.8
55.7
|
L
 77.9%
H
25.2
55.7
|
L
 70.6%
H
22.0
55.7
|
L
 119.1%
H
21.2
55.7
|
L
 9.2%
H
12.0
71.2
|
| Allogene Therapeutics Inc |
|
617.8
|
1.8
|
L
 -5.8%
H
1.7
1.9
|
L
 -14.8%
H
1.7
2.1
|
L
 -5.8%
H
1.7
2.3
|
L
 -24.5%
H
1.7
2.6
|
L
 45.5%
H
1.0
4.5
|
L
 -63.9%
H
0.9
5.8
|
L
 -92.1%
H
0.9
27.9
|
L
H
0.9
55
|
| Allarity Therapeutics Inc |
|
18.6
|
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
 -2.5%
H
1.1
1.2
|
L
 -18.2%
H
1.0
1.5
|
L
 -5.7%
H
1.0
1.8
|
L
 17%
H
0.8
2.1
|
L
 -98.1%
H
0.1
116
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
37,804.1
|
283.2
|
L
 1.4%
H
273.8
286.6
|
L
 -9.5%
H
273.8
322.5
|
L
 0.4%
H
273.1
380
|
L
 -11.6%
H
273.1
380
|
L
 -12.3%
H
273.1
495.6
|
L
 43.7%
H
142.0
495.6
|
L
 59.5%
H
117.6
495.6
|
L
 339.1%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
73.6
|
0.9
|
L
 -9.5%
H
0.9
1.0
|
L
 -14%
H
0.9
1
|
L
 -8.5%
H
0.9
1.1
|
L
 -49.4%
H
0.9
2.1
|
L
 -40.3%
H
0.9
2.2
|
L
 -55.7%
H
0.9
7.4
|
L
 -95.9%
H
0.9
25.4
|
L
H
0.9
309.6
|
| Altimmune Inc |
|
554.3
|
2.9
|
L
 -4.4%
H
2.8
3.0
|
L
 -8.7%
H
2.8
3.1
|
L
 8.8%
H
2.6
3.4
|
L
 -18.8%
H
2.6
3.6
|
L
 -31.8%
H
2.6
6.4
|
L
 -13.1%
H
2.1
14.8
|
L
 -67.6%
H
2.1
23.5
|
L
 -99.6%
H
1.5
1050
|
| Alvotech |
|
1,139.8
|
3.4
|
L
 -0.3%
H
3.3
3.4
|
L
 1.5%
H
3.2
3.5
|
L
 -12.9%
H
3.2
4.1
|
L
 -6.9%
H
2.9
4.6
|
L
 -60.0%
H
2.9
9.9
|
L
 -65.1%
H
2.9
18
|
L
H
2.9
18
|
L
H
2.9
18
|
| Kalaris Therapeutics Inc |
|
109.7
|
4.6
|
L
 -4.4%
H
4.4
4.8
|
L
 2.7%
H
4.2
4.9
|
L
 5.5%
H
3.9
4.9
|
L
 -30.1%
H
3.9
6.7
|
L
 87.4%
H
2.1
11.9
|
L
 31.7%
H
0.4
12.9
|
L
 -73.9%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Alx Oncology Holdings Inc |
|
278.5
|
2.1
|
L
 2.0%
H
1.9
2.1
|
L
 0.5%
H
1.9
2.2
|
L
 50%
H
1.4
2.4
|
L
 23.2%
H
1.4
2.4
|
L
 340.4%
H
0.4
2.7
|
L
 -69.4%
H
0.4
17.8
|
L
 -96.2%
H
0.4
81.2
|
L
H
0.4
117.5
|
| Alzamend Neuro Inc |
|
4.6
|
1.2
|
L
 -0.8%
H
1.2
1.3
|
L
 5.2%
H
1.1
1.3
|
L
 -4.7%
H
1.1
1.4
|
L
 22%
H
1
1.4
|
L
 -65.4%
H
0.8
3.6
|
L
 -99.8%
H
0.8
729
|
L
 -100.0%
H
0.8
11178
|
L
H
0.8
45292.5
|
| Amgen |
|
200,544.8
|
371.6
|
L
 3.7%
H
357.7
372.1
|
L
 2.2%
H
354.0
372.1
|
L
 6.8%
H
334.1
375.3
|
L
 6.4%
H
320.5
375.3
|
L
 24.3%
H
269.8
391.3
|
L
 63.4%
H
224.3
391.3
|
L
 49.9%
H
198.6
391.3
|
L
 127.6%
H
133.6
391.3
|
| Amylyx Pharma Inc |
|
1,892.4
|
17.0
|
L
 -4.3%
H
16.8
17.9
|
L
 -7.4%
H
16.8
18.5
|
L
 13.1%
H
15.0
19.2
|
L
 -4%
H
12.4
19.2
|
L
 101.9%
H
7.5
19.2
|
L
 -24.9%
H
1.6
25.5
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
875.7
|
19.9
|
L
 2.4%
H
19.4
20.1
|
L
 4.4%
H
18.4
20.1
|
L
 -0.5%
H
18.2
22
|
L
 -8.9%
H
16.6
24.3
|
L
 -6.6%
H
16.6
31.3
|
L
 -64.5%
H
16.6
67.7
|
L
 -1.0%
H
16.6
67.7
|
L
 13.9%
H
12.1
67.7
|
| AnaptysBio Inc |
|
1,603.3
|
54.2
|
L
 -3.0%
H
53.8
56.5
|
L
 -18.7%
H
53.8
70.9
|
L
 -6.0%
H
53.8
70.9
|
L
 -19.1%
H
44
72.4
|
L
 101.6%
H
17.1
73.3
|
L
 193.2%
H
12.2
73.3
|
L
 107.7%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,862.4
|
81.9
|
L
 1.4%
H
81.2
83.0
|
L
 -2.2%
H
79.7
85.9
|
L
 -1.3%
H
78.4
87.2
|
L
 4.9%
H
73.5
87.8
|
L
 23%
H
62.6
99.5
|
L
 62.9%
H
48.2
99.5
|
L
 150.1%
H
22.3
99.5
|
L
 49.2%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
113.0
|
3.3
|
L
 -5.1%
H
3.3
3.6
|
L
 3.1%
H
3.0
3.7
|
L
 27.2%
H
2.4
3.7
|
L
 17.3%
H
2.3
3.7
|
L
 -1.2%
H
2.3
5.5
|
L
 -8.8%
H
2.1
5.5
|
L
 -16.6%
H
2.1
6.5
|
L
 -1.5%
H
0.6
8.1
|
| Annexon Inc |
|
965.0
|
5.9
|
L
 -9.4%
H
5.8
6.6
|
L
 -0.8%
H
5.4
6.6
|
L
 30.3%
H
4.5
6.6
|
L
 -7.0%
H
4.5
6.6
|
L
 145.4%
H
2.0
7.2
|
L
 60.1%
H
1.3
8.4
|
L
 -74.4%
H
1.3
23.8
|
L
H
1.3
38.0
|
| AN2 Therapeutics Inc |
|
168.2
|
4.7
|
L
H
4.6
4.8
|
L
 0.9%
H
4.3
4.9
|
L
 -1.9%
H
4.1
5.5
|
L
 48.7%
H
3.1
5.5
|
L
 332.4%
H
1
6.9
|
L
 -41.0%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Aptorum Grp Ltd (Class A) |
|
5.6
|
0.7
|
L
 -15.9%
H
0.6
0.8
|
L
 -11.5%
H
0.6
0.8
|
L
 -17.9%
H
0.6
0.9
|
L
 -23.3%
H
0.6
1.4
|
L
 -64.4%
H
0.6
4.5
|
L
 -71.5%
H
0.5
17.5
|
L
 -97.6%
H
0.5
29.5
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
8.5
|
0.7
|
L
 -1.4%
H
0.7
0.7
|
L
 -5.5%
H
0.6
0.8
|
L
 -5.5%
H
0.6
0.9
|
L
 -24.2%
H
0.6
1.1
|
L
 -58.4%
H
0.6
2.2
|
L
 -78.0%
H
0.6
8.9
|
L
 -99.3%
H
0.6
117.8
|
L
H
0.6
1062.2
|
| Aptevo Therapeutics Inc |
|
5.6
|
4.5
|
L
 -1.5%
H
4.4
4.6
|
L
 14.2%
H
3.8
4.6
|
L
 -0.9%
H
3.7
4.9
|
L
 -19.8%
H
3.7
5.7
|
L
 -91.8%
H
3.7
59.4
|
L
 -100.0%
H
3.7
864468
|
L
 -100.0%
H
3.7
12940587.7
|
L
H
3.7
68020444.8
|
| AquaBounty Tech Inc |
|
5.0
|
1.0
|
L
 -2.0%
H
1.0
1.0
|
L
 5.4%
H
0.9
1.0
|
L
 -4.9%
H
0.9
1.3
|
L
 -3%
H
0.9
1.3
|
L
 24.4%
H
0.7
3.0
|
L
 -87.1%
H
0.5
8.2
|
L
 -99.0%
H
0.5
106.1
|
L
H
0.5
610
|
| Aquestive Therapeutics Inc |
|
494.3
|
3.9
|
L
 -0.3%
H
3.9
4.1
|
L
 -7.1%
H
3.9
4.3
|
L
 -7.5%
H
3.9
5.2
|
L
 -7.5%
H
3.9
5.2
|
L
 -2.2%
H
2.9
7.6
|
L
 152.6%
H
1.3
7.6
|
L
 18.7%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
175.7
|
6.2
|
L
 -3.3%
H
6.0
6.5
|
L
 -13.7%
H
6.0
7.2
|
L
 -13.5%
H
6.0
8.3
|
L
 -30.1%
H
6.0
9.6
|
L
 -51.9%
H
5.9
24.2
|
L
 -82.6%
H
5.9
45
|
L
 -78.0%
H
5.9
65
|
L
 -78.3%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,264.8
|
5.1
|
L
 -3.4%
H
5.1
5.3
|
L
 -4.8%
H
5.0
5.4
|
L
 -9.7%
H
4.9
6.5
|
L
 -18.5%
H
4.9
7.4
|
L
 11.3%
H
4.1
8.4
|
L
 50.6%
H
3.2
10.1
|
L
 -31.7%
H
0.5
10.1
|
L
 -48.7%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
3,469.8
|
27.7
|
L
 -0.1%
H
27.3
28.1
|
L
 -3.6%
H
26.0
29.0
|
L
 8.1%
H
25.3
29.8
|
L
 14.7%
H
19.3
29.8
|
L
 79.8%
H
13.7
31.8
|
L
 193.9%
H
1.8
31.8
|
L
 8.4%
H
1.8
31.8
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
4.0
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
 11.8%
H
1.0
1.2
|
L
 -11.6%
H
1.0
1.3
|
L
 -76.5%
H
1.0
5.6
|
L
 -97.5%
H
1.0
49.3
|
L
 -96.8%
H
1.0
85.8
|
L
 -99.6%
H
1.0
356.4
|
L
H
1.0
46656
|
| Arvinas Inc |
|
518.1
|
8.0
|
L
 -3.0%
H
8.0
8.3
|
L
 -6.0%
H
7.9
8.5
|
L
 8.2%
H
7.5
8.9
|
L
 -27%
H
7.0
11.4
|
L
 5.8%
H
6.1
14.5
|
L
 -66.8%
H
5.9
53.1
|
L
 -89.2%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
10,054.4
|
71.4
|
L
 -0.6%
H
70.0
73
|
L
 -15.0%
H
69.9
84.5
|
L
 -6.8%
H
69.9
87.8
|
L
 5%
H
68.1
87.8
|
L
 290.1%
H
14.3
87.8
|
L
 106.3%
H
9.6
87.8
|
L
 12.5%
H
9.6
87.8
|
L
 1128.6%
H
1.2
93.7
|
| Assembly Biosciences Inc |
|
512.1
|
25.8
|
L
 -3.3%
H
25.4
26.8
|
L
 -7.3%
H
25.4
28.0
|
L
 10.8%
H
23.2
29.9
|
L
 -11.9%
H
21.8
32.5
|
L
 36.3%
H
16.9
39.7
|
L
 99.4%
H
7.7
39.7
|
L
 -36.5%
H
7.7
47.3
|
L
 -63.2%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
496.1
|
3.9
|
L
 -14.0%
H
3.9
4.4
|
L
 -23.4%
H
3.9
5.4
|
L
 -38.8%
H
3.9
7.6
|
L
 -22.9%
H
3.9
8.5
|
L
 -51.8%
H
3.9
14.5
|
L
 535.5%
H
0.6
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| ATAI Life Sciences N.V. |
|
2,632.4
|
7.2
|
L
 33.4%
H
7.0
7.2
|
L
 34.2%
H
4.8
7.2
|
L
 72.7%
H
4.0
7.2
|
L
 74.8%
H
3.7
7.2
|
L
 164.8%
H
2.7
7.2
|
L
 254.0%
H
1.0
7.2
|
L
 -58.9%
H
1.0
17.9
|
L
H
1.0
22.9
|
| LeonaBio Inc |
|
73.4
|
7.8
|
L
 -8.4%
H
7.3
8.8
|
L
 -16.8%
H
7.3
10.1
|
L
 -0.9%
H
7.3
10.1
|
L
 -5.1%
H
7.3
11.4
|
L
 103.4%
H
3.2
14.2
|
L
 -74.6%
H
2.2
43.0
|
L
 -91.8%
H
2.2
166.5
|
L
H
2.2
347.9
|
| ETHZilla Corp |
|
77.1
|
5.8
|
L
 -2.3%
H
5.5
6.1
|
L
 -1.0%
H
5.4
7
|
L
 10.0%
H
4.8
7.2
|
L
 146.4%
H
2.8
7.2
|
L
 -33.6%
H
1.8
174.6
|
L
 -97.0%
H
1.8
212.8
|
L
 -100.0%
H
1.8
34401.4
|
L
H
1.8
49571
|
| Atossa Therapeutics Inc |
|
23.8
|
2.4
|
L
 -2.1%
H
2.3
2.5
|
L
 1.3%
H
2.2
2.5
|
L
 7.7%
H
1.7
2.6
|
L
 -58.6%
H
1.7
6.3
|
L
 -82.1%
H
1.7
19.4
|
L
 -87.2%
H
1.7
34.7
|
L
 -96.5%
H
1.7
68.6
|
L
 -99.7%
H
1.7
806.5
|
| Atara Biotherapeutics Inc |
|
78.6
|
8.7
|
L
 2.0%
H
8.4
8.8
|
L
 -12.3%
H
7.9
10.1
|
L
 -9.4%
H
7.9
12
|
L
 66.4%
H
4.5
12.5
|
L
 -6.0%
H
3.9
19.1
|
L
 -80.9%
H
0.4
63.4
|
L
 -97.4%
H
0.4
501
|
L
 -98.4%
H
0.4
1361.3
|
| Aurinia Pharma Inc |
|
2,049.9
|
15.9
|
L
 -1.0%
H
15.8
16.1
|
L
 -3.9%
H
15.4
16.5
|
L
 -1.7%
H
15.2
19.3
|
L
 0.7%
H
14.4
19.3
|
L
 80.1%
H
8.6
19.3
|
L
 43.3%
H
4.7
19.3
|
L
 41.7%
H
4.1
34.0
|
L
 424.3%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
712.7
|
6.9
|
L
 -1.7%
H
6.7
7
|
L
 -1.6%
H
6.6
7.3
|
L
 9.7%
H
6.2
7.9
|
L
 -2.4%
H
6.0
9.5
|
L
 -0.9%
H
4.7
9.5
|
L
 -43.6%
H
4.3
12.4
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Atea Pharma Inc |
|
377.7
|
4.7
|
L
 -2.9%
H
4.7
4.9
|
L
 -3.9%
H
4.6
5
|
L
 10.8%
H
4.2
5.0
|
L
 -17.2%
H
4.0
5.8
|
L
 35.2%
H
2.8
6.5
|
L
 29.7%
H
2.5
6.5
|
L
 -79.4%
H
2.5
46.9
|
L
H
2.5
94.2
|
| Tectonic Therapeutic Inc |
|
578.3
|
30.7
|
L
 -5.7%
H
30.3
32.7
|
L
 -13.1%
H
30.3
35.6
|
L
 2.1%
H
29.1
39.5
|
L
 3.3%
H
26.3
39.5
|
L
 35.8%
H
14.4
39.5
|
L
 81.1%
H
1.4
61.1
|
L
 -67.7%
H
1.4
97.4
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
1,246.4
|
20.5
|
L
 -6.3%
H
20
22.3
|
L
 -8.9%
H
19.8
23.3
|
L
 31.9%
H
15.3
23.5
|
L
 -6.4%
H
14.3
28
|
L
 132.5%
H
6.7
28
|
L
 -96.8%
H
6.6
1134.5
|
L
 -96.1%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Avalo Therapeutics Inc |
|
939.9
|
17.9
|
L
 -3.6%
H
17.8
18.9
|
L
 -10.4%
H
17.8
20.5
|
L
 24.8%
H
14.3
20.7
|
L
 24.0%
H
12.5
24.3
|
L
 268.7%
H
4.8
24.3
|
L
 5318.2%
H
0.0
34.5
|
L
 -47.9%
H
0.0
38.9
|
L
 -36.4%
H
0.0
91.8
|
| Anavex Life Sciences Corp |
|
216.9
|
2.3
|
L
 -6.4%
H
2.3
2.5
|
L
 -13.3%
H
2.3
2.7
|
L
 -7.1%
H
2.3
2.8
|
L
 -31.2%
H
2.3
3.8
|
L
 -79.2%
H
2.3
14.0
|
L
 -72.2%
H
2.3
14.4
|
L
 -89.2%
H
2.3
23.7
|
L
 -66.9%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
12,198.0
|
237.0
|
L
 -0.2%
H
233.2
240.9
|
L
 -4.8%
H
224.7
249.1
|
L
 -5.9%
H
224.7
260.2
|
L
 28.7%
H
180
260.2
|
L
 112.9%
H
96.1
260.2
|
L
 221.9%
H
55.0
260.2
|
L
 337.2%
H
19.4
260.2
|
L
 2844.6%
H
1.9
260.2
|
| Aytu BioPharma Inc |
|
23.2
|
2.2
|
L
 -2.7%
H
2.2
2.2
|
L
 -1.8%
H
2.2
2.3
|
L
 3.9%
H
2.1
2.3
|
L
 -16.3%
H
2.0
2.6
|
L
 -6.9%
H
1.7
3.1
|
L
 15.5%
H
1.0
3.5
|
L
 -97.5%
H
1.0
88.4
|
L
 -100.0%
H
1.0
323200
|
| Aziyo Biologics Inc (Class A) |
|
-
|
1.0
|
L
 -1.0%
H
1.0
1
|
L
 -2.1%
H
0.9
1.0
|
L
H
0.9
1.1
|
L
 -18.8%
H
0.9
1.3
|
L
 -53.2%
H
0.5
2.4
|
L
 -60.4%
H
0.5
2.6
|
L
 -87.4%
H
0.5
9.8
|
L
H
0.5
18.2
|
| Adagene Inc (ADR) |
|
236.5
|
3.6
|
L
 -2.5%
H
3.5
3.8
|
L
 -7.0%
H
3.5
4.1
|
L
 2.0%
H
3.3
4.9
|
L
 -7.0%
H
3.1
4.9
|
L
 81.7%
H
1.3
4.9
|
L
 145.2%
H
1.1
4.9
|
L
 -80.8%
H
0.9
21.0
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
7.5
|
5.9
|
L
 -3.9%
H
5.9
5.9
|
L
 0.9%
H
5.7
6.5
|
L
 -4.4%
H
5.6
7.1
|
L
 -12.8%
H
5.6
7.5
|
L
 -32.7%
H
5.4
12.1
|
L
 -49.6%
H
5
27.9
|
L
 -96.7%
H
5
205.6
|
L
H
5
750.4
|
| Akari Therapeutics PLC (ADR) |
|
20.1
|
11.5
|
L
 -4.7%
H
11.5
12.5
|
L
 -12.6%
H
11.5
15
|
L
 -11.5%
H
9.2
15.5
|
L
 124.6%
H
3.0
29.3
|
L
 -74.1%
H
3.0
49.6
|
L
 -91.6%
H
3.0
219.8
|
L
 -99.1%
H
3.0
1504
|
L
 -99.9%
H
3.0
17759.8
|
| Amarin Corp (ADR) |
|
297.3
|
14.2
|
L
 -1.9%
H
14.1
14.6
|
L
 -6.2%
H
14.1
15.2
|
L
 -6.5%
H
14.1
17.3
|
L
 -3.7%
H
13.0
17.3
|
L
 -10.5%
H
13.0
20.9
|
L
 1043.5%
H
0.4
20.9
|
L
 239.2%
H
0.4
20.9
|
L
 513.9%
H
0.4
26.1
|
| Argen X SE (ADR) |
|
53,675.5
|
858.0
|
L
 -0.6%
H
852.6
866.2
|
L
 -5.7%
H
852.6
904.8
|
L
 -2.3%
H
837.7
953.6
|
L
 3.6%
H
754.8
953.6
|
L
 48.5%
H
560.9
953.6
|
L
 126.3%
H
327.7
953.6
|
L
 177.3%
H
249.5
953.6
|
L
H
17.3
953.6
|
| Ascendis Pharma A/S (ADR) |
|
15,949.9
|
259.8
|
L
 -3.3%
H
259.2
267.4
|
L
 -5.7%
H
259.2
276.9
|
L
 12.4%
H
222.8
282.2
|
L
 6.9%
H
203.8
282.2
|
L
 48.1%
H
160.9
282.2
|
L
 200.2%
H
85.3
282.2
|
L
 114.6%
H
61.6
282.2
|
L
 1907.7%
H
12.7
282.2
|
| Alterity Therapeutics Ltd (ADR) |
|
92.1
|
5.1
|
L
 1.8%
H
4.9
5.2
|
L
 -5.6%
H
4.9
5.5
|
L
 9.3%
H
4.8
5.9
|
L
 28.0%
H
3.8
5.9
|
L
 9.5%
H
2.7
7
|
L
 79.5%
H
1
7
|
L
 -64.0%
H
1
18.2
|
L
 -89.2%
H
1
66.9
|
| Autolus Therapeutics PLC (ADR) |
|
388.6
|
1.5
|
L
 -3.3%
H
1.5
1.5
|
L
 -13.6%
H
1.4
1.7
|
L
 -2.0%
H
1.4
1.7
|
L
 -9.3%
H
1.4
2.0
|
L
 -40.2%
H
1.2
2.7
|
L
 -40.7%
H
1.1
7.5
|
L
 -75.8%
H
1.1
7.9
|
L
H
1.1
53.2
|
| Astrazeneca plc |
|
524,895.0
|
169.3
|
L
 0.6%
H
167.3
170.4
|
L
 -5.2%
H
164.5
175.9
|
L
 -5.3%
H
164.5
196.4
|
L
 -15.6%
H
164.5
205.3
|
L
 -10.2%
H
164.5
212.7
|
L
 -10.1%
H
164.5
212.7
|
L
 -10.1%
H
164.5
212.7
|
L
 -10.1%
H
164.5
212.7
|
| BridgeBio Pharma Inc |
|
15,727.7
|
80.3
|
L
 -2.9%
H
80.2
83.1
|
L
 -11.0%
H
80.2
91
|
L
 20.5%
H
65.6
93.4
|
L
 3.6%
H
62.5
93.4
|
L
 70.5%
H
42.1
93.4
|
L
 340.7%
H
21.6
93.4
|
L
 35.7%
H
5.0
93.4
|
L
H
5.0
93.4
|
| BioAtla Inc |
|
6.6
|
4.0
|
L
 -6.3%
H
3.8
4.3
|
L
 7.3%
H
3.6
4.3
|
L
 15.7%
H
3.3
4.7
|
L
 -18.7%
H
3.1
6.1
|
L
 -79.3%
H
3.1
71.5
|
L
 -97.0%
H
3.1
201
|
L
 -99.8%
H
3.1
2186.5
|
L
H
3.1
3831.5
|
| BioCardia Inc |
|
12.8
|
0.9
|
L
 -2.3%
H
0.9
0.9
|
L
 -3.4%
H
0.8
1.0
|
L
 -1.2%
H
0.8
1.3
|
L
 -27.7%
H
0.8
1.8
|
L
 -62.0%
H
0.8
2.4
|
L
 -97.5%
H
0.8
38.1
|
L
 -98.3%
H
0.8
59.4
|
L
 -99.6%
H
0.8
2073.6
|
| Biocryst Pharma Inc |
|
2,312.9
|
9.1
|
L
 -3.3%
H
9.1
9.4
|
L
 -15.1%
H
9.1
10.7
|
L
 2.0%
H
8.8
11.2
|
L
 -4.4%
H
7.8
11.2
|
L
 5.9%
H
6
11.2
|
L
 27.6%
H
4.0
11.3
|
L
 -41.7%
H
4.0
20.0
|
L
 207.4%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
33.5
|
3.9
|
L
 -2.3%
H
3.6
3.9
|
L
 5.8%
H
3.6
4
|
L
 36.0%
H
2.7
4
|
L
 -10.9%
H
2.6
4.5
|
L
 -95.3%
H
2.6
84.1
|
L
 -100.0%
H
2.6
11275.5
|
L
 -99.9%
H
2.6
18526.5
|
L
 -100.0%
H
2.6
83250
|
| Black Diamond Therapeutics Inc |
|
103.7
|
1.8
|
L
H
1.8
1.8
|
L
 -3.7%
H
1.8
2.0
|
L
 7.7%
H
1.6
2.2
|
L
 -38.0%
H
1.6
4.0
|
L
 -40.5%
H
1.6
4.9
|
L
 -62.7%
H
1.2
7.7
|
L
 -82.0%
H
1.2
10.5
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
2,920.7
|
28.4
|
L
 -7.9%
H
27.9
30.3
|
L
 -20.7%
H
27.9
35.6
|
L
 -8.4%
H
27.9
38.3
|
L
 -6.4%
H
25.9
38.3
|
L
 41.5%
H
15.6
38.3
|
L
 -8.0%
H
13.5
49.5
|
L
 -67.7%
H
13.5
116.9
|
L
H
13
138.5
|
| Biofrontera Inc |
|
14.2
|
1.1
|
L
 1.8%
H
1.1
1.1
|
L
 -2.6%
H
1.1
1.2
|
L
 15.6%
H
0.9
1.2
|
L
 2.8%
H
0.7
1.2
|
L
 32.1%
H
0.6
1.2
|
L
 -88.0%
H
0.5
13.0
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biogen |
|
30,844.3
|
208.9
|
L
 5.9%
H
194.7
209.6
|
L
 5.0%
H
186.0
210.9
|
L
 6.8%
H
186.0
219.7
|
L
 18.7%
H
175.7
219.7
|
L
 62.6%
H
121.1
219.7
|
L
 -25.1%
H
110.0
281.1
|
L
 -35.6%
H
110.0
351.9
|
L
 -12.9%
H
110.0
468.6
|
| BioVie Inc |
|
13.0
|
1.7
|
L
 -2.8%
H
1.7
1.8
|
L
 -23.2%
H
1.5
2.3
|
L
 -3.4%
H
1.5
2.3
|
L
 17.8%
H
1.3
2.3
|
L
 -76.5%
H
1.1
9.1
|
L
 -99.7%
H
1.1
582
|
L
 -99.9%
H
1.1
1698
|
L
 -99.9%
H
1.1
5625
|
| Biomea Fusion Inc |
|
91.1
|
1.3
|
L
 -2.3%
H
1.2
1.3
|
L
 -3.8%
H
1.2
1.4
|
L
 8.6%
H
1.2
1.5
|
L
 -34.7%
H
1.1
2.2
|
L
 -34.0%
H
0.9
3.0
|
L
 -94.5%
H
0.9
23.9
|
L
 -90.8%
H
0.9
43.7
|
L
H
0.9
43.7
|
| Biomarin pharma Inc - Registered Shares |
|
11,597.1
|
60
|
L
 1.8%
H
58.6
60.2
|
L
 0.1%
H
57.8
60.3
|
L
 8.9%
H
54.3
60.7
|
L
 10.9%
H
49.3
60.7
|
L
 2.8%
H
49.3
66.3
|
L
 -30.1%
H
49.3
99.6
|
L
 -23.9%
H
49.3
117.8
|
L
 -34.8%
H
49.3
131.9
|
| Bionano Genomics Inc |
|
13.4
|
1.2
|
L
 -1.7%
H
1.2
1.2
|
L
 2.6%
H
1.1
1.2
|
L
 1.7%
H
1.1
1.2
|
L
 -7.1%
H
1.1
1.4
|
L
 -65.6%
H
1.1
5.5
|
L
 -81.9%
H
0.1
11.6
|
L
 -98.0%
H
0.1
64.7
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
434.9
|
12.7
|
L
 -2.8%
H
12.5
12.9
|
L
 -6.1%
H
12.5
13.5
|
L
 14.1%
H
10.9
14.3
|
L
 -5.9%
H
10
14.3
|
L
 7.7%
H
9.9
16.8
|
L
 223.8%
H
1.9
17.2
|
L
 -80.0%
H
1.9
81.3
|
L
 -96.2%
H
1.9
1371.3
|
| Bolt Biotherapeutics Inc |
|
8.1
|
4.2
|
L
 -0.5%
H
4.1
4.3
|
L
 5.3%
H
3.8
4.3
|
L
 -2.8%
H
3.8
4.7
|
L
 -12.9%
H
3.8
5.7
|
L
 -27%
H
3.8
7.2
|
L
 -84.6%
H
3.8
31.2
|
L
 -98.4%
H
3.8
385.7
|
L
H
3.8
861.4
|
| Bon Natural Life Ltd |
|
9.6
|
1.2
|
L
H
1.2
1.2
|
L
 -0.8%
H
1.2
1.3
|
L
 -3.3%
H
1.1
1.3
|
L
 -9.2%
H
1.1
1.5
|
L
 -18.1%
H
1.1
3.4
|
L
 -99.2%
H
1.1
180
|
L
 -100.0%
H
1.1
4050
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
26.9
|
0.9
|
L
 -5.4%
H
0.9
0.9
|
L
 3.6%
H
0.8
1.2
|
L
 -27.5%
H
0.7
1.5
|
L
 -18.7%
H
0.7
1.5
|
L
 -55.4%
H
0.7
8.1
|
L
 -91.6%
H
0.2
12.2
|
L
 -96.8%
H
0.2
36.5
|
L
H
0.2
71.5
|
| Blue Water Biotech Inc |
|
14.1
|
0.8
|
L
 2.6%
H
0.8
0.8
|
L
 -19.4%
H
0.8
1.0
|
L
 -26.9%
H
0.8
1.2
|
L
 4.0%
H
0.1
1.4
|
L
 -77.5%
H
0.1
6.7
|
L
 -31.3%
H
0.1
6.7
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
52.6
|
1.3
|
L
 0.8%
H
1.2
1.4
|
L
 -14.1%
H
1.2
1.6
|
L
 -20%
H
1.2
1.9
|
L
 -23.8%
H
1.2
1.9
|
L
 -42.1%
H
1.2
2.4
|
L
 14.3%
H
0.7
4
|
L
 -87.1%
H
0.5
33
|
L
H
0.5
48.5
|
| Bicycle Therapeutics PLC (ADR) |
|
291.8
|
4.2
|
L
 -1.0%
H
4.1
4.3
|
L
H
4.1
4.4
|
L
 4.0%
H
3.9
4.5
|
L
 -18.7%
H
3.9
5.4
|
L
 -46.3%
H
3.9
9.2
|
L
 -84.1%
H
3.9
28.7
|
L
 -87.7%
H
3.9
62.1
|
L
H
3.9
62.1
|
| Biodexa Pharma PLC (ADR) |
|
1.9
|
2.1
|
L
 -4.9%
H
2.1
2.3
|
L
 -17.8%
H
2.1
2.5
|
L
 -28.5%
H
2.1
3.2
|
L
 -38.6%
H
2.1
5.1
|
L
 -94.9%
H
2.1
59.4
|
L
 -100.0%
H
2.1
301250
|
L
 -100.0%
H
2.1
104500000
|
L
 -100.0%
H
2.1
10000000000
|
| BeiGene Ltd (ADR) |
|
33,813.5
|
317.4
|
L
 2.0%
H
312.0
323.8
|
L
 4.8%
H
295.4
323.8
|
L
 20.3%
H
259.1
323.8
|
L
 -1.0%
H
254.0
328.4
|
L
 13.7%
H
254.0
385.2
|
L
 61.7%
H
127.0
385.2
|
L
 -2.6%
H
118.2
426.6
|
L
 974.5%
H
24.5
426.6
|
| Bioline Rx Ltd (ADR) |
|
13.0
|
3.0
|
L
 2.4%
H
2.9
3.1
|
L
 -1.7%
H
2.8
3.2
|
L
 -2.3%
H
2.8
3.5
|
L
 24.7%
H
2.2
4.0
|
L
 -35.2%
H
2.2
4.8
|
L
 -95.5%
H
0.1
101.2
|
L
 -97.6%
H
0.1
137.2
|
L
 -99.3%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
6,039.6
|
150.7
|
L
 0.8%
H
146.6
151.2
|
L
 -1.7%
H
144.1
154.3
|
L
 9.0%
H
136.2
158.9
|
L
 -4.7%
H
130
173.3
|
L
 142.8%
H
59.1
200
|
L
 1021.1%
H
13.6
200
|
L
H
6
200
|
L
H
6
200
|
| Neuphoria Therapeutics Inc |
|
19.1
|
3.5
|
L
 0.3%
H
3.5
3.7
|
L
 0.6%
H
3.4
3.7
|
L
 -17.5%
H
3.2
4.6
|
L
 -25.2%
H
3.2
5.5
|
L
 -52.7%
H
3.2
21.4
|
L
 31.2%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| BioNTech SE (ADR) |
|
23,154.1
|
91.6
|
L
 -0.5%
H
90.8
92.8
|
L
 -1.5%
H
88.4
93.4
|
L
 2.3%
H
88.4
98.8
|
L
 -10.3%
H
85.0
113.3
|
L
 -18.6%
H
79.5
124
|
L
 -15.4%
H
76.5
131.5
|
L
 -60.4%
H
76.5
464
|
L
H
12.5
464
|
| Biondvax Pharma Ltd (ADR) |
|
-
|
0.3
|
L
 -3.9%
H
0.2
0.3
|
L
 -3.9%
H
0.2
0.3
|
L
 -28.6%
H
0.2
0.4
|
L
 -58.3%
H
0.2
1.1
|
L
 -88.4%
H
0.2
3.5
|
L
 -82.8%
H
0.2
6.2
|
L
 -99.0%
H
0.2
99
|
L
 -99.3%
H
0.2
620
|
| Cabaletta Bio Inc |
|
435.4
|
2.7
|
L
 -3.6%
H
2.6
2.8
|
L
 -14.4%
H
2.6
3.1
|
L
 -4.6%
H
2.6
3.3
|
L
 -24.2%
H
2.6
4.2
|
L
 58.0%
H
1.3
4.2
|
L
 -78.0%
H
1.0
26.4
|
L
 -66.0%
H
0.6
26.4
|
L
H
0.6
26.4
|
| Candel Therapeutics Inc |
|
694.6
|
9.5
|
L
 -1.7%
H
9.2
9.7
|
L
 -4.2%
H
9.2
10.2
|
L
 19.0%
H
7.9
11.4
|
L
 83.7%
H
5.2
11.4
|
L
 38.4%
H
4.4
11.4
|
L
 717.2%
H
0.7
14.6
|
L
H
0.7
14.8
|
L
H
0.7
14.8
|
| CalciMedica Inc |
|
10.9
|
0.7
|
L
 -11.5%
H
0.7
0.8
|
L
 -27.4%
H
0.7
1.0
|
L
 -19.8%
H
0.5
1.2
|
L
 13.1%
H
0.5
1.2
|
L
 -68.4%
H
0.5
7.2
|
L
 -81.3%
H
0.5
8.4
|
L
 -98.8%
H
0.5
64.1
|
L
H
0.5
530.3
|
| Capricor Therapeutics Inc |
|
1,107.3
|
19.1
|
L
 -6.0%
H
19
20.5
|
L
 -15.0%
H
19
22.6
|
L
 -26.6%
H
19
30.9
|
L
 -44.7%
H
19
36.8
|
L
 164.1%
H
4.3
40.4
|
L
 326.8%
H
2.7
40.4
|
L
 341.6%
H
2.6
40.4
|
L
 -55.2%
H
0.9
44.4
|
| Tvardi Therapeutics Inc |
|
28.9
|
3.1
|
L
 5.1%
H
3.0
3.4
|
L
 -19.0%
H
2.9
3.9
|
L
 17.1%
H
1.5
5.7
|
L
 -4.4%
H
1.5
5.7
|
L
 -86.5%
H
1.5
43.7
|
L
 -97.0%
H
1.5
124.2
|
L
 -99.3%
H
1.5
681.5
|
L
 -98.3%
H
1.5
1067.3
|
| Crescent Biopharma Inc |
|
-
|
15.1
|
L
 -3.6%
H
15
16.9
|
L
 -9.8%
H
14.7
17.6
|
L
 -15.8%
H
14.7
19.2
|
L
 -22.3%
H
14.7
27.4
|
L
 15.0%
H
8.7
27.4
|
L
 165.1%
H
4.8
27.4
|
L
 41.6%
H
0.9
27.4
|
L
 -69.9%
H
0.9
90.3
|
| C4 Therapeutics Inc |
|
395.8
|
3.6
|
L
 -5.8%
H
3.5
3.8
|
L
 -16.6%
H
3.5
4.3
|
L
 -6.8%
H
3.5
5.2
|
L
 23.5%
H
2.5
5.2
|
L
 77.2%
H
1.7
5.2
|
L
 6.9%
H
1.1
11.9
|
L
 -91.0%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Niagen Bioscience Inc |
|
270.8
|
3.4
|
L
 -2.0%
H
3.4
3.5
|
L
 -2.6%
H
3.3
3.5
|
L
 -0.9%
H
3.2
3.6
|
L
 -28.1%
H
3.2
5.1
|
L
 -70.4%
H
3.2
11.6
|
L
 109.9%
H
1.3
14.7
|
L
 -62.6%
H
1.2
14.7
|
L
 -11.0%
H
1.2
23.7
|
| Cullinan Oncology Inc |
|
1,008.5
|
16.4
|
L
 -8.0%
H
16.4
17.8
|
L
 -10.7%
H
16.4
18.4
|
L
 21.1%
H
13.6
19.4
|
L
 11.3%
H
11.7
19.4
|
L
 114.0%
H
5.7
19.4
|
L
 40.0%
H
5.7
30.2
|
L
 -39.1%
H
5.7
30.3
|
L
H
5.7
59.9
|
| Compugen Ltd |
|
220.4
|
2.3
|
L
 -1.3%
H
2.3
2.4
|
L
 -5.7%
H
2.2
2.5
|
L
 14.8%
H
2.0
2.6
|
L
 -19.4%
H
2.0
3.2
|
L
 47.5%
H
1.3
3.2
|
L
 86.4%
H
0.5
3.2
|
L
 -66.2%
H
0.5
7.5
|
L
 -64.3%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
84.1
|
0.9
|
L
 -1.1%
H
0.9
1.0
|
L
 -13.8%
H
0.9
1.1
|
L
 -25.4%
H
0.9
1.8
|
L
 -15.3%
H
0.9
1.8
|
L
 51.6%
H
0.6
3.8
|
L
 -45.7%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Coherus Biosciences Inc |
|
214.4
|
1.4
|
L
 -3.5%
H
1.4
1.5
|
L
 -14.7%
H
1.4
1.6
|
L
 0.7%
H
1.4
1.7
|
L
 -26.8%
H
1.3
2.1
|
L
 54.4%
H
0.8
2.6
|
L
 -65.8%
H
0.7
5.5
|
L
 -89.3%
H
0.7
19.3
|
L
 -94.1%
H
0.7
32.0
|
| Cingulate Inc |
|
59.7
|
4.4
|
L
 -3.5%
H
4.3
4.6
|
L
 -10.5%
H
4.3
5.0
|
L
 -6.5%
H
4.3
6.0
|
L
 -15.8%
H
3.2
6.6
|
L
 -6.1%
H
3.2
11.9
|
L
 460.8%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Celldex Therapeutics Inc |
|
2,778.6
|
35.4
|
L
 -7.6%
H
35.0
37.9
|
L
 -9.2%
H
35.0
39.2
|
L
 9.5%
H
32.3
40.3
|
L
 4.6%
H
28.4
40.3
|
L
 54.1%
H
19.7
40.3
|
L
 -5.1%
H
14.4
53.2
|
L
 -12.9%
H
14.4
57.2
|
L
 -49.8%
H
1.5
75.3
|
| Clene Inc |
|
72.7
|
5.7
|
L
 -5.5%
H
5.6
6.1
|
L
 -9.0%
H
5.6
6.6
|
L
 -2.7%
H
5.6
6.6
|
L
 -10.4%
H
5.2
8.7
|
L
 50.9%
H
3.3
13.5
|
L
 -64.4%
H
2.3
17
|
L
 -96.8%
H
2.3
196.8
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
20.6
|
2.6
|
L
 -1.2%
H
2.5
2.6
|
L
 -6.9%
H
2.5
2.9
|
L
 5.3%
H
2.4
3.1
|
L
 -14.3%
H
2.2
4.7
|
L
 -48.8%
H
2.2
6.5
|
L
 -95.3%
H
2.2
133.5
|
L
 -99.2%
H
2.2
345
|
L
 -100.0%
H
2.2
10410
|
| Compass Therapeutics Inc |
|
378.2
|
2.1
|
L
 -1.9%
H
2.1
2.2
|
L
 -9.1%
H
2.1
2.4
|
L
 6.6%
H
2.0
2.4
|
L
 -67.8%
H
1.6
6.7
|
L
 -32.9%
H
1.6
6.9
|
L
 -26.8%
H
0.8
6.9
|
L
 -58%
H
0.8
6.9
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
6.9
|
4.7
|
L
 1.3%
H
4.7
5.2
|
L
 -10.9%
H
4.6
5.3
|
L
 2.4%
H
3.9
5.5
|
L
 78.2%
H
1.9
10.5
|
L
 -54.3%
H
1.9
11.2
|
L
 -100.0%
H
1.9
4125000
|
L
 -100.0%
H
1.9
83250000
|
L
H
1.9
256050000
|
| Context Therapeutics Inc |
|
57.0
|
0.6
|
L
 -1.6%
H
0.6
0.6
|
L
 3.3%
H
0.6
0.7
|
L
 -4.6%
H
0.5
0.7
|
L
 -72.9%
H
0.5
3.1
|
L
 -24.4%
H
0.5
3.6
|
L
 -48.3%
H
0.5
3.6
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
13.1
|
1.0
|
L
 -1.0%
H
1.0
1.0
|
L
 -5.9%
H
0.9
1.0
|
L
H
0.9
1.1
|
L
 -39.5%
H
0.9
1.6
|
L
 -43.1%
H
0.9
2.7
|
L
 -62.5%
H
0.9
3.3
|
L
 -92.9%
H
0.9
17.9
|
L
 -99.5%
H
0.9
205.2
|
| Co-Diagnostics Inc |
|
9.1
|
2.5
|
L
 -0.4%
H
2.3
2.5
|
L
 -6.1%
H
2.3
2.7
|
L
 -35.4%
H
2.3
4.6
|
L
 69.9%
H
1.3
13.5
|
L
 -68.5%
H
1.3
46.5
|
L
 -93.9%
H
1.3
66.9
|
L
 -98.9%
H
1.3
354.6
|
L
H
1.3
929.7
|
| Z Squared Inc |
|
287.4
|
5.5
|
L
 5.4%
H
4.6
5.5
|
L
 -35.8%
H
4.4
8.8
|
L
 -63.4%
H
4.4
16.9
|
L
 -60.3%
H
4.4
18.8
|
L
 -44.3%
H
4.4
21.4
|
L
 -79.2%
H
2.3
28.2
|
L
 -44.8%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
6,482.7
|
37.9
|
L
 -3.5%
H
37.4
39.7
|
L
 -6.3%
H
37.0
40.5
|
L
 14.7%
H
33.0
40.9
|
L
 4.8%
H
30.9
40.9
|
L
 219.9%
H
10.4
43.7
|
L
 202.8%
H
3.7
43.7
|
L
 505.1%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Collegium pharma Inc |
|
1,176.4
|
36.3
|
L
 -1.2%
H
36.2
37.7
|
L
 1.3%
H
34.3
37.7
|
L
 4.7%
H
31.7
38.5
|
L
 9.8%
H
30.1
40.5
|
L
 14.2%
H
29.2
50.8
|
L
 67.8%
H
21.0
50.8
|
L
 51.8%
H
14.0
50.8
|
L
 184.5%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
9,631.6
|
89.7
|
L
 0.2%
H
88.9
92.6
|
L
 -3.8%
H
84.9
93.2
|
L
 7.2%
H
77.4
95.1
|
L
 104.1%
H
44.2
95.1
|
L
 23.2%
H
28.7
95.1
|
L
 293.2%
H
20.8
117.3
|
L
 344.2%
H
15.8
117.3
|
L
 1465.8%
H
5.2
117.3
|
| Cosmos Health Inc |
|
17.4
|
0.3
|
L
H
0.3
0.3
|
L
 7.7%
H
0.2
0.4
|
L
 12%
H
0.2
0.4
|
L
 -31.7%
H
0.2
0.5
|
L
 -37.8%
H
0.2
1.3
|
L
 -90.7%
H
0.2
3.1
|
L
 -99.8%
H
0.2
150
|
L
 -99.8%
H
0.2
312.5
|
| Coya Therapeutics Inc |
|
107.9
|
4.6
|
L
 -5.0%
H
4.5
4.9
|
L
 -12.6%
H
4.5
5.6
|
L
 -4.6%
H
4.5
6.2
|
L
 2.7%
H
3.9
6.2
|
L
 -20.6%
H
3.7
7.8
|
L
 14.7%
H
3.2
10.7
|
L
H
3.2
10.7
|
L
H
3.2
10.7
|
| Cumberland Pharma Inc |
|
114.8
|
7.7
|
L
 -1.8%
H
7.5
8.1
|
L
 26.8%
H
5.8
8.1
|
L
 35.1%
H
5.5
8.1
|
L
 147.9%
H
3.0
8.1
|
L
 97.4%
H
1.9
8.1
|
L
 410.7%
H
1.0
8.1
|
L
 142.4%
H
1.0
8.1
|
L
 64.7%
H
1.0
8.1
|
| Corbus Pharma Holdings Inc |
|
163.0
|
8.8
|
L
 -2.3%
H
8.6
9.1
|
L
 -8.9%
H
8.6
9.7
|
L
 11.7%
H
7.9
9.9
|
L
 -13.2%
H
7.1
12.9
|
L
 3.3%
H
7.1
20.6
|
L
 14.7%
H
3.0
61.9
|
L
 -80.2%
H
2.1
61.9
|
L
 -89.8%
H
2.1
323.4
|
| Caribou Biosciences Inc |
|
164.6
|
1.7
|
L
 -4.1%
H
1.6
1.7
|
L
 -14.4%
H
1.6
1.9
|
L
 -1.8%
H
1.6
2.1
|
L
 -22.8%
H
1.6
2.5
|
L
 -9.3%
H
1.4
3.5
|
L
 -73.7%
H
0.7
8.3
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
141.8
|
1.2
|
L
 10.8%
H
1.1
1.3
|
L
 24.2%
H
1.0
1.3
|
L
 16.0%
H
1.0
1.3
|
L
 -12.8%
H
1.0
1.7
|
L
 -5.4%
H
0.9
1.7
|
L
 51.9%
H
0.7
3.1
|
L
 -54.4%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
9.7
|
5.0
|
L
 5.3%
H
4.4
5.1
|
L
 0.4%
H
4.4
5.1
|
L
 -34.5%
H
3.6
11.4
|
L
 -57.9%
H
3.6
13.4
|
L
 -86.2%
H
3.6
39
|
L
 -98.4%
H
3.6
349.8
|
L
 -99.8%
H
3.6
3616
|
L
 -99.9%
H
3.6
7440
|
| CorMedix Inc |
|
650.4
|
8.3
|
L
 -1.5%
H
8.3
8.5
|
L
 -4.4%
H
8.1
8.7
|
L
 -4.3%
H
7.5
9.1
|
L
 16.3%
H
7.1
9.1
|
L
 -25.5%
H
6.1
15.0
|
L
 113.1%
H
2.6
17.4
|
L
 32.4%
H
2.6
17.4
|
L
 -5.8%
H
0.9
18.8
|
| Crinetics Pharma Inc |
|
8,881.1
|
83.9
|
L
 0.0%
H
83.8
84
|
L
 0.4%
H
83.6
84
|
L
 139.7%
H
34.7
84
|
L
 115.0%
H
32.3
84
|
L
 163.0%
H
25.8
84
|
L
 311.9%
H
15.8
84
|
L
 325.5%
H
15.2
84
|
L
H
10.6
84
|
| Cronos Grp Inc |
|
1,027.6
|
2.8
|
L
 0.4%
H
2.7
2.8
|
L
 -1.1%
H
2.7
2.8
|
L
 5.8%
H
2.6
2.9
|
L
 2.6%
H
2.5
3.3
|
L
 36.8%
H
1.9
3.4
|
L
 44.0%
H
1.6
3.4
|
L
 -61.7%
H
1.6
7.8
|
L
 1045.8%
H
0.2
25.1
|
| CRISPR Therapeutics AG |
|
4,783.4
|
48.6
|
L
 -5.5%
H
47.9
50.8
|
L
 -13.8%
H
47.9
56.7
|
L
 -6.6%
H
47.9
63.5
|
L
 -12.8%
H
46.9
63.5
|
L
 -11.9%
H
44.1
78.5
|
L
 -14.7%
H
30.0
91.1
|
L
 -61.5%
H
30.0
142.6
|
L
H
11.6
220.2
|
| Corvus Pharma Inc |
|
1,200.0
|
14.3
|
L
 -4.4%
H
14.0
14.8
|
L
 -11.9%
H
14.0
16.2
|
L
 21.6%
H
11.7
16.5
|
L
 -5.1%
H
10.8
19.7
|
L
 235.8%
H
4.0
27.0
|
L
 480.1%
H
1.1
27.0
|
L
 517.7%
H
0.6
27.0
|
L
 1.6%
H
0.6
27.0
|
| Champions Oncology Inc |
|
81.1
|
5.8
|
L
 1.0%
H
5.7
6.1
|
L
 0.5%
H
5.6
6.2
|
L
 -15.1%
H
5.6
7
|
L
 -4.3%
H
5.6
7
|
L
 -25.1%
H
5.5
8.7
|
L
 -11.6%
H
3.6
12.0
|
L
 -35.9%
H
3.6
12.0
|
L
 170.4%
H
1.1
17.9
|
| CytomX Therapeutics Inc |
|
796.8
|
3.7
|
L
 -0.5%
H
3.5
3.7
|
L
 -7.6%
H
3.5
4.0
|
L
 24.9%
H
2.9
4.0
|
L
 -25.2%
H
2.8
5.1
|
L
 53.1%
H
1.7
8.2
|
L
 101.1%
H
0.4
8.2
|
L
 -36.8%
H
0.4
8.2
|
L
 -65.8%
H
0.4
35
|
| Cue Biopharma Inc |
|
116.7
|
27.8
|
L
 -2.5%
H
26.7
28.9
|
L
 -23.9%
H
26.7
45.5
|
L
 16.3%
H
23.9
45.5
|
L
 50.6%
H
10.8
45.5
|
L
 8.2%
H
5.0
45.5
|
L
 -79.2%
H
5.0
146.7
|
L
 -90.9%
H
5.0
552.6
|
L
H
5.0
950.7
|
| Cadrenal Therapeutics Inc |
|
7.2
|
2.3
|
L
 -0.9%
H
2.3
2.6
|
L
 -22.6%
H
2.3
3.2
|
L
 -23.4%
H
2.3
3.9
|
L
 -52.0%
H
2.3
7.3
|
L
 -79.1%
H
2.3
14.6
|
L
 80.6%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Cyclacel Pharma Inc |
|
5.2
|
1.0
|
L
 5.6%
H
0.8
1.0
|
L
 3.3%
H
0.8
1.0
|
L
 15.9%
H
0.6
1.2
|
L
 -9.5%
H
0.6
2.8
|
L
 -88.4%
H
0.6
19.9
|
L
 -100.0%
H
0.6
3168
|
L
 -100.0%
H
0.6
21960
|
L
 -100.0%
H
0.6
784800
|
| Cyclerion Therapeutics Inc |
|
15.8
|
3.7
|
L
 -1.4%
H
3.6
3.8
|
L
 -6.9%
H
3.5
3.9
|
L
 15.1%
H
3.0
4.0
|
L
 22.8%
H
2.8
4.0
|
L
 20%
H
1.0
8.5
|
L
 -10.7%
H
1.0
8.5
|
L
 -94.5%
H
1.0
84.6
|
L
H
1.0
457
|
| Cytokinetics Inc |
|
10,910.5
|
80.4
|
L
 -2.7%
H
79.8
83.7
|
L
 -6.6%
H
79.8
86.5
|
L
 6.9%
H
75.8
88.3
|
L
 22.8%
H
58.6
88.3
|
L
 107.8%
H
32.9
88.3
|
L
 130.1%
H
26.0
110
|
L
 317.9%
H
26.0
110
|
L
 712.5%
H
5.8
110
|
| Cellectis (ADR) |
|
268.9
|
2.7
|
L
 -5.0%
H
2.7
2.8
|
L
 -15.8%
H
2.7
3.1
|
L
 -12.5%
H
2.7
3.4
|
L
 -37.5%
H
2.7
4.5
|
L
 34.2%
H
1.8
5.5
|
L
 19.2%
H
1.0
5.5
|
L
 -81.1%
H
1.0
15.5
|
L
 -89.7%
H
1.0
38.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
11.1
|
1.5
|
L
H
1.5
1.6
|
L
 -16.9%
H
1.5
1.8
|
L
 -7.3%
H
1.5
2.8
|
L
 -9.0%
H
1.5
2.8
|
L
 -66.7%
H
1.4
4.8
|
L
 -73.0%
H
1.4
10.2
|
L
 -97.9%
H
1.4
77.6
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
1,677.4
|
12.4
|
L
 -6.6%
H
12.3
14.6
|
L
 -8.6%
H
12.3
14.6
|
L
 8.2%
H
11.5
15.4
|
L
 86.6%
H
6.6
15.4
|
L
 216.3%
H
3.8
15.4
|
L
 36.9%
H
2.3
15.4
|
L
 -64.5%
H
2.3
49.5
|
L
H
2.3
61.7
|
| Connect Biopharma Holdings Ltd (ADR) |
|
130.4
|
2.3
|
L
 -3.7%
H
2.3
2.4
|
L
 -12.0%
H
2.2
2.8
|
L
 17.6%
H
1.9
2.8
|
L
 -21.7%
H
1.9
3.1
|
L
 44.4%
H
1.2
3.8
|
L
 116.7%
H
0.5
3.8
|
L
 -89.4%
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
29.1
|
1.9
|
L
 -6.3%
H
1.9
2.1
|
L
 -6.3%
H
1.9
2.1
|
L
 -8.1%
H
1.9
2.2
|
L
 -28.7%
H
1.9
3.8
|
L
 -26.0%
H
1.3
3.8
|
L
 -81.4%
H
0.3
10.9
|
L
 -89.0%
H
0.3
30.1
|
L
 -99.3%
H
0.3
429.6
|
| Journey Medical Corp |
|
195.8
|
7.1
|
L
 -2.2%
H
7.1
7.4
|
L
 1.6%
H
6.7
7.5
|
L
 16.4%
H
5.8
7.5
|
L
 37.5%
H
4.8
7.5
|
L
 -1.3%
H
4.3
9.6
|
L
 297.2%
H
1.6
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| DiaMedica Therapeutics Inc |
|
384.2
|
7.1
|
L
 -6.7%
H
7
7.6
|
L
 -7.5%
H
7
8.0
|
L
 25.3%
H
5.6
8.5
|
L
 7.7%
H
5.2
8.5
|
L
 79.2%
H
3.7
10.4
|
L
 88.6%
H
1.9
10.4
|
L
 85.7%
H
1.1
10.4
|
L
 35.8%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
3,607.5
|
22.7
|
L
 -1.3%
H
22.0
23
|
L
 -16.5%
H
22.0
27.1
|
L
 3.7%
H
22.0
27.3
|
L
 9.8%
H
17.7
27.3
|
L
 52.9%
H
12.6
27.3
|
L
 -22.5%
H
10.6
33.3
|
L
 -64.7%
H
10.6
66.8
|
L
H
10.6
93.9
|
| Dermata Therapeutics Inc |
|
5.1
|
1.3
|
L
 -1.5%
H
1.3
1.4
|
L
 -4.5%
H
1.3
1.4
|
L
 7.6%
H
1.2
1.5
|
L
 -5.2%
H
1.2
1.5
|
L
 82.9%
H
0.6
7.1
|
L
 -18.5%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| Bright Minds Biosciences Inc |
|
728.3
|
74.2
|
L
 -2.2%
H
73
77.7
|
L
 -5.1%
H
71.0
78.3
|
L
 24.1%
H
58.1
78.9
|
L
 -16.3%
H
56.5
92.4
|
L
 199.1%
H
24.6
123.8
|
L
 1917.1%
H
0.9
123.8
|
L
 233.6%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
787.6
|
12.6
|
L
 -6.7%
H
12.3
14.2
|
L
 -18.2%
H
12.3
15.6
|
L
 17.6%
H
10.8
15.9
|
L
 0.8%
H
9.9
17.3
|
L
 203.9%
H
3.8
17.3
|
L
 81.7%
H
1.9
17.3
|
L
 -29.0%
H
1.9
26.3
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
214.7
|
8.3
|
L
 -5.6%
H
8.2
8.8
|
L
 -9.2%
H
8.0
9.2
|
L
 31.9%
H
6.3
9.6
|
L
 10.5%
H
6
9.6
|
L
 84.1%
H
3.5
9.6
|
L
 1123.5%
H
0.3
19.4
|
L
 -21.2%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
3,755.9
|
22.7
|
L
 -5.3%
H
21.3
23.8
|
L
 -6.4%
H
21.3
24.3
|
L
 25.7%
H
18.2
24.6
|
L
 14.1%
H
15.9
24.6
|
L
 143.5%
H
8.9
25
|
L
 104.7%
H
6.4
47.5
|
L
 19.6%
H
4.3
47.5
|
L
H
4.3
47.5
|
| DBV Tech (ADR) |
|
879.5
|
14.9
|
L
 -5.4%
H
14.8
16.1
|
L
 -7.6%
H
14.8
16.7
|
L
 -11.3%
H
14.8
17.4
|
L
 -27.9%
H
14.8
21.6
|
L
 51.8%
H
8.5
26.2
|
L
 -13.6%
H
0.5
26.2
|
L
 -71.6%
H
0.5
59.9
|
L
 -95.6%
H
0.5
505.7
|
| Editas Medicine Inc |
|
442.0
|
2.9
|
L
 -5.3%
H
2.8
3.0
|
L
 -12.7%
H
2.8
3.3
|
L
 22.0%
H
2.4
3.8
|
L
 -14.0%
H
2.4
3.9
|
L
 1.4%
H
1.7
4.5
|
L
 -66.6%
H
0.9
11.7
|
L
 -93.2%
H
0.9
73.0
|
L
 -88.4%
H
0.9
100.0
|
| Edesa Biotech Inc |
|
64.7
|
6.7
|
L
 -2.2%
H
6.5
6.9
|
L
 -4.3%
H
6.5
7.2
|
L
 7.2%
H
6.3
8.9
|
L
 30.7%
H
4.6
20.3
|
L
 197.4%
H
0.7
20.3
|
L
 15.7%
H
0.7
20.3
|
L
 -80.8%
H
0.7
84
|
L
 -99.3%
H
0.7
1005.5
|
| Eledon Pharma Inc |
|
296.4
|
3.8
|
L
 -4.5%
H
3.8
4.1
|
L
 -7.0%
H
3.8
4.1
|
L
 10.3%
H
3.5
4.5
|
L
 3.0%
H
3.3
4.5
|
L
 1.6%
H
1.4
4.6
|
L
 166.7%
H
1.1
5.4
|
L
 -46.0%
H
1.1
8.5
|
L
 -99.6%
H
1.1
900.7
|
| Eloxx Pharma |
|
41.3
|
12.0
|
L
 -4.5%
H
11.4
14.3
|
L
 1.0%
H
11
14.3
|
L
 -5.7%
H
10
15.9
|
L
 195.3%
H
8.2
17.5
|
L
 195.3%
H
8.2
17.5
|
L
 50.8%
H
0
17.5
|
L
 -78.2%
H
0
75.6
|
L
 -92.5%
H
0
984
|
| Elicio Therapeutics Inc |
|
84.0
|
3.2
|
L
 5.3%
H
3.0
3.3
|
L
 -8.3%
H
2.9
3.6
|
L
 15.9%
H
2.8
6.6
|
L
 -74.6%
H
2.7
16
|
L
 -64.6%
H
2.7
16
|
L
 -69.0%
H
2.7
16
|
L
 -97.1%
H
2.7
141.8
|
L
H
2.7
263
|
| Enliven Therapeutics Inc |
|
3,633.4
|
50.9
|
L
 -4.3%
H
50.0
53.9
|
L
 -2.5%
H
49.5
53.9
|
L
 19.5%
H
42.2
53.9
|
L
 12.2%
H
33.5
53.9
|
L
 137%
H
14.8
53.9
|
L
 181.3%
H
9.8
53.9
|
L
 128.7%
H
3.9
53.9
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
720.4
|
12.6
|
L
 -9.3%
H
12.0
13.8
|
L
 -9.0%
H
12.0
14.3
|
L
 17.5%
H
10.8
14.4
|
L
 42.6%
H
7.9
14.4
|
L
 798.6%
H
1.4
14.4
|
L
 344.5%
H
1.1
14.4
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
80.0
|
4.8
|
L
 -18.7%
H
4.7
5.9
|
L
 -35.8%
H
4.7
7.4
|
L
 654.0%
H
0.4
7.6
|
L
 433.7%
H
0.4
7.6
|
L
 286.2%
H
0.4
7.6
|
L
 99.6%
H
0.4
7.6
|
L
 -36.3%
H
0.4
14.0
|
L
 -92.7%
H
0.4
81.6
|
| Enochian Biosciences Inc |
|
-
|
2.9
|
L
 -3.4%
H
2.8
3.0
|
L
 5.5%
H
2.7
3.0
|
L
 1.4%
H
2.7
5.0
|
L
 860%
H
0.2
5.0
|
L
 747.1%
H
0.1
5.0
|
L
 405.3%
H
0.1
5.0
|
L
 -37.0%
H
0.1
13.8
|
L
 15.7%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
4.3
|
0.3
|
L
 -3.5%
H
0.3
0.3
|
L
H
0.2
0.3
|
L
H
0.2
0.3
|
L
 -45.1%
H
0.2
0.5
|
L
 -87.0%
H
0.2
2.8
|
L
 -85.7%
H
0.1
9.9
|
L
 -100.0%
H
0.1
2318.5
|
L
H
0.1
5757.6
|
| Enanta Pharma Inc |
|
383.5
|
13.2
|
L
 -0.3%
H
12.9
13.6
|
L
 -7.4%
H
12.8
14.5
|
L
 9.3%
H
12.1
15.5
|
L
 -6.2%
H
10.9
15.9
|
L
 86.0%
H
6.5
17.2
|
L
 -31.4%
H
4.1
20.0
|
L
 -68.5%
H
4.1
102
|
L
 -40.2%
H
4.1
127.8
|
| Entera Bio Ltd |
|
98.6
|
2
|
L
 12.4%
H
1.8
2.1
|
L
 17.7%
H
1.6
2.1
|
L
 69.5%
H
1.2
2.8
|
L
 66.7%
H
1.1
2.8
|
L
 -2.0%
H
0.9
3.2
|
L
 135.3%
H
0.5
3.4
|
L
 -61.8%
H
0.5
5.8
|
L
H
0.5
10.2
|
| Enveric Biosciences Inc |
|
5.5
|
1.4
|
L
 3.0%
H
1.3
1.5
|
L
 -4.9%
H
1.3
1.5
|
L
 -0.7%
H
1.3
1.6
|
L
 -42.1%
H
1.3
7.9
|
L
 -91.0%
H
1.3
17.6
|
L
 -99.7%
H
1.3
701.6
|
L
 -100.0%
H
1.3
33660
|
L
 -100.0%
H
1.3
12150000
|
| Evolus Inc |
|
370.8
|
5.6
|
L
 -5.5%
H
5.6
6.0
|
L
 -17.8%
H
5.6
6.9
|
L
 -15.1%
H
5.6
7.3
|
L
 24.3%
H
4.6
7.3
|
L
 -38.8%
H
3.9
10.2
|
L
 -23.9%
H
3.9
17.8
|
L
 -49.3%
H
3.9
17.8
|
L
H
2.9
39.5
|
| Equillium Inc |
|
158.1
|
2.5
|
L
 -4.6%
H
2.5
2.7
|
L
 -15.5%
H
2.5
3.1
|
L
 -9.1%
H
2.5
3.5
|
L
 26.3%
H
1.8
3.5
|
L
 495.2%
H
0.4
3.5
|
L
 190.7%
H
0.3
3.5
|
L
 -55.4%
H
0.3
7.1
|
L
H
0.3
27.1
|
| Erasca Inc |
|
6,602.4
|
19.0
|
L
 -10.5%
H
18.8
20.9
|
L
 -0.8%
H
17.6
21.6
|
L
 42.2%
H
13.4
21.6
|
L
 4.3%
H
8.7
24.3
|
L
 1220.8%
H
1.3
24.3
|
L
 623.2%
H
1.0
24.3
|
L
 9.1%
H
1.0
24.5
|
L
H
1.0
24.5
|
| Eterna Therapeutics Inc |
|
8.3
|
7.1
|
L
 5.8%
H
6.7
7.6
|
L
 20.1%
H
5.5
9.9
|
L
 16.7%
H
5.2
9.9
|
L
 44.7%
H
3.2
15.9
|
L
 -85.5%
H
3.2
71.5
|
L
 -99.3%
H
3.2
1110
|
L
 -100.0%
H
3.2
102225
|
L
 -100.0%
H
3.2
605025
|
| Eton Pharma Inc |
|
1,018.7
|
37.2
|
L
 -3.4%
H
36.9
39.5
|
L
 -0.4%
H
35
39.5
|
L
 15.0%
H
31.4
39.5
|
L
 52.2%
H
22.5
39.5
|
L
 167.8%
H
13.8
39.5
|
L
 1152.2%
H
2.4
39.5
|
L
 583.6%
H
2.0
39.5
|
L
H
2.0
39.5
|
| Evogene Ltd |
|
7.0
|
0.6
|
L
H
0.5
0.6
|
L
 16%
H
0.4
0.6
|
L
 3.6%
H
0.4
0.6
|
L
 -27.5%
H
0.4
0.9
|
L
 -53.6%
H
0.4
1.5
|
L
 -95.9%
H
0.4
12
|
L
 -98.1%
H
0.4
35.8
|
L
 -99.1%
H
0.4
102.4
|
| Edgewise Therapeutics Inc |
|
4,109.0
|
38.2
|
L
 -6.5%
H
37.4
40.7
|
L
 -21.0%
H
37.4
48.1
|
L
 12.5%
H
33.7
48.4
|
L
 15.3%
H
30.1
48.4
|
L
 180.0%
H
12.3
48.4
|
L
 428.9%
H
5.1
48.4
|
L
 93.3%
H
5.1
48.4
|
L
H
5.1
48.4
|
| Exelixis Inc |
|
13,995.5
|
55.7
|
L
 0.2%
H
55.3
56.8
|
L
 -2.5%
H
54.4
57.3
|
L
 6.9%
H
50.8
57.6
|
L
 25.5%
H
43.5
57.6
|
L
 24.3%
H
33.8
57.6
|
L
 187.2%
H
18.6
57.6
|
L
 231.4%
H
14.9
57.6
|
L
 559.7%
H
8.3
57.6
|
| Hyperion DeFi Inc |
|
41.7
|
2.8
|
L
 -8.9%
H
2.8
3.0
|
L
 -11.9%
H
2.8
3.2
|
L
 -15.1%
H
2.8
4
|
L
 -29.7%
H
2.5
5.0
|
L
 -82.8%
H
2.5
15.9
|
L
 -98.6%
H
0.0
205.6
|
L
 -99.2%
H
0.0
530.4
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,093.3
|
13.0
|
L
 -5.9%
H
12.9
14.2
|
L
 -12.1%
H
12.9
14.8
|
L
 1.2%
H
12.8
15.9
|
L
 -12.0%
H
11.3
15.9
|
L
 29.6%
H
9.4
19.1
|
L
 18.9%
H
3.9
31.0
|
L
 69.8%
H
2.2
31.0
|
L
 -62.0%
H
2.2
42.5
|
| Evaxion Biotech A/S (ADR) |
|
26.0
|
3.1
|
L
 2.3%
H
3
3.3
|
L
 -2.5%
H
3.0
3.3
|
L
 -8.8%
H
3.0
3.6
|
L
 -24.6%
H
3.0
4.8
|
L
 19.1%
H
2.5
12.2
|
L
 -75.2%
H
0.8
13.8
|
L
 -94.4%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
318.2
|
2.7
|
L
 -8.7%
H
2.7
2.9
|
L
 -12.2%
H
2.7
3.2
|
L
 43.7%
H
1.8
3.2
|
L
 99.3%
H
1.2
3.2
|
L
 141.6%
H
0.9
3.2
|
L
 -42.3%
H
0.7
8.8
|
L
 -96.5%
H
0.7
97.4
|
L
 52.5%
H
0.7
121.2
|
| Fortress Biotech Inc |
|
113.6
|
3.4
|
L
 -7.8%
H
3.4
3.7
|
L
 4.0%
H
3.1
3.8
|
L
 16.7%
H
2.7
3.8
|
L
 45.5%
H
2.2
3.8
|
L
 73.6%
H
1.8
4.5
|
L
 -56.2%
H
1.2
10.4
|
L
 -92.6%
H
1.2
57.2
|
L
 -92.2%
H
1.2
91.5
|
| Forte Biosciences Inc |
|
921.3
|
45.0
|
L
 1.9%
H
40.7
46.4
|
L
 22.6%
H
37.5
46.4
|
L
 162.3%
H
16.9
46.4
|
L
 43.1%
H
15.5
46.4
|
L
 364.8%
H
9.1
46.4
|
L
 80.0%
H
4.1
46.4
|
L
 -94.2%
H
4.1
921.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
566.7
|
10.8
|
L
 -7.2%
H
10.8
11.6
|
L
 -15.9%
H
10.8
13.0
|
L
 25.0%
H
8.7
14
|
L
 7.8%
H
8.1
14
|
L
 154.5%
H
4.1
14
|
L
 -42.7%
H
2.2
36.3
|
L
 -55.4%
H
2.2
36.3
|
L
H
2.2
55.1
|
| Fennec Pharma Inc |
|
362.7
|
10.4
|
L
 -1.5%
H
10.4
10.8
|
L
 1.3%
H
10.1
11.2
|
L
 16.5%
H
8.9
11.3
|
L
 65.7%
H
6.1
11.3
|
L
 17.0%
H
5.7
11.3
|
L
 18.9%
H
4.0
11.9
|
L
 58.7%
H
3.8
11.9
|
L
 374.5%
H
1.6
15.0
|
| Kyntra Bio Inc |
|
29.9
|
7.4
|
L
 2.5%
H
7.2
7.5
|
L
 1.0%
H
7.2
7.7
|
L
 7.0%
H
6.7
7.8
|
L
 2.8%
H
6.6
8.0
|
L
 -1.7%
H
6.3
12.6
|
L
 -88.5%
H
4.5
73.3
|
L
 -97.9%
H
4.5
642.3
|
L
 -98.3%
H
4.5
1713.8
|
| Foghorn Therapeutics Inc |
|
297.7
|
5.1
|
L
 -7.0%
H
4.9
5.4
|
L
 -15.6%
H
4.9
6.1
|
L
 26.4%
H
4.0
6.6
|
L
 4.3%
H
3.5
6.6
|
L
 -13.8%
H
3.3
7.0
|
L
 -35%
H
2.7
10.2
|
L
 -47.2%
H
2.7
24.3
|
L
H
2.7
28.3
|
| Q32 Bio Inc |
|
349.6
|
15.2
|
L
 -3.1%
H
14.7
16.0
|
L
 20.8%
H
10.8
23.6
|
L
 19.3%
H
10.6
23.6
|
L
 165.9%
H
4.8
23.6
|
L
 447.1%
H
1.6
23.6
|
L
 -11.1%
H
1.3
53.8
|
L
 -86.8%
H
1.3
160.2
|
L
H
1.3
572.4
|
| ZeroStack Corp |
|
4.5
|
1.9
|
L
 -2.6%
H
1.9
1.9
|
L
 -24.9%
H
1.8
2.5
|
L
 -59.7%
H
1.8
4.8
|
L
 -72.9%
H
1.8
7.6
|
L
 -92.5%
H
1.8
47
|
L
 -98.1%
H
1.8
213.7
|
L
 -99.9%
H
1.8
16731
|
L
H
1.8
16731
|
| Frequency Therapeutics Inc |
|
-
|
12.3
|
L
 -5.8%
H
12.1
13.1
|
L
 -14.1%
H
12.1
14.7
|
L
 15.2%
H
10.7
15.6
|
L
 -8.8%
H
9.1
15.6
|
L
 -6.7%
H
5.2
55.9
|
L
 -65.4%
H
5.2
55.9
|
L
 -96.9%
H
5.2
430
|
L
H
5.2
2918.5
|
| Fulcrum Therapeutics Inc |
|
233.2
|
3.5
|
L
 -1.7%
H
3.5
3.8
|
L
 -2.5%
H
3.4
3.8
|
L
 1.2%
H
3.4
4.0
|
L
 -56.2%
H
2.8
8.4
|
L
 -55.6%
H
2.8
15.7
|
L
 -4.9%
H
2.3
15.7
|
L
 -63.7%
H
2.3
33.1
|
L
H
2.3
33.1
|
| First Wave BioPharma Inc |
|
5.9
|
3.8
|
L
 -5.9%
H
3.8
4.1
|
L
 -8.4%
H
3.7
4.5
|
L
 -25.2%
H
3.7
5.7
|
L
 56.2%
H
2.1
6.9
|
L
 746.7%
H
0.4
6.9
|
L
 -79.9%
H
0.4
22.2
|
L
 -100.0%
H
0.4
35991.6
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
277.9
|
4.2
|
L
 -11.3%
H
4.2
4.7
|
L
 -3.4%
H
4.0
5.6
|
L
 59.9%
H
2.6
5.6
|
L
 86.7%
H
2.0
5.6
|
L
 48.1%
H
2.0
7.1
|
L
 158.9%
H
0.7
7.1
|
L
 58.6%
H
0.7
7.1
|
L
 177.6%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
70.8
|
1.7
|
L
 -1.2%
H
1.6
1.7
|
L
 -8.8%
H
1.6
1.9
|
L
 -7.3%
H
1.6
2.2
|
L
 -19.0%
H
1.5
2.2
|
L
 2.5%
H
1.4
4.3
|
L
 -62.6%
H
0.9
5.3
|
L
 -82.5%
H
0.9
9.8
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
12.1
|
1.0
|
L
H
0.9
1.0
|
L
 4.1%
H
0.9
1.1
|
L
 -8.1%
H
0.9
1.2
|
L
H
0.7
1.4
|
L
 -49.5%
H
0.7
3.7
|
L
 -76.5%
H
0.7
5.5
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
911.0
|
1.4
|
L
H
1.4
1.5
|
L
 -9.0%
H
1.4
1.6
|
L
 20.3%
H
1.2
1.6
|
L
 -16.0%
H
1.1
1.7
|
L
 11.8%
H
1.0
2.0
|
L
 -55.9%
H
1.0
5.3
|
L
 11.8%
H
1.0
5.3
|
L
 -46.6%
H
0.8
7.0
|
| GH Research PLC |
|
1,998.6
|
29.1
|
L
 8.2%
H
28.1
31
|
L
 7.1%
H
25
31
|
L
 45.8%
H
20.0
31
|
L
 64.2%
H
17.6
31
|
L
 68.5%
H
11.3
31
|
L
 124.1%
H
5.1
31
|
L
 66.5%
H
5.1
31
|
L
H
5.1
31
|
| Gilead Sciences |
|
169,226.0
|
136.3
|
L
 3.5%
H
131.3
136.4
|
L
 1.1%
H
127.9
136.4
|
L
 7.1%
H
122.4
137.7
|
L
 -1.6%
H
121.4
139.8
|
L
 24.1%
H
107.8
157.3
|
L
 76.6%
H
62.1
157.3
|
L
 98.6%
H
57.2
157.3
|
L
 57.3%
H
56.6
157.3
|
| Galmed Pharma Ltd |
|
4.2
|
0.6
|
L
 7.8%
H
0.5
0.6
|
L
 -3.5%
H
0.5
0.6
|
L
 -8.3%
H
0.5
0.7
|
L
 -25.7%
H
0.4
0.8
|
L
 -74.9%
H
0.4
2.3
|
L
 -96.8%
H
0.2
18
|
L
 -99.9%
H
0.2
615.6
|
L
 -99.9%
H
0.2
4870.8
|
| Greenwich LifeSciences Inc |
|
279.0
|
19.0
|
L
 -2.7%
H
18.6
21.7
|
L
 -2.9%
H
18.2
21.7
|
L
 -20.4%
H
16.5
25.5
|
L
 -29.9%
H
16.5
30.3
|
L
 69.9%
H
7.8
34.1
|
L
 103.5%
H
7.6
34.1
|
L
 -53.7%
H
6.8
48.5
|
L
H
3.3
158.1
|
| Galecto Inc |
|
1,861.4
|
30.2
|
L
 -2.3%
H
29.6
31.3
|
L
 -1.8%
H
26.3
31.8
|
L
 46.9%
H
20.1
31.8
|
L
 12%
H
18.6
31.8
|
L
 764%
H
2.5
38.3
|
L
 1160%
H
0.5
38.3
|
L
 626.9%
H
0.5
38.3
|
L
H
0.5
38.3
|
| Monte Rosa Therapeutics Inc |
|
1,956.5
|
23.2
|
L
 -1.1%
H
22.7
23.5
|
L
 -5.6%
H
20.9
24.2
|
L
 30.4%
H
17.9
25.2
|
L
 23.9%
H
16.1
25.2
|
L
 312.8%
H
4.1
25.8
|
L
 232.3%
H
2.4
25.8
|
L
 20.1%
H
2.4
45.6
|
L
H
2.4
45.6
|
| GlycoMimetics Inc |
|
975.1
|
15.1
|
L
 -3.6%
H
15
16.9
|
L
 -9.8%
H
14.7
17.6
|
L
 -15.8%
H
14.7
19.2
|
L
 -22.3%
H
14.7
27.4
|
L
 15.0%
H
8.7
27.4
|
L
 -90.8%
H
8.7
353
|
L
 -92.6%
H
8.7
416
|
L
 -98.1%
H
8.7
2605
|
| Genelux Corp |
|
126.4
|
2.8
|
L
 -3.1%
H
2.8
2.9
|
L
 -5.4%
H
2.8
3.0
|
L
 -6.9%
H
2.7
3.2
|
L
 1.8%
H
2.5
3.3
|
L
 -7.8%
H
2.3
8.5
|
L
 -91.1%
H
1.6
32.9
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
4.0
|
8
|
L
 -25.9%
H
7.7
10.0
|
L
 1328.6%
H
0.5
10.0
|
L
 1718.2%
H
0.4
10.0
|
L
 515.4%
H
0.4
10.0
|
L
 2658.6%
H
0.1
13.0
|
L
 875.6%
H
0.1
13.0
|
L
 175.9%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
83.1
|
0.2
|
L
 6.3%
H
0.1
0.2
|
L
 -5.6%
H
0.1
0.2
|
L
H
0.1
0.2
|
L
 -61.4%
H
0.1
0.5
|
L
 -89.8%
H
0.1
3.9
|
L
 -88.6%
H
0.1
3.9
|
L
 -97.7%
H
0.1
15.2
|
L
H
0.1
27.2
|
| Geovax Labs Inc |
|
4.5
|
0.9
|
L
 -13.9%
H
0.8
1.0
|
L
 -25.6%
H
0.8
1.2
|
L
 -25.6%
H
0.8
1.4
|
L
 -29.3%
H
0.8
4.4
|
L
 -95.3%
H
0.8
23.1
|
L
 -99.6%
H
0.8
276.8
|
L
 -99.9%
H
0.8
2812.5
|
L
 -100.0%
H
0.8
379518072.3
|
| GRI Bio Inc |
|
2.7
|
1.5
|
L
 -4.9%
H
1.5
1.6
|
L
 -13.5%
H
1.5
1.8
|
L
 -29.0%
H
1.5
2.3
|
L
 -38.2%
H
1.5
2.7
|
L
 -97.3%
H
1.5
80.4
|
L
 -100.0%
H
1.5
176296.1
|
L
 -100.0%
H
1.5
13462627.3
|
L
H
1.5
13462627.3
|
| Graphite Bio Inc |
|
284.2
|
4.9
|
L
 -2.2%
H
4.7
5.0
|
L
 -15.7%
H
4.7
5.9
|
L
 -25.2%
H
4.7
6.8
|
L
 -49.4%
H
4.7
10.6
|
L
 -86.1%
H
4.7
50.4
|
L
 -96.2%
H
4.7
413
|
L
 -99.6%
H
4.7
1420.5
|
L
H
4.7
1666
|
| GT Biopharma Inc |
|
13.7
|
0.4
|
L
 8.6%
H
0.3
0.4
|
L
 -15.6%
H
0.3
0.5
|
L
 -15.6%
H
0.3
0.6
|
L
 -5%
H
0.3
0.6
|
L
 -81.4%
H
0.3
2.3
|
L
 15.2%
H
0.2
10.7
|
L
 -96.9%
H
0.2
13
|
L
 -100.0%
H
0.2
1887
|
| Galapagos NV (ADR) |
|
1,950.6
|
29.6
|
L
 0.4%
H
29.6
29.9
|
L
 -3.2%
H
29.4
30.5
|
L
 5.0%
H
28
30.9
|
L
 2.6%
H
26.4
30.9
|
L
 -2.2%
H
26.4
37.8
|
L
 -29.2%
H
22.4
44.3
|
L
 -50.7%
H
22.4
72.1
|
L
 -44.3%
H
22.4
274.0
|
| Genmab (ADR) |
|
17,791.9
|
29.0
|
L
 -0.3%
H
28.5
29.1
|
L
 -2.7%
H
28.4
29.5
|
L
 17.1%
H
24.9
29.8
|
L
 2.4%
H
23.6
29.8
|
L
 32.5%
H
21
35.4
|
L
 -27.6%
H
17.2
42.7
|
L
 -32.9%
H
17.2
49.1
|
L
 70.4%
H
12.1
49.1
|
| Genenta Science SpA (ADR) |
|
69.4
|
1.4
|
L
 -4%
H
1.4
1.5
|
L
 -9.4%
H
1.2
1.6
|
L
 -23.0%
H
1.2
2.0
|
L
 100%
H
0.6
2.6
|
L
 -62.6%
H
0.6
10
|
L
 -75.8%
H
0.6
10
|
L
H
0.6
13.1
|
L
H
0.6
13.1
|
| Structure Therapeutics Inc (ADR) |
|
3,271.6
|
46.0
|
L
 -7.2%
H
46.0
49.5
|
L
 -16.5%
H
46.0
55.0
|
L
 7.3%
H
42.8
57.1
|
L
 -14.0%
H
35.8
57.1
|
L
 134.9%
H
15.8
94.9
|
L
 36.6%
H
13.2
94.9
|
L
H
13.2
94.9
|
L
H
13.2
94.9
|
| Grifols SA (ADR) - Level III |
|
4,988.6
|
7.3
|
L
 1.7%
H
7.2
7.4
|
L
 0.6%
H
7
7.4
|
L
 -3.4%
H
7.0
7.6
|
L
 -14.8%
H
7.0
8.8
|
L
 -27.4%
H
7.0
11.1
|
L
 -22.4%
H
5.3
12.2
|
L
 -53.3%
H
5.3
16.4
|
L
 -56.1%
H
5.3
25.7
|
| Halozyme Therapeutics Inc |
|
9,197.3
|
77.5
|
L
 2.3%
H
75.5
77.9
|
L
 -1.4%
H
73.9
79.2
|
L
 11.3%
H
67.0
82.3
|
L
 16.4%
H
62.4
82.3
|
L
 33.7%
H
55.6
82.3
|
L
 102.9%
H
32.8
82.3
|
L
 84.4%
H
29.9
82.3
|
L
 774.2%
H
8.2
82.3
|
| HCW Biologics Inc |
|
6.5
|
4.1
|
L
 -5.6%
H
4.0
4.5
|
L
 -12.5%
H
4.0
4.8
|
L
 -40.6%
H
4.0
7.5
|
L
 61.8%
H
1.8
23.9
|
L
 -85.9%
H
1.5
44.1
|
L
 -100.0%
H
1.5
24192
|
L
H
1.5
74640
|
L
H
1.5
74640
|
| Hillstream BioPharma Inc |
|
27.5
|
2.3
|
L
 -2.1%
H
2.3
2.4
|
L
 2.2%
H
2.2
2.4
|
L
 -29.1%
H
2.2
3.6
|
L
 -33.0%
H
2.1
3.9
|
L
 43.6%
H
1.1
9.1
|
L
 -75.5%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Hoth Therapeutics Inc |
|
19.0
|
0.9
|
L
 -5.6%
H
0.8
0.9
|
L
 -6.6%
H
0.8
0.9
|
L
 -27.4%
H
0.8
1.2
|
L
 14.9%
H
0.5
2.5
|
L
 -36.6%
H
0.5
2.5
|
L
 -69.3%
H
0.5
3.8
|
L
 -97.5%
H
0.5
43.8
|
L
H
0.5
347
|
| Werewolf Therapeutics Inc |
|
18.0
|
0.4
|
L
 8.8%
H
0.3
0.4
|
L
 -2.6%
H
0.3
0.4
|
L
 2.8%
H
0.3
0.4
|
L
 -59.3%
H
0.3
1.0
|
L
 -72.6%
H
0.3
2.4
|
L
 -88.3%
H
0.3
8.2
|
L
 -97.7%
H
0.3
21.7
|
L
H
0.3
24.0
|
| Harmony Biosciences Holdings Inc |
|
1,941.1
|
33.5
|
L
 -3.9%
H
32.3
34.2
|
L
 -12.3%
H
32.3
38.5
|
L
 -0.9%
H
32.3
38.9
|
L
 14.0%
H
28.7
38.9
|
L
 -4.8%
H
25.5
40.9
|
L
 -5.1%
H
18.6
41.6
|
L
 19.5%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,672.9
|
44.9
|
L
 4.5%
H
42.8
46.4
|
L
 4.5%
H
40.9
46.4
|
L
 16.9%
H
38.5
46.6
|
L
 10.4%
H
28.5
46.6
|
L
 29.9%
H
28.5
54.9
|
L
 147.5%
H
7.6
59.2
|
L
 542.1%
H
5.4
59.2
|
L
 1116.3%
H
1.4
59.2
|
| Heron Therapeutics Inc |
|
90.9
|
0.5
|
L
 9.1%
H
0.4
0.5
|
L
 11.6%
H
0.4
0.5
|
L
 26.3%
H
0.4
0.5
|
L
 -48.9%
H
0.4
1.3
|
L
 -76.2%
H
0.4
2.1
|
L
 -62.2%
H
0.4
3.9
|
L
 -96.3%
H
0.4
13.3
|
L
 -97.2%
H
0.4
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
21.6
|
3.4
|
L
 -0.9%
H
3.3
3.5
|
L
 -1.2%
H
3.2
3.6
|
L
 -7.4%
H
3.1
4.4
|
L
 6.3%
H
3.1
10.8
|
L
 -85%
H
2.1
31.9
|
L
 -95.6%
H
2.1
109.2
|
L
 -96.7%
H
2.1
136.5
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
178.0
|
0.7
|
L
 -2.9%
H
0.6
0.7
|
L
 -5.7%
H
0.6
0.7
|
L
 -35.9%
H
0.6
1.1
|
L
 -2.9%
H
0.6
1.5
|
L
 -72.4%
H
0.6
2.8
|
L
 -78.2%
H
0.6
10.0
|
L
 -93.4%
H
0.6
17.5
|
L
H
0.6
17.5
|
| HUTCHMED (China) Ltd (ADR) |
|
1,996.3
|
11.6
|
L
 0.2%
H
11.6
11.7
|
L
 5.7%
H
11
11.8
|
L
 10.7%
H
9.8
11.8
|
L
 -24.4%
H
9.8
15.8
|
L
 -32.2%
H
9.8
19.5
|
L
 -10.3%
H
9.8
21.9
|
L
 -70.6%
H
7.4
43.9
|
L
 -13.9%
H
7.4
43.9
|
| ImmunityBio Inc |
|
7,802.8
|
7.5
|
L
 -3.6%
H
7.3
7.7
|
L
 -16.0%
H
7.3
8.9
|
L
 10.9%
H
6.7
9.6
|
L
 2.8%
H
6.7
9.6
|
L
 170.9%
H
2.0
12.4
|
L
 168.0%
H
1.3
12.4
|
L
 -31.2%
H
1.2
12.4
|
L
H
1.2
40.8
|
| Immucell Corp |
|
100.7
|
11.1
|
L
 3.7%
H
10.7
11.4
|
L
 -2.9%
H
10.7
12.1
|
L
 18.7%
H
9.3
12.1
|
L
 47.6%
H
7.5
12.1
|
L
 72.3%
H
4.5
12.1
|
L
 118.7%
H
3.3
12.1
|
L
 22.0%
H
3.3
12.1
|
L
 62.5%
H
3.3
13.2
|
| Ideaya Biosciences Inc |
|
3,459.2
|
35.9
|
L
 -2.2%
H
35.4
36.9
|
L
 -3.6%
H
35.4
37.4
|
L
 17.5%
H
30.5
40.6
|
L
 10.5%
H
26.8
40.6
|
L
 62.2%
H
21.3
40.6
|
L
 58.5%
H
13.5
47.7
|
L
 92.7%
H
8.1
47.7
|
L
H
3.0
47.7
|
| InflaRx N.V. |
|
281.3
|
1.9
|
L
 -5.5%
H
1.9
2.1
|
L
 -7.3%
H
1.9
2.1
|
L
 19.4%
H
1.6
2.6
|
L
 59.2%
H
1.2
3.0
|
L
 124.7%
H
0.7
3.0
|
L
 -54.0%
H
0.7
4.3
|
L
 -26.8%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
61.5
|
5.5
|
L
 -9.3%
H
5.4
6.0
|
L
 -7.6%
H
5.4
6.3
|
L
H
5.4
6.3
|
L
 -5.7%
H
5.1
6.3
|
L
 -64.8%
H
3.9
18
|
L
 -92.6%
H
3.9
77.2
|
L
 -96.6%
H
3.9
211.2
|
L
H
3.9
451.3
|
| Inhibikase Therapeutics Inc |
|
315.6
|
2.0
|
L
 -2.4%
H
2.0
2.1
|
L
 -1.5%
H
1.9
2.4
|
L
 20.4%
H
1.7
2.4
|
L
 18.2%
H
1.5
2.4
|
L
 8.1%
H
1.3
2.4
|
L
 -28.7%
H
0.8
4.2
|
L
 -86.2%
H
0.8
16.4
|
L
H
0.8
70.8
|
| Immix Biopharma Inc |
|
716.2
|
10.1
|
L
 -4.5%
H
9.8
10.5
|
L
 -9.3%
H
9.8
11.2
|
L
 15.1%
H
8.6
12.1
|
L
 1%
H
7.7
12.1
|
L
 241.0%
H
1.9
12.1
|
L
 339.3%
H
1.3
12.1
|
L
H
0.7
12.1
|
L
H
0.7
12.1
|
| Immunome Inc |
|
2,514.2
|
22.2
|
L
 -3.1%
H
21.6
23.4
|
L
 -8.2%
H
21.6
24.2
|
L
 24.0%
H
18.0
25
|
L
 -4.6%
H
17.8
25
|
L
 129.6%
H
8.7
27.7
|
L
 185.7%
H
5.2
31.0
|
L
 43.0%
H
2.1
31.0
|
L
H
2.1
63.8
|
| Imunon Inc |
|
7.9
|
1.9
|
L
 -2.1%
H
1.9
2.0
|
L
 -6.0%
H
1.9
2.1
|
L
 0.5%
H
1.7
2.2
|
L
 -39.0%
H
1.7
3.2
|
L
 -74.5%
H
1.7
12.0
|
L
 -90.1%
H
1.7
54.8
|
L
 -99.2%
H
1.7
281.3
|
L
 -100.0%
H
1.7
4410
|
| Immuneering Corp (Class A) |
|
309.3
|
4.8
|
L
 -7.4%
H
4.8
5.2
|
L
 -10.8%
H
4.8
5.3
|
L
 16.6%
H
4.2
5.7
|
L
 -14.2%
H
3.9
6.9
|
L
 20.7%
H
2.9
10.1
|
L
 -51.7%
H
1
11.1
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immatics N.V |
|
1,284.7
|
9.4
|
L
 -0.7%
H
9.1
9.5
|
L
 -5.6%
H
9.1
9.9
|
L
 3.4%
H
9
10.9
|
L
 -13.5%
H
8.8
11.9
|
L
 53.3%
H
5.1
12.4
|
L
 -16.4%
H
3.3
13.8
|
L
 -21.9%
H
3.3
16.3
|
L
H
3.3
18.4
|
| Immunic Inc |
|
204.7
|
15.0
|
L
 -0.5%
H
14.3
15.2
|
L
 1.7%
H
14.1
15.5
|
L
 9.6%
H
13.5
15.8
|
L
 50.3%
H
8.5
15.8
|
L
 67.8%
H
5.1
15.8
|
L
 -40.6%
H
5.1
27.8
|
L
 -84.3%
H
5.1
145
|
L
 -99.4%
H
5.1
3900
|
| Immunovant Inc |
|
7,998.8
|
39.0
|
L
 -2.3%
H
38.5
39.9
|
L
 -5.2%
H
37.5
41.1
|
L
 15.9%
H
33.7
41.2
|
L
 42.5%
H
25.8
41.2
|
L
 118.8%
H
14.3
41.2
|
L
 87.8%
H
12.7
45.6
|
L
 284.2%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
13.2
|
1.4
|
L
 -4.2%
H
1.4
1.5
|
L
 -1.4%
H
1.3
1.5
|
L
H
1.3
1.5
|
L
 -4.8%
H
1.3
1.9
|
L
 -37.3%
H
1.2
2.7
|
L
 -14.8%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
4,220.0
|
89.1
|
L
 -2.4%
H
86.2
91
|
L
 -14.2%
H
86.2
102.2
|
L
 -4.3%
H
86.2
106.4
|
L
 7.2%
H
80.8
155.3
|
L
 276.6%
H
20.6
155.3
|
L
 266.4%
H
10.8
155.3
|
L
 252.1%
H
7.7
155.3
|
L
H
7.7
155.3
|
| Incyte |
|
23,304.6
|
116.7
|
L
 1.4%
H
114.1
117.2
|
L
 -1.6%
H
110.6
118.9
|
L
 16.9%
H
96.1
119.0
|
L
 22.4%
H
92.2
119.0
|
L
 68.5%
H
67.2
119.0
|
L
 88.9%
H
50.3
119.0
|
L
 48.9%
H
50.3
119.0
|
L
 39.2%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
337.1
|
2.5
|
L
 -10.3%
H
2.5
2.8
|
L
 1.2%
H
2.5
3
|
L
 -32.0%
H
2.4
4.9
|
L
 -16.8%
H
0.9
6.0
|
L
 -78.7%
H
0.9
12.2
|
L
 33.2%
H
0.3
13.4
|
L
 -81.2%
H
0.3
28.8
|
L
 -99.3%
H
0.3
8800
|
| Indivior PLC |
|
4,797.9
|
40.6
|
L
 -0.8%
H
40.2
41.8
|
L
 -1.7%
H
39.3
41.8
|
L
 6.8%
H
37.6
42.8
|
L
 28.8%
H
31.7
42.8
|
L
 160.2%
H
15.5
42.8
|
L
 73.9%
H
7.3
42.8
|
L
 1814.6%
H
2.0
42.8
|
L
 1079.9%
H
0.4
42.8
|
| MiNK Therapeutics Inc |
|
53.9
|
10.8
|
L
 -2.5%
H
10.8
11.3
|
L
 -5.7%
H
10.7
11.6
|
L
 -8.5%
H
10.5
12.6
|
L
 -23.5%
H
9.5
14.9
|
L
 -53.2%
H
8.5
30.3
|
L
 -40.9%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| InMed Pharma Inc |
|
8.5
|
1.6
|
L
H
1.6
1.6
|
L
 -4.2%
H
1.6
1.7
|
L
 7.4%
H
1.5
1.7
|
L
 127.1%
H
0.6
2.0
|
L
 -39.3%
H
0.6
2.8
|
L
 -91.7%
H
0.6
41.6
|
L
 -99.9%
H
0.6
1475
|
L
 -99.8%
H
0.6
32175
|
| INmune Bio Inc |
|
55.0
|
2.1
|
L
H
2.0
2.1
|
L
 15.6%
H
1.7
2.2
|
L
 61.7%
H
1.3
2.2
|
L
 54.5%
H
1.2
2.2
|
L
 -11.5%
H
1.1
3.2
|
L
 -81.0%
H
1.1
14.7
|
L
 -90.2%
H
1.1
30.4
|
L
H
1.1
30.4
|
| Inovio Pharma Inc |
|
92.1
|
1.1
|
L
 -4.3%
H
1.1
1.2
|
L
 -5.9%
H
1.1
1.2
|
L
 0.9%
H
1.1
1.3
|
L
 -3.5%
H
1.1
1.8
|
L
 -16.4%
H
1.0
3.0
|
L
 115.4%
H
0.3
14.8
|
L
 -86.4%
H
0.3
14.8
|
L
 -87.4%
H
0.3
33.8
|
| Insmed Inc |
|
23,292.2
|
107.5
|
L
 -2.1%
H
105.1
110.3
|
L
 -9.1%
H
105.1
118.9
|
L
 12.5%
H
94
119.5
|
L
 -24.7%
H
90.4
145.6
|
L
 2.7%
H
90.4
212.8
|
L
 421.7%
H
20.2
212.8
|
L
 303.1%
H
16.0
212.8
|
L
 842.6%
H
10.2
212.8
|
| Innoviva Inc |
|
1,639.3
|
22.2
|
L
 1.5%
H
22.0
22.3
|
L
 0.1%
H
21.6
22.7
|
L
 -1.8%
H
21.6
24.2
|
L
 -5.9%
H
21.2
24.5
|
L
 9.7%
H
16.5
25.1
|
L
 78.0%
H
12.2
25.1
|
L
 70.1%
H
10.6
25.1
|
L
 86.8%
H
7.6
25.1
|
| Ionis Pharma Inc |
|
9,031.6
|
54.7
|
L
 -0.2%
H
53.4
56.0
|
L
 -15.0%
H
53.4
64.4
|
L
 -25.2%
H
53.4
86.7
|
L
 -27.4%
H
53.4
86.7
|
L
 27.8%
H
40.0
86.7
|
L
 28.6%
H
24.0
86.7
|
L
 49.5%
H
24.0
86.7
|
L
 100.3%
H
24.0
86.7
|
| Iovance Biotherapeutics Inc |
|
2,080.7
|
4.7
|
L
 -1.7%
H
4.6
5.1
|
L
 6.6%
H
3.8
5.1
|
L
 22.0%
H
3.8
5.1
|
L
 22.6%
H
3.3
5.1
|
L
 109.0%
H
1.8
5.6
|
L
 -39.9%
H
1.6
18.3
|
L
 -79.3%
H
1.6
28.0
|
L
 -43.2%
H
1.6
54.2
|
| MindWalk Holdings Corp |
|
65.9
|
1.4
|
L
 -5.4%
H
1.4
1.5
|
L
 -3.4%
H
1.4
1.5
|
L
 -4.1%
H
1.4
1.7
|
L
 6.8%
H
1.2
2.0
|
L
 -26.9%
H
1.0
3.3
|
L
 -50%
H
0.3
3.3
|
L
 -74.0%
H
0.3
16.5
|
L
 6950%
H
0.3
33.3
|
| Century Therapeutics Inc |
|
407.6
|
2.3
|
L
 4.2%
H
2.1
2.3
|
L
 -2.2%
H
2.1
2.3
|
L
 3.7%
H
2.1
2.6
|
L
 -7.4%
H
2.0
2.6
|
L
 276.7%
H
0.4
3.0
|
L
 -25.2%
H
0.3
5.5
|
L
 -91.8%
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,806.5
|
73.5
|
L
 -3.4%
H
73.0
76.2
|
L
 -6.9%
H
72.4
79.8
|
L
 5.2%
H
69.1
82.5
|
L
 5.8%
H
63.8
82.5
|
L
 28.1%
H
40
99.5
|
L
 59.1%
H
25.6
99.5
|
L
 41.8%
H
11.6
99.5
|
L
H
11.6
190.9
|
| Ironwood Pharma Inc (Class A) |
|
637.1
|
3.9
|
L
 -3.3%
H
3.8
3.9
|
L
 -17.1%
H
3.8
4.7
|
L
 5.7%
H
3.5
4.9
|
L
 -10.6%
H
3.1
4.9
|
L
 423.0%
H
0.7
5.8
|
L
 -62.6%
H
0.5
15.7
|
L
 -69.0%
H
0.5
15.7
|
L
 -66.0%
H
0.5
17.7
|
| Invivyd Inc |
|
232.7
|
0.8
|
L
 -3.7%
H
0.8
0.8
|
L
 -1.3%
H
0.8
0.8
|
L
 -11.2%
H
0.8
1.0
|
L
 -53.8%
H
0.7
1.8
|
L
 14.5%
H
0.5
3.1
|
L
 -43.2%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| I-Mab (ADR) |
|
206.3
|
1.8
|
L
 -3.2%
H
1.8
1.9
|
L
 -3.8%
H
1.8
2.0
|
L
 18.5%
H
1.5
2.3
|
L
 -33.0%
H
1.5
2.8
|
L
 -16.7%
H
1.5
6.8
|
L
 -35.8%
H
0.6
6.8
|
L
 -97.7%
H
0.6
81.1
|
L
H
0.6
85.4
|
| Immunocore Holdings PLC (ADR) |
|
1,753.3
|
34.5
|
L
 -0.6%
H
33.9
35.3
|
L
 4.2%
H
30.3
35.3
|
L
 22.4%
H
28.0
35.3
|
L
 9.9%
H
27.6
35.3
|
L
 -3.6%
H
27.6
40.7
|
L
 -45.6%
H
23.2
77.0
|
L
 -3.0%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
64.8
|
0.4
|
L
H
0.4
0.5
|
L
 4.8%
H
0.4
0.5
|
L
 22.2%
H
0.4
0.5
|
L
 -24.1%
H
0.4
0.7
|
L
 -73.2%
H
0.3
3.5
|
L
 -79.8%
H
0.3
3.5
|
L
 -87.9%
H
0.3
5
|
L
 -85.7%
H
0.3
8.0
|
| Immuron Ltd (ADR) |
|
9.1
|
1.1
|
L
 -5.0%
H
1.1
1.2
|
L
 -10.3%
H
1.1
1.3
|
L
 0.9%
H
1.0
1.4
|
L
 34.5%
H
0.8
1.6
|
L
 -39.6%
H
0.7
2.4
|
L
 -44.9%
H
0.7
6.0
|
L
 -76.7%
H
0.7
6.0
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
167.1
|
1.8
|
L
 -1.1%
H
1.8
1.8
|
L
 -0.6%
H
1.7
1.9
|
L
 -0.6%
H
1.7
2.0
|
L
 9.9%
H
1.3
2.6
|
L
 -1.1%
H
1.2
2.6
|
L
 -44.9%
H
1.2
3.5
|
L
 -44.2%
H
1.2
12.0
|
L
H
1.2
12.0
|
| Inventiva (ADR) |
|
1,067.8
|
4.5
|
L
 1.1%
H
4.4
4.6
|
L
 -0.2%
H
4.2
4.6
|
L
 26.3%
H
3.4
4.7
|
L
 -19.7%
H
3.4
6.1
|
L
 36.1%
H
2.9
8.0
|
L
 6.1%
H
1.5
8.0
|
L
 -68.5%
H
1.5
15.8
|
L
H
1.5
19.1
|
| Jaguar Health Inc |
|
6.6
|
1.3
|
L
 -31.3%
H
1.3
2.0
|
L
 -43.5%
H
1.3
2.4
|
L
 -42.0%
H
1.3
3.1
|
L
 -90.8%
H
1.3
15.4
|
L
 -98.4%
H
1.3
92.8
|
L
 -100.0%
H
1.3
36540
|
L
 -100.0%
H
1.3
19254375
|
L
 -100.0%
H
1.3
880621875
|
| Janux Therapeutics Inc |
|
966.0
|
15.8
|
L
 -1.2%
H
15.7
16.1
|
L
 -5.4%
H
15.5
16.8
|
L
 15.6%
H
13.7
16.9
|
L
 4.3%
H
13.0
16.9
|
L
 -41.3%
H
12.1
35.3
|
L
 27.1%
H
5.7
71.7
|
L
 -40.8%
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jazz Pharma PLC |
|
15,213.2
|
242.2
|
L
 1.2%
H
238
243.2
|
L
 -1.9%
H
233.5
247.3
|
L
 6.7%
H
220.7
250.5
|
L
 22.4%
H
194.8
250.5
|
L
 108.6%
H
105
250.5
|
L
 91.2%
H
95.5
250.5
|
L
 38.1%
H
95.5
250.5
|
L
 70.1%
H
86.9
250.5
|
| Jasper Therapeutics Inc |
|
21.6
|
0.8
|
L
 11.6%
H
0.7
0.8
|
L
 32.8%
H
0.5
0.8
|
L
 71.1%
H
0.3
0.8
|
L
 -20.6%
H
0.3
1.1
|
L
 -77.0%
H
0.3
3.5
|
L
 -45.4%
H
0.3
31.0
|
L
H
0.3
31.0
|
L
H
0.3
31.0
|
| Jupiter Wellness Inc |
|
46.5
|
1.3
|
L
 -3.9%
H
1.2
1.3
|
L
 -2.3%
H
1.1
1.4
|
L
 -6.0%
H
1.1
1.7
|
L
 -54.6%
H
1.1
3.3
|
L
 177.8%
H
0.1
7.2
|
L
 166.0%
H
0.1
7.5
|
L
 -70.3%
H
0.1
7.5
|
L
H
0.1
8.9
|
| Kala Pharma Inc |
|
15.8
|
0.9
|
L
 -17.5%
H
0.8
1.0
|
L
 -37.0%
H
0.8
1.4
|
L
 -72.9%
H
0.8
3.7
|
L
 -91.1%
H
0.8
10.4
|
L
 -99.7%
H
0.8
1030
|
L
 -99.9%
H
0.8
1030
|
L
 -100.0%
H
0.8
10035.3
|
L
H
0.8
66943.3
|
| Kamada Ltd |
|
398.7
|
6.9
|
L
 -3.4%
H
6.9
7
|
L
 -3.4%
H
6.9
7.3
|
L
 -7.4%
H
6.9
7.7
|
L
 -16.1%
H
6.9
8.7
|
L
 -8.6%
H
6.5
9.4
|
L
 34.7%
H
4.1
9.4
|
L
 24.5%
H
3.7
9.4
|
L
 75.8%
H
3.7
13.3
|
| Kiniksa Pharma Ltd (Class A) |
|
4,701.7
|
61.1
|
L
 -0.9%
H
60.3
61.7
|
L
 -6.5%
H
60.1
65.7
|
L
 16.9%
H
52.7
67.5
|
L
 34.8%
H
41.5
67.5
|
L
 115.0%
H
26.3
67.5
|
L
 320.6%
H
14.1
67.5
|
L
 351.7%
H
7.4
67.5
|
L
H
5.0
67.5
|
| Kodiak Sciences Inc |
|
2,581.4
|
41.3
|
L
 -2.8%
H
40.7
43.2
|
L
 2.9%
H
37.1
44.3
|
L
 25.2%
H
32.9
44.3
|
L
 2.1%
H
29.2
47.8
|
L
 770.3%
H
4.6
47.8
|
L
 502.2%
H
1.4
47.8
|
L
 -53.0%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Kiora Pharma Inc |
|
11.3
|
2.6
|
L
 2.8%
H
2.5
2.6
|
L
H
2.4
2.6
|
L
 -2.7%
H
2.4
2.7
|
L
 2.4%
H
2.3
2.9
|
L
 -19.1%
H
1.8
3.3
|
L
 298.4%
H
0.4
5.6
|
L
 -98.1%
H
0.4
257.2
|
L
 -99.8%
H
0.4
2340
|
| Karyopharm Therapeutics Inc |
|
212.6
|
9.4
|
L
 -1.6%
H
9.4
9.8
|
L
 -8.0%
H
9.4
10.6
|
L
 3.1%
H
8.8
10.9
|
L
 8.3%
H
6.9
10.9
|
L
 124.4%
H
3.7
11.0
|
L
 -59.9%
H
0.6
29.3
|
L
 -93.2%
H
0.6
221.0
|
L
 -91.8%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
210.0
|
10.6
|
L
 -3.8%
H
10.4
11.0
|
L
 -11.8%
H
10.4
12.2
|
L
 5.8%
H
10.1
12.2
|
L
 -9.5%
H
9.7
12.2
|
L
 -26.8%
H
9.7
22.6
|
L
 -73.9%
H
9.1
73
|
L
 -73.5%
H
9.1
73
|
L
H
9.1
88.8
|
| Krystal Biotech Inc |
|
10,075.9
|
341.8
|
L
 -2.4%
H
337.0
351.2
|
L
 -7.9%
H
328.0
375
|
L
 5.7%
H
323.0
382.5
|
L
 29.4%
H
252.0
382.5
|
L
 127.7%
H
130.5
382.5
|
L
 170.7%
H
94.0
382.5
|
L
 437.7%
H
38.9
382.5
|
L
H
8.0
382.5
|
| TuHURA Biosciences Inc |
|
141.4
|
2.2
|
L
 -2.6%
H
2.2
2.3
|
L
 -5.1%
H
2.2
2.6
|
L
 -0.5%
H
2.1
2.8
|
L
 -25%
H
1.9
3.1
|
L
 -5.9%
H
0.4
3.9
|
L
 -98.6%
H
0.2
175
|
L
 -99.9%
H
0.2
2974.8
|
L
 -100.0%
H
0.2
154000
|
| Pasithea Therapeutics Corp |
|
15.4
|
0.5
|
L
 -4.2%
H
0.4
0.5
|
L
 -8%
H
0.4
0.5
|
L
 -9.8%
H
0.4
0.6
|
L
 -37.8%
H
0.4
1.0
|
L
 -34.3%
H
0.3
2.1
|
L
 -2.1%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kura Oncology Inc |
|
966.8
|
10.9
|
L
 -3.9%
H
10.8
11.2
|
L
 -9.9%
H
10.8
12.1
|
L
 15.9%
H
9.4
12.2
|
L
 21.8%
H
8.4
12.2
|
L
 70.7%
H
5.5
12.5
|
L
 8.5%
H
5.4
24.2
|
L
 -41.5%
H
5.4
24.2
|
L
 109.8%
H
3.8
43
|
| Kymera Therapeutics Inc |
|
9,376.5
|
114.0
|
L
 -0.1%
H
112.3
115.9
|
L
 -4.2%
H
108.9
120.6
|
L
 30.4%
H
87.6
130.1
|
L
 32.3%
H
69.5
130.1
|
L
 150.5%
H
36.7
130.1
|
L
 414.9%
H
9.6
130.1
|
L
 127.0%
H
9.6
130.1
|
L
H
9.6
130.1
|
| Kazia Therapeutics Ltd (ADR) |
|
149.9
|
13.1
|
L
 -2.4%
H
12.9
13.6
|
L
 1.1%
H
11.9
14.1
|
L
 -4.7%
H
11.9
15.3
|
L
 20.2%
H
9.9
15.3
|
L
 28.8%
H
4.9
17.4
|
L
 -70.0%
H
2.9
79
|
L
 -97.2%
H
2.9
614
|
L
 -96.5%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
13.9
|
0.6
|
L
 -5.1%
H
0.5
0.6
|
L
 -9.7%
H
0.5
0.7
|
L
 -5.1%
H
0.5
0.7
|
L
 -42.9%
H
0.5
1.1
|
L
 -35.6%
H
0.5
1.6
|
L
 -32.5%
H
0.5
6.9
|
L
 -91.4%
H
0.5
12.5
|
L
 -84.6%
H
0.5
76.2
|
| Lifecore Biomedical Inc |
|
185.7
|
5.0
|
L
 1.9%
H
4.9
5.3
|
L
 4.2%
H
4.5
5.3
|
L
 -7.5%
H
4.5
6.0
|
L
 -4.8%
H
4.2
6.0
|
L
 -35.6%
H
3.6
9.0
|
L
 -49.8%
H
3.6
11.5
|
L
 -57.3%
H
1.5
12.6
|
L
 -56.5%
H
1.5
15.6
|
| Lifevantage Corp |
|
78.0
|
6.2
|
L
 -0.3%
H
6
6.3
|
L
 -1.1%
H
5.8
6.4
|
L
 2.3%
H
5.8
7
|
L
 35.2%
H
4.6
11.7
|
L
 -51.1%
H
3.9
15
|
L
 38.3%
H
3.9
27.4
|
L
 -14.6%
H
3.0
27.4
|
L
 -59.5%
H
2.9
27.4
|
| Ligand Pharma Inc (Class B) |
|
5,941.2
|
296.5
|
L
 0.1%
H
293.7
303.6
|
L
 -8.1%
H
292.2
322.8
|
L
 16.1%
H
245
326.6
|
L
 32.8%
H
200.0
326.6
|
L
 128.7%
H
129.5
326.6
|
L
 336.9%
H
49.3
326.6
|
L
 305.9%
H
46.8
326.6
|
L
 264.5%
H
36.9
326.6
|
| Longeveron Inc (Class A) |
|
19.3
|
0.6
|
L
 -4.7%
H
0.6
0.6
|
L
 -6.2%
H
0.6
0.7
|
L
 -20.8%
H
0.6
0.9
|
L
 -44.6%
H
0.6
1.1
|
L
 -58.2%
H
0.5
1.8
|
L
 -98.3%
H
0.5
43.0
|
L
 -99.0%
H
0.5
450
|
L
H
0.5
450
|
| Atyr Pharma Inc |
|
51.0
|
0.5
|
L
 -1.9%
H
0.5
0.5
|
L
 -10.3%
H
0.5
0.6
|
L
 15.6%
H
0.4
0.7
|
L
 -37.4%
H
0.4
1.1
|
L
 -91.1%
H
0.4
7.3
|
L
 -73.3%
H
0.4
7.3
|
L
 -88.4%
H
0.4
13.1
|
L
 -98.6%
H
0.4
90.9
|
| Lixte biotech Holdings Inc |
|
98.6
|
5.4
|
L
 -8.3%
H
5.1
5.9
|
L
 -14.2%
H
5.1
6.7
|
L
 -21.7%
H
5.1
8.4
|
L
 67.4%
H
3.2
8.4
|
L
 44.9%
H
2.4
8.4
|
L
 -0.7%
H
0.6
9.5
|
L
 -81.3%
H
0.6
49.5
|
L
 -64.1%
H
0.6
110.4
|
| Lipocine Inc |
|
18.9
|
2.3
|
L
 -3.0%
H
2.3
2.4
|
L
 -7.3%
H
2.3
2.5
|
L
 -0.4%
H
2.2
2.7
|
L
 -10.6%
H
1.9
2.7
|
L
 -27.8%
H
1.8
12.4
|
L
 -47.0%
H
1.8
12.4
|
L
 -89.3%
H
1.8
32.1
|
L
 -96.0%
H
1.8
100.3
|
| Leap Therapeutics Inc |
|
75.6
|
0.7
|
L
 -5.3%
H
0.7
0.7
|
L
 1.4%
H
0.7
0.8
|
L
 -10.1%
H
0.6
0.8
|
L
 -21.1%
H
0.5
1.4
|
L
 102.9%
H
0.2
3.7
|
L
 -77.5%
H
0.2
5
|
L
 -94.9%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Liquidia Corp |
|
6,693.6
|
75.3
|
L
 -3.2%
H
73.5
80.4
|
L
 -7.6%
H
69.7
80.8
|
L
 10.7%
H
66.8
83.0
|
L
 81.8%
H
35.8
83.0
|
L
 430.4%
H
14.0
83.0
|
L
 858.9%
H
5.7
83.0
|
L
 2922.9%
H
2.3
83.0
|
L
H
2.3
83.0
|
| Larimar Therapeutics Inc |
|
381.3
|
3.7
|
L
 -3.7%
H
3.5
3.8
|
L
 -11.1%
H
3.5
4.3
|
L
 7.9%
H
2.9
4.3
|
L
 -22.3%
H
2.9
4.9
|
L
 14.7%
H
2.7
6.4
|
L
 14.3%
H
1.6
13.7
|
L
 -61.8%
H
1.5
15.3
|
L
 -95.4%
H
1.5
148.3
|
| Lisata Therapeutics Inc |
|
31.9
|
3.5
|
L
 -6.7%
H
3.5
3.9
|
L
 8.0%
H
3.3
3.9
|
L
 0.3%
H
3.2
3.9
|
L
 3.9%
H
2.8
4.0
|
L
 36.2%
H
1.8
5.1
|
L
 -5.7%
H
1.8
5.1
|
L
 -83.3%
H
1.8
21.6
|
L
 -96.0%
H
1.8
174.8
|
| Lantern Pharma Inc |
|
37.1
|
2.9
|
L
 -6.1%
H
2.9
3.1
|
L
 -13.1%
H
2.9
3.8
|
L
 -25.6%
H
2.9
4.3
|
L
 14.6%
H
2.0
4.3
|
L
 -27.1%
H
1.1
5.7
|
L
 -41.2%
H
1.1
12.0
|
L
 -77.6%
H
1.1
15
|
L
H
1.1
24.8
|
| Lexicon Pharma Inc |
|
995.0
|
2.2
|
L
 1.8%
H
2.2
2.3
|
L
 -0.4%
H
2.0
2.3
|
L
 14.9%
H
2.0
2.7
|
L
 21.7%
H
1.5
2.7
|
L
 73.6%
H
1
2.7
|
L
 1.4%
H
0.3
3.7
|
L
 -39.6%
H
0.3
6.3
|
L
 -85.0%
H
0.3
19.6
|
| Lyell Immunopharma Inc |
|
340.4
|
13.9
|
L
 -2.6%
H
13.2
14.4
|
L
 -8.7%
H
13.2
15.5
|
L
 11.7%
H
11.5
16.8
|
L
 -41.4%
H
11.5
25.0
|
L
 45.8%
H
9.1
45
|
L
 -76.3%
H
7.7
68.2
|
L
 -95.9%
H
7.7
396.8
|
L
H
7.7
396.8
|
| Legend Biotech Corp (ADR) |
|
4,393.0
|
22.7
|
L
 -1.4%
H
22.3
23.4
|
L
 -17.1%
H
22.3
27.5
|
L
 -32.0%
H
22.3
34.1
|
L
 7.7%
H
20.8
37.5
|
L
 -42.9%
H
16.2
45.3
|
L
 -67.3%
H
16.2
77.3
|
L
 -44.2%
H
16.2
77.3
|
L
H
16.2
77.3
|
| Mustang Bio Inc |
|
4.8
|
0.6
|
L
 1.6%
H
0.6
0.7
|
L
 -13.5%
H
0.6
0.7
|
L
 -8.6%
H
0.6
0.8
|
L
 -15.8%
H
0.6
0.9
|
L
 -71.0%
H
0.5
2.4
|
L
 -99.8%
H
0.1
283.2
|
L
 -100.0%
H
0.1
2317.5
|
L
H
0.1
10012.5
|
| Microbot Medical Inc |
|
120.2
|
1.8
|
L
 -3.8%
H
1.8
1.9
|
L
 -3.8%
H
1.8
1.9
|
L
 -1.7%
H
1.8
2.0
|
L
 -25.1%
H
1.7
2.4
|
L
 -29.8%
H
1.6
4.7
|
L
 -27.8%
H
0.8
4.7
|
L
 -74.4%
H
0.8
9.6
|
L
 -96.5%
H
0.8
403.7
|
| Moleculin Biotech Inc |
|
15.3
|
2.2
|
L
 -6.1%
H
2.2
2.3
|
L
 -11.1%
H
2.2
2.4
|
L
 -19.6%
H
2.2
3.7
|
L
 -9.6%
H
2
3.7
|
L
 -86.4%
H
1.8
24
|
L
 -99.1%
H
1.8
3318.8
|
L
 -99.8%
H
1.8
3318.8
|
L
 -100.0%
H
1.8
16560
|
| Seres Therapeutics Inc |
|
50.2
|
5.2
|
L
 -5.0%
H
5.1
5.6
|
L
 -23.2%
H
5.0
6.9
|
L
 -13.2%
H
5.0
8.3
|
L
 -41.3%
H
5.0
9.1
|
L
 -62.9%
H
5.0
30.0
|
L
 14.6%
H
0.4
30.0
|
L
 -75.1%
H
0.4
30.0
|
L
 -84.2%
H
0.4
38.5
|
| Madrigal Pharma Inc |
|
12,577.6
|
545.5
|
L
 -0.9%
H
532.6
553.6
|
L
 -2.6%
H
522.7
564.9
|
L
 8.9%
H
485.6
569.4
|
L
 4.0%
H
445.2
569.4
|
L
 58.1%
H
286.4
615
|
L
 141.6%
H
119.8
615
|
L
 481.2%
H
52.3
615
|
L
 5672.8%
H
6.6
615
|
| MediWound Ltd |
|
187.8
|
14.6
|
L
 3.0%
H
14.2
14.8
|
L
 -0.7%
H
14
14.8
|
L
 5.3%
H
13.9
15.4
|
L
 -14.6%
H
13.5
17.7
|
L
 -27.0%
H
13.5
21.1
|
L
 46.4%
H
7.1
24
|
L
 -54.9%
H
7.1
34.7
|
L
 -73.1%
H
7.1
60.1
|
| MEI Pharma Inc |
|
33.0
|
1.0
|
L
 -2.0%
H
1.0
1.0
|
L
 -2.0%
H
0.9
1.0
|
L
 5.4%
H
0.8
1.0
|
L
 -17.8%
H
0.7
1.3
|
L
 -74.9%
H
0.7
9
|
L
 -87.0%
H
0.7
9
|
L
 -98.2%
H
0.7
71
|
L
 -96.5%
H
0.7
102.8
|
| Macrogenics Inc |
|
261.9
|
4.1
|
L
 -4.6%
H
4
4.3
|
L
 -9.9%
H
4
4.6
|
L
 6.2%
H
3.9
5.1
|
L
 20.8%
H
2.9
5.1
|
L
 171.1%
H
1.3
5.1
|
L
 -16.3%
H
1.0
21.9
|
L
 -83.2%
H
1.0
28.1
|
L
 -84.9%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
6.7
|
0.4
|
L
 2.6%
H
0.4
0.4
|
L
 5.4%
H
0.4
0.4
|
L
 18.2%
H
0.3
0.5
|
L
 -17.0%
H
0.3
0.6
|
L
 -72.7%
H
0.2
2.8
|
L
 -76.8%
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
95.4
|
L
 -4.6%
H
93.5
99.8
|
L
 -4.7%
H
93.5
102.4
|
L
 20.9%
H
78.7
102.4
|
L
 2.6%
H
68.9
102.4
|
L
 380.6%
H
18.1
102.4
|
L
 673.9%
H
10.9
102.4
|
L
 -32.6%
H
5.1
147.0
|
L
H
5.1
336
|
| MeiraGTx Holdings PLC |
|
1,141.9
|
12.3
|
L
 -1.8%
H
12.1
12.5
|
L
 -11.6%
H
12.1
14.0
|
L
 27.0%
H
10
15.4
|
L
 30.1%
H
8.8
15.4
|
L
 42.2%
H
6.6
15.4
|
L
 86.5%
H
3.5
15.4
|
L
 -15.1%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mirum Pharma Inc |
|
7,156.8
|
117.4
|
L
 -3.0%
H
116.5
120.5
|
L
 -8.1%
H
115.9
127.5
|
L
 15.6%
H
101.2
130
|
L
 22.4%
H
88.3
130
|
L
 122.3%
H
50.3
130
|
L
 347.1%
H
23.1
130
|
L
 648.9%
H
12.8
130
|
L
H
6.5
130
|
| Milestone Pharma Inc |
|
154.4
|
1.2
|
L
 -2.4%
H
1.2
1.3
|
L
 -5.3%
H
1.2
1.3
|
L
 -3.9%
H
1.2
1.4
|
L
 -40.7%
H
1.2
2.2
|
L
 -25.8%
H
1
3.1
|
L
 -64.8%
H
0.6
3.6
|
L
 -77.1%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,588.5
|
19.0
|
L
 -4.8%
H
18.9
19.9
|
L
 -4.6%
H
18.9
21.3
|
L
 0.2%
H
18.5
23.3
|
L
 6.9%
H
15.8
23.3
|
L
 -63.8%
H
6.0
62.8
|
L
 -65.0%
H
6.0
65.0
|
L
 87.3%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mineralys Therapeutics Inc |
|
2,387.3
|
27.1
|
L
 -0.8%
H
26.5
27.3
|
L
 -6.5%
H
26.4
28.9
|
L
 12.9%
H
24.3
31.1
|
L
 -11.4%
H
22.3
32.1
|
L
 89.1%
H
12.6
47.7
|
L
 74.5%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Mannkind Corp |
|
1,248.2
|
4.0
|
L
 -1.2%
H
4.0
4.2
|
L
 -2.4%
H
3.9
4.2
|
L
 4.4%
H
3.8
4.6
|
L
 46.9%
H
2.6
4.6
|
L
 2.0%
H
2.2
6.5
|
L
 -4.3%
H
2.2
7.6
|
L
 -8.6%
H
2.2
7.6
|
L
 -20%
H
0.7
7.6
|
| Mind Medicine Inc |
|
5,854.0
|
44.1
|
L
 -3.4%
H
43.0
48.5
|
L
 -9.0%
H
43.0
48.5
|
L
 82.5%
H
23.8
49.2
|
L
 96.4%
H
19.3
49.2
|
L
 414.0%
H
8.0
49.2
|
L
 1008.0%
H
2.4
49.2
|
L
 -7.3%
H
2.1
49.2
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
69.9
|
1.4
|
L
 1.4%
H
1.3
1.4
|
L
 2.9%
H
1.3
1.4
|
L
 8.4%
H
1.3
1.6
|
L
 -1.4%
H
1.2
1.6
|
L
 16.4%
H
1.2
2.0
|
L
 -44.5%
H
1.1
2.6
|
L
 -62.5%
H
1.1
4.7
|
L
 -79.3%
H
1.1
14.5
|
| Monopar Therapeutics Inc |
|
727.0
|
108.5
|
L
 -0.2%
H
105.3
110
|
L
 3.9%
H
97.9
110
|
L
 74.1%
H
63.0
112.6
|
L
 88.1%
H
50.1
112.6
|
L
 164.2%
H
29.2
112.6
|
L
 2070.4%
H
1.4
112.6
|
L
 325.6%
H
1.4
112.6
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
22.3
|
1.3
|
L
 -5.0%
H
1.3
1.4
|
L
 -15.2%
H
1.3
1.6
|
L
 -0.7%
H
1.3
1.7
|
L
 -16.8%
H
1.3
1.7
|
L
 -16.3%
H
0.8
4.1
|
L
 -74.5%
H
0.8
9.7
|
L
 -94.0%
H
0.7
23.8
|
L
 -97.6%
H
0.7
135.5
|
| Moderna |
|
25,057.1
|
63.2
|
L
 -7.5%
H
62.8
67.4
|
L
 -17.5%
H
62.8
76.7
|
L
 14.0%
H
54.5
85.6
|
L
 15.5%
H
43.7
85.6
|
L
 97.0%
H
22.3
85.6
|
L
 -48.0%
H
22.3
170.5
|
L
 -78.0%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
1,045.8
|
7.1
|
L
 0.7%
H
6.7
7.1
|
L
 18.8%
H
5.8
7.1
|
L
 41.5%
H
5.0
7.1
|
L
 107.9%
H
3.3
7.1
|
L
 181.4%
H
2.0
7.1
|
L
 -44.6%
H
1.7
12.9
|
L
 -80.7%
H
1.7
63.6
|
L
H
1.7
63.6
|
| Mannatech Inc |
|
9.4
|
4.9
|
L
 3.2%
H
4.7
4.9
|
L
 -6.9%
H
4.2
5.1
|
L
 -10.5%
H
4.2
5.9
|
L
 -8.3%
H
3.8
6.5
|
L
 -39.3%
H
3.8
12.5
|
L
 -58.8%
H
3.8
16.5
|
L
 -82.8%
H
3.8
43.1
|
L
 -76.2%
H
3.8
49.1
|
| MaxCyte Inc |
|
144.6
|
1.4
|
L
 -4.9%
H
1.3
1.5
|
L
 5.5%
H
1.3
1.5
|
L
 18.4%
H
1.1
1.5
|
L
 64.6%
H
0.8
1.5
|
L
 -36.3%
H
0.6
2.4
|
L
 -73.5%
H
0.6
5.5
|
L
 -76.9%
H
0.6
17.4
|
L
H
0.6
17.4
|
| TNF Pharma Inc |
|
25.9
|
3.3
|
L
 -5.2%
H
3.3
3.5
|
L
 -11.3%
H
3.3
3.7
|
L
 -14.7%
H
3.3
4.2
|
L
 -11.3%
H
3.3
5.5
|
L
 -69.7%
H
2.5
17.4
|
L
 -99.9%
H
2.5
6387
|
L
 -100.0%
H
2.5
29850
|
L
 -100.0%
H
2.5
29850
|
| Mainz Biomed N.V. |
|
27.1
|
1.2
|
L
 -3.3%
H
1.1
1.3
|
L
 -16.8%
H
1.1
1.4
|
L
 -38.7%
H
1.1
2.1
|
L
 138%
H
0.3
4.9
|
L
 -34.6%
H
0.3
4.9
|
L
 -99.4%
H
0.3
195.6
|
L
H
0.3
1200
|
L
H
0.3
1200
|
| Mesoblast Ltd (ADR) |
|
2,313.0
|
17.9
|
L
 -2.1%
H
17.7
19.4
|
L
 20.4%
H
15.2
19.4
|
L
 29.9%
H
13.1
19.4
|
L
 11%
H
13.1
19.4
|
L
 57.4%
H
11.9
21.5
|
L
 272.1%
H
1.0
22
|
L
 154.8%
H
1.0
22
|
L
 338.8%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
153.8
|
4.1
|
L
 4.9%
H
4.0
4.1
|
L
 2.0%
H
3.7
4.1
|
L
 4.6%
H
3.7
4.2
|
L
 -1.9%
H
3.7
4.5
|
L
 12.3%
H
3.4
5.4
|
L
 -37.3%
H
3.3
12.7
|
L
 -77.6%
H
3.3
32.0
|
L
 -83.5%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
51.1
|
0.3
|
L
 -3.0%
H
0.3
0.3
|
L
H
0.3
0.3
|
L
 10.3%
H
0.3
0.4
|
L
 -3.0%
H
0.2
0.4
|
L
 -81.7%
H
0.2
2.4
|
L
 -74.4%
H
0.2
5.0
|
L
 -88.7%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Natural Alternatives Intl Inc |
|
14.2
|
2.3
|
L
H
2.3
2.3
|
L
 0.9%
H
2.1
2.3
|
L
 -9.6%
H
2.1
2.7
|
L
 -16.0%
H
2.1
2.9
|
L
 -34.1%
H
2.1
5.0
|
L
 -67.9%
H
2.1
7.6
|
L
 -87.0%
H
2.1
19.9
|
L
 -78.6%
H
2.1
19.9
|
| NewAmsterdam Pharma Co NV |
|
3,629.9
|
31.1
|
L
 -2.9%
H
31.0
33.2
|
L
 -13.6%
H
31.0
36.2
|
L
 2.9%
H
29.6
37.4
|
L
 -6.5%
H
27.9
42.2
|
L
 48.4%
H
20.5
42.2
|
L
 159.6%
H
5.6
42.2
|
L
 218.8%
H
5.6
42.2
|
L
H
5.6
42.2
|
| Nature`s Sunshine Products Inc |
|
375.1
|
21.3
|
L
 1.6%
H
21.0
21.6
|
L
 0.3%
H
20.4
21.8
|
L
 6.2%
H
19.6
22.4
|
L
 -18.8%
H
19.4
28
|
L
 40.2%
H
13.0
28.1
|
L
 58.7%
H
10.8
28.1
|
L
 16.8%
H
7.9
28.1
|
L
 88.6%
H
5.5
28.1
|
| Nautilus biotech Inc |
|
208.4
|
1.6
|
L
 -5.8%
H
1.6
1.7
|
L
 -13.7%
H
1.6
2.1
|
L
 -24.4%
H
1.6
2.4
|
L
 -47.4%
H
1.6
3.2
|
L
 118.7%
H
0.6
4.3
|
L
 -52.0%
H
0.6
4.3
|
L
 -82.0%
H
0.6
12.4
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
17,249.3
|
171.6
|
L
 -0.3%
H
169.0
172.6
|
L
 -5.0%
H
169.0
181.2
|
L
 9.7%
H
155.7
181.2
|
L
 33.6%
H
126.5
181.2
|
L
 28.5%
H
122.1
181.2
|
L
 80.4%
H
84.2
181.2
|
L
 80.6%
H
71.9
181.2
|
L
 270.1%
H
37.3
181.2
|
| Minerva Neurosciences Inc |
|
196.1
|
4.2
|
L
 -2.6%
H
4.1
4.5
|
L
 -10.8%
H
3.9
4.9
|
L
 -3.7%
H
3.9
5.8
|
L
 -33.1%
H
3.9
7.6
|
L
 100.5%
H
1.8
12.5
|
L
 -65.1%
H
1.2
13.5
|
L
 -72.7%
H
1.2
17.0
|
L
 -95.0%
H
1.2
121.7
|
| Nektar Therapeutics |
|
2,265.4
|
67.1
|
L
 -1.8%
H
65.8
69
|
L
 -8.1%
H
64.5
73.0
|
L
 11.3%
H
59.3
77.2
|
L
 -20.2%
H
54.1
109
|
L
 177.8%
H
21.0
109
|
L
 712.7%
H
6.2
109
|
L
 -72.3%
H
6.2
290.6
|
L
 -71.1%
H
6.2
1670.4
|
| Nkarta Inc |
|
186.0
|
2.6
|
L
 -2.3%
H
2.5
2.6
|
L
 -19%
H
2.5
3.2
|
L
 -0.8%
H
2.5
3.7
|
L
 -7.1%
H
2.3
3.7
|
L
 42.1%
H
1.7
3.7
|
L
 30.7%
H
1.3
16.2
|
L
 -91.6%
H
1.3
40.6
|
L
H
1.3
79.2
|
| NLS Pharmaceutics Ltd |
|
21.1
|
3.9
|
L
 -0.5%
H
3.7
4
|
L
 -5.3%
H
3.7
4.3
|
L
 21.8%
H
3.1
4.6
|
L
 57.0%
H
2.5
5.1
|
L
 -82.6%
H
1.8
28.0
|
L
 -98.9%
H
1.2
482
|
L
 -99.7%
H
1.2
1250
|
L
H
1.2
2940
|
| Neoleukin Therapeutics Inc |
|
-
|
36.5
|
L
 -7.5%
H
36.2
39.6
|
L
 -14.8%
H
36.2
43
|
L
 24.4%
H
29
43.7
|
L
 42.4%
H
24.9
43.7
|
L
 61.9%
H
15.9
43.7
|
L
 107.4%
H
12.2
43.7
|
L
 -78.4%
H
7.5
178.2
|
L
 -75.5%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
9.2
|
L
 -0.3%
H
9.2
9.3
|
L
 0.4%
H
9.0
9.3
|
L
 -1.5%
H
8.6
9.6
|
L
 21%
H
7.7
9.6
|
L
 36.0%
H
6.2
9.6
|
L
 1255.9%
H
0.0
9.6
|
L
 -57.3%
H
0.0
29.2
|
L
 -98.7%
H
0.0
1010
|
| MetaVia Inc |
|
9.3
|
1.8
|
L
 -2.7%
H
1.8
1.9
|
L
 4.1%
H
1.7
2.6
|
L
 9.1%
H
1.4
2.6
|
L
 28.6%
H
1.0
4.3
|
L
 -75.7%
H
1.0
19.0
|
L
 -95.3%
H
1.0
74.3
|
L
 -100.0%
H
1.0
14863.2
|
L
H
1.0
1424940
|
| Nurix Therapeutics Inc |
|
2,394.2
|
23.1
|
L
 -3.3%
H
22.9
24.0
|
L
 -6.6%
H
21.2
24.9
|
L
 35.2%
H
17.0
25.1
|
L
 38.2%
H
14.2
25.1
|
L
 85.8%
H
8.2
25.1
|
L
 136.4%
H
4.2
29.6
|
L
 -11.2%
H
4.2
37.4
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
25.3
|
0.7
|
L
 -2.8%
H
0.7
0.7
|
L
 -2.8%
H
0.7
0.7
|
L
H
0.7
1.0
|
L
 -1.4%
H
0.7
1.0
|
L
 -65.5%
H
0.6
2.1
|
L
 -48.5%
H
0.4
2.6
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
181.5
|
4.2
|
L
 -4.9%
H
4.2
4.5
|
L
 3.2%
H
4.0
4.6
|
L
 6.8%
H
3.1
4.6
|
L
 68.9%
H
2.5
5.1
|
L
 40.9%
H
1.6
5.1
|
L
 14.6%
H
1.1
54
|
L
 -95.0%
H
1.1
262.4
|
L
H
1.1
769.9
|
| Intellia Therapeutics Inc |
|
1,657.1
|
11.9
|
L
 -9.1%
H
11.7
12.6
|
L
 -23.2%
H
11.7
15.4
|
L
 -18.5%
H
11.7
18.5
|
L
 -16.2%
H
11.7
18.5
|
L
 -0.8%
H
8.0
28.3
|
L
 -73.0%
H
5.9
46
|
L
 -91.2%
H
5.9
180.6
|
L
 -33.0%
H
5.9
202.7
|
| Natera Inc |
|
38,643.8
|
269.8
|
L
 -2.7%
H
268.2
282
|
L
 -4.3%
H
261.6
283.9
|
L
 22.6%
H
217.7
288.0
|
L
 37.6%
H
184.8
288.0
|
L
 81.8%
H
131.8
288.0
|
L
 444.5%
H
36.9
288.0
|
L
 138.5%
H
26.1
288.0
|
L
 2063.8%
H
7.4
288.0
|
| Novavax Inc |
|
1,355.0
|
8.2
|
L
 -2.3%
H
8.2
8.4
|
L
 -12.3%
H
8.2
9.4
|
L
 -10.4%
H
8.2
10.1
|
L
 -4.6%
H
7.7
11.6
|
L
 18.4%
H
6.2
12.0
|
L
 -5.1%
H
3.5
23.9
|
L
 -95.6%
H
3.5
277.8
|
L
 -94.6%
H
3.5
331.7
|
| Nuvectis Pharma Inc |
|
586.4
|
18.6
|
L
 -5.1%
H
18.4
20.0
|
L
 -2.1%
H
18.0
20.0
|
L
 55.8%
H
12.0
29.3
|
L
 122.8%
H
8.3
29.3
|
L
 127.7%
H
5.6
29.3
|
L
 24.2%
H
4.4
29.3
|
L
H
3.1
29.3
|
L
H
3.1
29.3
|
| Nextcure Inc |
|
25.1
|
6.2
|
L
 -6.9%
H
5.8
7
|
L
 208.5%
H
1.7
9.9
|
L
 214.8%
H
1.6
9.9
|
L
 -43.9%
H
1.6
13.3
|
L
 28.0%
H
1.6
15.7
|
L
 -70.8%
H
1.6
30.8
|
L
 -92.9%
H
1.6
110.2
|
L
H
1.6
1308
|
| Nanobiotix (ADR) |
|
1,906.0
|
37.5
|
L
 -6.1%
H
36.2
38.6
|
L
 -3.7%
H
36.2
42.5
|
L
 4.3%
H
33.1
42.9
|
L
 15.6%
H
30.2
57.1
|
L
 619.0%
H
4.9
57.1
|
L
 489.2%
H
2.8
57.1
|
L
 151.2%
H
1.8
57.1
|
L
H
1.8
57.1
|
| NuCana PLC (ADR) |
|
5.5
|
1.3
|
L
 -1.5%
H
1.3
1.4
|
L
 7.3%
H
1.2
1.5
|
L
 -25.7%
H
1.2
2.0
|
L
 -37.6%
H
1.2
2.4
|
L
 -99.9%
H
1.2
2600
|
L
 -100.0%
H
1.2
861000
|
L
 -100.0%
H
1.2
3319720
|
L
H
1.2
32000000
|
| Ocugen Inc |
|
463.8
|
1.4
|
L
 -4.2%
H
1.4
1.4
|
L
 -6.8%
H
1.4
1.5
|
L
 16.1%
H
1.2
1.7
|
L
 -29.0%
H
1.2
2.0
|
L
 31.7%
H
0.9
2.7
|
L
 136.2%
H
0.3
2.7
|
L
 -79.4%
H
0.3
17.7
|
L
 -98.8%
H
0.2
268.2
|
| Ocular Therapeutix Inc |
|
2,005.7
|
9.2
|
L
 -8.0%
H
8.9
9.9
|
L
 -13.1%
H
8.9
10.5
|
L
 2.5%
H
8.6
10.9
|
L
 3.4%
H
7.9
10.9
|
L
 -18.6%
H
6.2
16.4
|
L
 92.0%
H
2
16.4
|
L
 -25.0%
H
2
16.4
|
L
 82.5%
H
2
24.3
|
| Opus Genetics Inc |
|
270.8
|
3.3
|
L
 -5.8%
H
3.2
3.5
|
L
 -18.4%
H
3.2
4.0
|
L
 -15.9%
H
3.2
4.4
|
L
 -43.0%
H
3.2
5.8
|
L
 192.9%
H
1.0
5.8
|
L
 -20.8%
H
0.7
5.8
|
L
 -18.4%
H
0.7
6.6
|
L
 -97.4%
H
0.7
340.8
|
| Insight Molecular Diagnostics Inc |
|
152.1
|
4.7
|
L
 -2.3%
H
4.6
4.9
|
L
 -2.9%
H
4.3
5.2
|
L
 -11.5%
H
4.3
6.1
|
L
 34.2%
H
3.3
6.9
|
L
 66.4%
H
2.3
8.5
|
L
 8.3%
H
1.9
8.5
|
L
 -95.6%
H
1.9
113.8
|
L
 -93.9%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
72.4
|
1.4
|
L
 -7.4%
H
1.3
1.5
|
L
 -17.9%
H
1.3
1.7
|
L
 -8%
H
1.3
1.9
|
L
 -13.2%
H
1.3
1.9
|
L
 -53.4%
H
1.3
3.4
|
L
 17.9%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Olema Pharma Inc |
|
966.9
|
11.1
|
L
 -6.4%
H
10.9
12.0
|
L
 -9.9%
H
10.9
12.3
|
L
 20.5%
H
9.1
13.1
|
L
 -32.8%
H
9.1
17.5
|
L
 142.8%
H
4.4
36.3
|
L
 35.2%
H
2.9
36.3
|
L
 -54.7%
H
2
36.3
|
L
H
2
60.3
|
| Omeros Corp |
|
667.3
|
9.2
|
L
 -11.1%
H
9.2
10.3
|
L
 -10.2%
H
9.2
10.7
|
L
 -2.7%
H
7.4
10.8
|
L
 -26.5%
H
6.7
15.3
|
L
 162.7%
H
3.3
17.7
|
L
 78.7%
H
0.9
17.7
|
L
 -32.2%
H
0.9
17.7
|
L
 -21.1%
H
0.9
27.1
|
| Oncolytics Biotech Inc |
|
105.0
|
0.9
|
L
 -2.2%
H
0.9
0.9
|
L
 -4.4%
H
0.9
1.1
|
L
 -7.4%
H
0.8
1.1
|
L
 -17.0%
H
0.8
1.2
|
L
 -29.6%
H
0.8
1.5
|
L
 -70.2%
H
0.3
3.1
|
L
 -62.9%
H
0.3
3.4
|
L
 -73.5%
H
0.3
8.5
|
| Traws Pharma Inc |
|
10.1
|
0.7
|
L
 1.5%
H
0.7
0.7
|
L
 -2.9%
H
0.7
0.8
|
L
 -21.4%
H
0.7
0.9
|
L
 -45.5%
H
0.6
3.2
|
L
 -58.2%
H
0.6
3.3
|
L
 -97.6%
H
0.6
28.8
|
L
 -99.5%
H
0.6
169.3
|
L
 -100.0%
H
0.6
26718.8
|
| VivoSim Labs Inc |
|
2.1
|
0.6
|
L
 -28.2%
H
0.6
0.7
|
L
 -23.8%
H
0.6
1.6
|
L
 -47.9%
H
0.6
1.6
|
L
 -59.3%
H
0.6
1.9
|
L
 -66.3%
H
0.6
5.3
|
L
 -97.1%
H
0.3
24.6
|
L
 -99.3%
H
0.3
99.6
|
L
 -99.9%
H
0.3
1197.6
|
| ORIC Pharma Inc |
|
1,110.7
|
10.7
|
L
 -3.7%
H
10.4
11.2
|
L
 -1.9%
H
10.3
11.3
|
L
 29.1%
H
8.3
12.1
|
L
 4.9%
H
7.3
12.1
|
L
 -4.0%
H
7.2
14.9
|
L
 37.7%
H
3.9
16.7
|
L
 -44.8%
H
2.4
26.7
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
165.8
|
4.1
|
L
 -0.3%
H
4
4.3
|
L
 -3.1%
H
3.9
4.3
|
L
 7.4%
H
3.8
5.2
|
L
 4.9%
H
3.6
5.2
|
L
 91.9%
H
2.0
5.2
|
L
 26.2%
H
1.7
5.2
|
L
 -67.1%
H
1.7
31.5
|
L
 -49.9%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
216.9
|
1.5
|
L
 -6.4%
H
1.5
1.6
|
L
 -13.1%
H
1.5
1.8
|
L
 -7.0%
H
1.3
1.9
|
L
 440.7%
H
0.2
1.9
|
L
 -39.4%
H
0.2
3.0
|
L
 -99.8%
H
0.2
740.0
|
L
 -99.8%
H
0.2
1308
|
L
 -100.0%
H
0.2
17568
|
| Ovid Therapeutics Inc |
|
457.3
|
2.5
|
L
 -1.6%
H
2.4
2.5
|
L
 -5.8%
H
2.4
2.6
|
L
 3.8%
H
2.2
2.8
|
L
 -12.5%
H
2.2
3.0
|
L
 528.2%
H
0.4
3.1
|
L
 -27.7%
H
0.2
4.1
|
L
 -33.8%
H
0.2
4.2
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
1,400.3
|
34.5
|
L
 2.3%
H
33.7
34.9
|
L
 6.6%
H
30.6
34.9
|
L
 8.3%
H
30.5
34.9
|
L
 -35.9%
H
28.3
58.7
|
L
 13.0%
H
25.6
60.1
|
L
 136.8%
H
9.4
60.1
|
L
 38.7%
H
9.4
60.1
|
L
 68.8%
H
9.4
60.1
|
| Palisade Bio Inc |
|
328.4
|
1.9
|
L
 -6.9%
H
1.9
2.0
|
L
 -4.1%
H
1.9
2.1
|
L
 6.2%
H
1.7
2.3
|
L
 -18.9%
H
1.6
2.9
|
L
 152%
H
0.5
2.9
|
L
 -93.5%
H
0.4
36.6
|
L
 -99.9%
H
0.4
3045
|
L
 -100.0%
H
0.4
594000
|
| Passage Bio Inc |
|
15.8
|
4.9
|
L
H
4.9
5.0
|
L
 4.3%
H
4.3
5.0
|
L
 -10.7%
H
3.3
6.3
|
L
 -58.0%
H
3.3
12.1
|
L
 -11.7%
H
3.3
20
|
L
 -75.6%
H
3.3
35.8
|
L
 -98.0%
H
3.3
268.6
|
L
H
3.3
764.6
|
| Paranovus Entertainment Tech Ltd (Class A) |
|
3.9
|
4.5
|
L
 -5.3%
H
4.4
4.6
|
L
 -21.3%
H
4.4
5.8
|
L
 -76.6%
H
4.4
18.7
|
L
 -97.3%
H
4.4
2669
|
L
 -100%
H
4.4
148800
|
L
 -100.0%
H
4.4
580800
|
L
 -100.0%
H
4.4
3696000
|
L
H
4.4
14640000
|
| Puma biotech Inc |
|
427.6
|
8.4
|
L
 -0.1%
H
8.4
8.7
|
L
 6.3%
H
7.7
8.7
|
L
 17.2%
H
7.1
8.7
|
L
 16.0%
H
6.6
8.7
|
L
 144.2%
H
3.0
8.7
|
L
 152.3%
H
2.1
8.7
|
L
 3.7%
H
1.6
8.7
|
L
 -74.5%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
1,007.3
|
25.6
|
L
 1.1%
H
24.8
26.0
|
L
 0.4%
H
24.6
26.0
|
L
 12.2%
H
22
26.7
|
L
 7.3%
H
21.9
27.1
|
L
 13.3%
H
18.8
27.6
|
L
 -31.3%
H
11.2
40.2
|
L
 -53.7%
H
11.2
82.2
|
L
 -30.4%
H
11.2
82.2
|
| Processa Pharma Inc |
|
6.2
|
2.2
|
L
 -6.3%
H
2.2
2.4
|
L
 13.7%
H
1.9
2.5
|
L
 7.2%
H
1.7
2.5
|
L
 -29.6%
H
1.7
3.5
|
L
 -58.7%
H
1.7
14.3
|
L
 -99.0%
H
1.7
450
|
L
 -99.9%
H
1.7
4495.5
|
L
 -100.0%
H
1.7
17937.5
|
| Vaxcyte Inc |
|
8,092.0
|
56.0
|
L
 -1.2%
H
55.0
56.8
|
L
 -6.3%
H
55.0
59.9
|
L
 13.7%
H
49.4
61.8
|
L
 -9.9%
H
45.3
63.3
|
L
 53.2%
H
29.1
65
|
L
 12.9%
H
27.7
121.1
|
L
 160.7%
H
16.8
121.1
|
L
H
15.5
121.1
|
| PDS biotech Corp |
|
39.7
|
0.7
|
L
 -5.3%
H
0.7
0.8
|
L
 -10.1%
H
0.7
0.8
|
L
 -26.0%
H
0.7
1
|
L
 -44.5%
H
0.7
1.6
|
L
 -41.3%
H
0.5
1.6
|
L
 -86.2%
H
0.5
6.9
|
L
 -92.6%
H
0.5
17.9
|
L
 -99.6%
H
0.5
355.4
|
| PepGen Inc |
|
155.6
|
2.3
|
L
 -6.3%
H
2.2
2.4
|
L
 -2.2%
H
2.1
2.6
|
L
 41.5%
H
1.6
2.6
|
L
 34.7%
H
1.3
2.6
|
L
 75.8%
H
1.0
7.8
|
L
 -72.1%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,764.7
|
5.0
|
L
 -3.3%
H
4.9
5.1
|
L
 -10.5%
H
4.9
5.5
|
L
 4.2%
H
4.6
6.0
|
L
 25.3%
H
3.5
6.0
|
L
 169.0%
H
1.5
6.0
|
L
 319.5%
H
0.7
6.0
|
L
 -11.6%
H
0.7
6.5
|
L
 -79.8%
H
0.7
32.9
|
| Phathom Pharma Inc |
|
874.9
|
11.0
|
L
 -0.7%
H
10.9
11.3
|
L
 -9.8%
H
10.7
12.6
|
L
 5.2%
H
10.0
12.6
|
L
 -13.0%
H
8.8
13.7
|
L
 31.7%
H
7.6
18.3
|
L
 -22.0%
H
2.2
19.7
|
L
 -67.7%
H
2.2
37.2
|
L
H
2.2
64.5
|
| Phio Pharma Corp |
|
11.6
|
1
|
L
 12.4%
H
0.9
1.0
|
L
 -3.9%
H
0.8
1.1
|
L
 -5.7%
H
0.8
1.1
|
L
 -21.3%
H
0.8
1.3
|
L
 -58.0%
H
0.8
4.2
|
L
 -95.9%
H
0.6
29.1
|
L
 -99.5%
H
0.6
261.4
|
L
 -100.0%
H
0.6
174042
|
| Pharvaris NV |
|
2,352.2
|
33.7
|
L
 -4.3%
H
33.2
35.2
|
L
 -6.4%
H
33.2
36.3
|
L
 7.0%
H
31.4
36.6
|
L
 17.0%
H
26.7
36.6
|
L
 46.4%
H
19.1
36.6
|
L
 115.6%
H
11.5
36.6
|
L
 136.7%
H
1.8
36.6
|
L
H
1.8
42.9
|
| Pliant Therapeutics Inc |
|
68.7
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
 -1.8%
H
1.1
1.2
|
L
 -6.7%
H
1.1
1.2
|
L
 -14.6%
H
1.1
1.4
|
L
 -17.2%
H
1.1
2.0
|
L
 -93.9%
H
1.1
20.2
|
L
 -95.5%
H
1.1
36.6
|
L
H
1.1
43.9
|
| Pluri Inc |
|
19.4
|
1.8
|
L
 2.9%
H
1.7
2.0
|
L
 1.1%
H
1.6
2.0
|
L
 -20%
H
1.6
2.4
|
L
 -48.7%
H
1.6
3.9
|
L
 -65.0%
H
1.6
5.7
|
L
 -70%
H
0.7
8.5
|
L
 -93.7%
H
0.7
29.8
|
L
 -98.4%
H
0.7
169.6
|
| PharmaCyte Biotech Inc |
|
7.1
|
0.7
|
L
 -5.7%
H
0.7
0.7
|
L
 -5.7%
H
0.7
0.7
|
L
 -20.5%
H
0.7
0.8
|
L
 -9.6%
H
0.7
1.0
|
L
 -41.1%
H
0.6
1.5
|
L
 -76.7%
H
0.6
2.9
|
L
 -95.0%
H
0.6
16.9
|
L
 -99.2%
H
0.6
253.4
|
| ProMIS Neurosciences Inc |
|
119.3
|
13.3
|
L
 -5%
H
13.2
14.1
|
L
 -6.8%
H
12.8
14.8
|
L
 30.9%
H
10.2
15
|
L
 12.3%
H
9.1
15
|
L
 18.2%
H
6.3
39.8
|
L
 -81.1%
H
6.3
220
|
L
 -93.9%
H
6.3
322.8
|
L
 -91.2%
H
6.3
1050
|
| PMV Pharmaceuticals Inc |
|
69.3
|
1.3
|
L
 -7.1%
H
1.3
1.4
|
L
 4.8%
H
1.2
1.5
|
L
 20.4%
H
1.1
1.5
|
L
 -5.1%
H
1.0
1.5
|
L
 -3.0%
H
1.0
1.9
|
L
 -79.9%
H
0.8
9.7
|
L
 -96.1%
H
0.8
37.3
|
L
H
0.8
63.2
|
| Praxis Precision Medicines Inc |
|
8,592.2
|
308.2
|
L
 -3.2%
H
303.3
318.8
|
L
 -7.5%
H
303.3
343.1
|
L
 19.8%
H
259.1
354.2
|
L
 -3.8%
H
238.8
366.5
|
L
 474.7%
H
37.2
366.5
|
L
 1686.7%
H
12.8
366.5
|
L
 18.0%
H
11.9
366.5
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
3.6
|
1.2
|
L
 -7.1%
H
1.2
1.3
|
L
 -16.9%
H
1.2
1.4
|
L
 -35.9%
H
1.2
2.3
|
L
 -56.0%
H
1.2
5.4
|
L
 -18.6%
H
0.6
5.4
|
L
 -97.6%
H
0.2
69.3
|
L
 -99.3%
H
0.2
470.4
|
L
H
0.2
471
|
| Prelude Therapeutics Inc |
|
332.9
|
4.2
|
L
 -6.3%
H
4.0
4.4
|
L
 -14.9%
H
4.0
5.0
|
L
 -0.5%
H
4.0
5.7
|
L
 -5.6%
H
3.4
5.7
|
L
 409.8%
H
0.8
5.7
|
L
 -4.1%
H
0.6
6.8
|
L
 -85.3%
H
0.6
43.6
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
581.6
|
3.2
|
L
 -7.7%
H
3.2
3.5
|
L
 -23.9%
H
3.2
4.3
|
L
 12.2%
H
2.9
4.8
|
L
 -12.3%
H
2.7
4.8
|
L
 -20.3%
H
2.7
6.9
|
L
 -78.5%
H
1.1
15.8
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
330.4
|
1.6
|
L
 0.6%
H
1.6
1.6
|
L
 -10.6%
H
1.5
1.8
|
L
 -4.7%
H
1.5
2.2
|
L
 -17.4%
H
1.5
2.2
|
L
 -56.8%
H
1.5
4.1
|
L
 -85.5%
H
0.5
13.5
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| ProQR Therapeutics NV |
|
235.7
|
1.7
|
L
 -5.7%
H
1.7
1.8
|
L
 -5.1%
H
1.7
1.9
|
L
 9.9%
H
1.4
2.0
|
L
 -14.4%
H
1.4
2.1
|
L
 -28.9%
H
1.3
3.1
|
L
 -4.6%
H
1.1
4.6
|
L
 -70.2%
H
0.5
9.1
|
L
 -65.5%
H
0.5
24
|
| Prothena Corporation plc |
|
443.4
|
8.5
|
L
 0.5%
H
8.1
8.7
|
L
 -12.1%
H
8.1
9.8
|
L
 2.2%
H
8.1
10.2
|
L
 -19.5%
H
7.7
11.8
|
L
 34.0%
H
6.2
11.8
|
L
 -87.9%
H
4.3
73.1
|
L
 -83.4%
H
4.3
79.8
|
L
 -82.6%
H
4.3
79.8
|
| Plus Therapeutics Inc |
|
26.8
|
3.9
|
L
 -4.4%
H
3.8
4.1
|
L
 -2.5%
H
3.8
4.4
|
L
 -14.7%
H
3.7
4.6
|
L
 -34.5%
H
3.7
8
|
L
 -51.9%
H
2.9
23.4
|
L
 -92.5%
H
2.9
80.3
|
L
 -99.5%
H
2.9
975
|
L
 -100.0%
H
2.9
429375
|
| PTC Therapeutics Inc |
|
6,513.2
|
78.5
|
L
 -0.4%
H
77.9
80.2
|
L
 -12.3%
H
76.6
89.7
|
L
 7.2%
H
74.9
90.9
|
L
 9.5%
H
63.2
90.9
|
L
 63.1%
H
43.2
90.9
|
L
 100.4%
H
17.5
90.9
|
L
 81.9%
H
17.5
90.9
|
L
 998.2%
H
4.0
90.9
|
| Protagonist Therapeutics Inc |
|
8,490.4
|
132.0
|
L
 -2.5%
H
131.4
136.6
|
L
 -4.1%
H
125.3
139.2
|
L
 19.3%
H
110.1
141.1
|
L
 27.3%
H
92.8
141.1
|
L
 133.1%
H
50.5
141.1
|
L
 521.3%
H
13.7
141.1
|
L
 188.1%
H
6.9
141.1
|
L
H
4.5
141.1
|
| Pulmatrix Inc |
|
5.9
|
1.6
|
L
 2.6%
H
1.6
1.6
|
L
 -10.6%
H
1.6
1.8
|
L
 8.1%
H
1.4
1.9
|
L
 28.8%
H
1.2
1.9
|
L
 -73.7%
H
1.2
6.5
|
L
 -40.6%
H
1.2
10.4
|
L
 -90.4%
H
1.2
20.8
|
L
 -99.6%
H
1.2
1396
|
| Polypid Ltd |
|
99.5
|
5.2
|
L
 -0.4%
H
5.1
5.4
|
L
 -4.2%
H
5.0
5.5
|
L
 11.4%
H
4.5
5.6
|
L
 11.4%
H
4.2
5.6
|
L
 37.7%
H
3.1
5.6
|
L
 -55.6%
H
2.3
12
|
L
 -97.8%
H
2.3
289.2
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
141.3
|
2.2
|
L
 -8.2%
H
2.2
2.4
|
L
 -15.5%
H
2.2
2.7
|
L
 27.4%
H
1.8
3.4
|
L
 31.2%
H
1.5
3.4
|
L
 87.4%
H
1.0
5.6
|
L
 -15.8%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
938.6
|
13.3
|
L
 -0.8%
H
13.1
13.4
|
L
 -5.3%
H
13
14.3
|
L
 6.2%
H
12.6
14.8
|
L
 -23.3%
H
11.8
17.9
|
L
 29.7%
H
9.5
21.3
|
L
 8.9%
H
6.7
21.3
|
L
 17.6%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
1.4
|
1.5
|
L
 2.8%
H
1.4
1.5
|
L
 -10.4%
H
1.4
1.6
|
L
 -10.4%
H
1.4
1.9
|
L
 -63.9%
H
1.4
5
|
L
 -94.1%
H
1.4
29
|
L
 -100.0%
H
1.4
7200
|
L
 -100.0%
H
1.4
23280
|
L
 -100.0%
H
1.4
182000
|
| Qilian Intl Holding Grp ltd (Class A) |
|
116.2
|
0.3
|
L
 -6.5%
H
0.3
0.3
|
L
 -14.7%
H
0.3
0.4
|
L
 -34.1%
H
0.3
0.5
|
L
 -9.4%
H
0.3
0.5
|
L
 -97.0%
H
0.3
11.8
|
L
 -93.3%
H
0.3
17.2
|
L
 -98.6%
H
0.3
22.5
|
L
H
0.3
110
|
| Quince Therapeutics Inc |
|
18.3
|
18.7
|
L
 0.5%
H
18.5
20.7
|
L
 6.8%
H
16.2
20.7
|
L
 1974.4%
H
0.9
20.7
|
L
 1293.3%
H
0.8
20.7
|
L
 11.1%
H
0.8
45.5
|
L
 14.5%
H
0.8
45.5
|
L
 -96.5%
H
0.8
1219.8
|
L
H
0.8
1219.8
|
| uniQure NV |
|
2,706.2
|
39.4
|
L
 -4%
H
39.0
40.7
|
L
 -11.5%
H
39.0
44.9
|
L
 45.8%
H
39.0
50.5
|
L
 134.2%
H
16.6
50.5
|
L
 173.0%
H
8.7
71.5
|
L
 261.4%
H
3.7
71.5
|
L
 46.6%
H
3.7
71.5
|
L
 425.5%
H
3.7
82.5
|
| Quoin Pharma Ltd (ADR) |
|
8.4
|
4.2
|
L
 -1.2%
H
4.2
4.4
|
L
 -10.9%
H
4.1
4.6
|
L
 -6.7%
H
3.3
5.1
|
L
 -36.8%
H
3.3
6.7
|
L
 -51.6%
H
3.3
41.8
|
L
 -99.9%
H
3.3
8400
|
L
 -100.0%
H
3.3
3003840
|
L
H
3.3
3003840
|
| Rani Therapeutics Holdings Inc |
|
75.3
|
0.7
|
L
 -1.5%
H
0.7
0.7
|
L
 -4.3%
H
0.6
0.7
|
L
 -11.8%
H
0.6
0.8
|
L
 -27.2%
H
0.6
1.1
|
L
 63.4%
H
0.4
3.9
|
L
 -84.1%
H
0.4
8.8
|
L
 -99.7%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Ultragenyx Pharmaceutical Inc |
|
2,976.3
|
30.2
|
L
 -4.7%
H
29.8
31.9
|
L
 -12.7%
H
29.8
34.8
|
L
 21.6%
H
25.1
36.6
|
L
 23.3%
H
21.3
36.6
|
L
 10.7%
H
18.3
39.9
|
L
 -31.6%
H
18.3
60.4
|
L
 -64.6%
H
18.3
104.4
|
L
 -43.2%
H
18.3
179.7
|
| Rocket Pharmaceuticals Inc |
|
372.4
|
3.4
|
L
 -6.6%
H
3.4
3.6
|
L
 -18.6%
H
3.4
4.2
|
L
 21.8%
H
2.8
4.3
|
L
 -12.6%
H
2.5
4.3
|
L
 19.2%
H
2.5
5.5
|
L
 -82.7%
H
2.2
32.5
|
L
 -92.2%
H
2.2
49.7
|
L
 -89.7%
H
2.2
67.5
|
| Regeneron Pharma |
|
71,179.4
|
678.9
|
L
 2.2%
H
661.4
680.3
|
L
 1.7%
H
648.7
680.3
|
L
 10.5%
H
594.9
680.3
|
L
 -9.0%
H
591.5
767.2
|
L
 23.9%
H
541
821.1
|
L
 -5.5%
H
476.5
1211.2
|
L
 16.4%
H
476.5
1211.2
|
L
 81.6%
H
271.4
1211.2
|
| Replimune Grp Inc |
|
799.2
|
9.5
|
L
 -1.7%
H
8.9
9.6
|
L
 -14.3%
H
8.9
11.1
|
L
 8.4%
H
8.9
12.5
|
L
 334.7%
H
1.8
12.5
|
L
 -24.6%
H
1.5
13.2
|
L
 -53.9%
H
1.5
22.2
|
L
 -69.6%
H
1.5
37.0
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
4.4
|
1.1
|
L
 3.7%
H
1.1
1.2
|
L
 15.3%
H
1.0
1.2
|
L
 17.7%
H
1.0
1.2
|
L
 -5.8%
H
0.9
1.3
|
L
 -90.5%
H
0.9
12.9
|
L
 -100.0%
H
0.9
5417.6
|
L
 -100.0%
H
0.9
2276064
|
L
H
0.9
2276064
|
| Regencell Bioscience Holdings Ltd |
|
2,363.7
|
4.8
|
L
 -6.6%
H
4.7
5.2
|
L
 -21.3%
H
4.7
6.1
|
L
 -71.4%
H
4.7
17.0
|
L
 -84.4%
H
4.7
32
|
L
 -68.7%
H
4.7
69
|
L
 738.6%
H
0.1
83.6
|
L
 1607.1%
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
8,379.4
|
148.6
|
L
 0.3%
H
147.4
150.9
|
L
 3.2%
H
141.6
150.9
|
L
 12.8%
H
124.9
150.9
|
L
 16.9%
H
101.0
150.9
|
L
 24.1%
H
101.0
175.8
|
L
 -1.3%
H
101.0
211.1
|
L
 -25.8%
H
101.0
327.3
|
L
 449.0%
H
25.9
327.3
|
| Regenxbio Inc |
|
579.0
|
11.2
|
L
 -8.7%
H
11.0
12.2
|
L
 -28.4%
H
11.0
15.7
|
L
 61.6%
H
7.2
15.9
|
L
 21.9%
H
5.5
15.9
|
L
 31.8%
H
5.5
16.2
|
L
 -40.6%
H
5.0
28.8
|
L
 -69.1%
H
5.0
46.5
|
L
 41.8%
H
5.0
85.1
|
| Rigel Pharma |
|
771.0
|
41.7
|
L
 1.2%
H
40.4
43.3
|
L
 -4.8%
H
40.0
44.0
|
L
 28.4%
H
32.4
44.0
|
L
 31.2%
H
25.5
44.0
|
L
 116.1%
H
18.7
52.2
|
L
 3207.1%
H
0.7
52.2
|
L
 926.4%
H
0.6
52.2
|
L
 1811.5%
H
0.6
52.2
|
| Relay Therapeutics Inc |
|
4,221.5
|
19.4
|
L
 -0.7%
H
18.9
20.2
|
L
 -6.7%
H
18.3
20.8
|
L
 28.7%
H
15.2
20.8
|
L
 20.2%
H
11.6
20.8
|
L
 432.1%
H
3.0
20.8
|
L
 58.4%
H
1.8
20.8
|
L
 -41.9%
H
1.8
38.2
|
L
H
1.8
64.4
|
| Relmada Therapeutics Inc |
|
573.2
|
5.5
|
L
 -12.1%
H
5.4
6.3
|
L
 -16.1%
H
5.4
6.6
|
L
 -16.6%
H
5.4
7.1
|
L
 -22%
H
5.4
8
|
L
 795.1%
H
0.6
8
|
L
 92.3%
H
0.2
8
|
L
 -82.5%
H
0.2
38.7
|
L
 -34.7%
H
0.2
54
|
| Rallybio Corp |
|
84.7
|
16.0
|
L
 -1.1%
H
15.7
16.5
|
L
 0.8%
H
15.7
16.5
|
L
 0.4%
H
15.6
16.5
|
L
 91.6%
H
8.1
17.6
|
L
 361.3%
H
3.2
17.6
|
L
 -63.4%
H
1.8
51.0
|
L
H
1.8
206.2
|
L
H
1.8
206.2
|
| TransCode Therapeutics Inc |
|
7.9
|
8.3
|
L
 -4.9%
H
8.3
8.7
|
L
 -13.9%
H
7.9
10.7
|
L
 49.3%
H
4.1
10.7
|
L
 -4.9%
H
3.8
10.7
|
L
 -11.8%
H
3.8
21.0
|
L
 -100.0%
H
3.8
118272
|
L
 -100.0%
H
3.8
3901941.1
|
L
H
3.8
5174400
|
| RenovoRx Inc |
|
39.7
|
0.9
|
L
 2.3%
H
0.9
0.9
|
L
 -6.4%
H
0.8
0.9
|
L
H
0.8
1
|
L
 -12%
H
0.8
1.0
|
L
 -32.3%
H
0.7
1.5
|
L
 -59.1%
H
0.6
2.4
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
24,404.8
|
33.9
|
L
 -2.8%
H
33.7
34.7
|
L
 -7.8%
H
33.7
37
|
L
 11.6%
H
30.5
37
|
L
 16.2%
H
27.1
37
|
L
 194.0%
H
10.9
37
|
L
 190.7%
H
8.2
37
|
L
 242.7%
H
2.5
37
|
L
H
2.5
37
|
| Royalty Pharma PLC (Class A) |
|
25,944.8
|
58.5
|
L
 3.9%
H
56.5
58.6
|
L
 1.0%
H
55.0
58.6
|
L
 8.0%
H
51.2
58.8
|
L
 20.7%
H
48.4
58.8
|
L
 64.4%
H
34.1
58.8
|
L
 90.5%
H
24.1
58.8
|
L
 44.3%
H
24.1
58.8
|
L
H
24.1
58.8
|
| Revolution Medicines Inc |
|
38,093.0
|
179.2
|
L
 -2.9%
H
177.2
184.9
|
L
 -6.3%
H
177.2
192.3
|
L
 14.4%
H
156.4
193.8
|
L
 20.0%
H
131.0
193.8
|
L
 366.6%
H
34
193.8
|
L
 572.1%
H
15.5
193.8
|
L
 501.1%
H
14.1
193.8
|
L
H
14.1
193.8
|
| Recursion Pharma Inc (Class A) |
|
1,602.9
|
3.0
|
L
 -8.8%
H
3.0
3.3
|
L
 -19.7%
H
3.0
3.8
|
L
 -5.0%
H
3.0
4.1
|
L
 -16.1%
H
2.8
4.1
|
L
 -44.0%
H
2.8
7.2
|
L
 -74.6%
H
2.8
16.7
|
L
 -90.9%
H
2.8
37.6
|
L
H
2.8
42.8
|
| Rhythm Pharma Inc |
|
7,277.1
|
106.1
|
L
 -3.3%
H
104.5
109.8
|
L
 -8.1%
H
104.5
115.0
|
L
 18.3%
H
89.8
115.9
|
L
 20.4%
H
79.4
115.9
|
L
 16.0%
H
74.5
122.2
|
L
 566.0%
H
16.0
122.2
|
L
 455.4%
H
3.0
122.2
|
L
H
3.0
122.2
|
| Rezolute Inc |
|
420.8
|
4.4
|
L
 -7.8%
H
4.3
4.7
|
L
 -14.8%
H
4.3
5.1
|
L
 -4.4%
H
4.3
5.4
|
L
 23.5%
H
2.8
5.4
|
L
 -18.3%
H
1.1
11.5
|
L
 132.4%
H
0.7
11.5
|
L
 -58.2%
H
0.7
11.8
|
L
 -91.3%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
4.4
|
0.7
|
L
 -1.4%
H
0.7
0.8
|
L
 4.3%
H
0.6
0.8
|
L
 -7.6%
H
0.6
0.9
|
L
 -6.4%
H
0.6
1.1
|
L
 -62.8%
H
0.6
3.3
|
L
 -98.4%
H
0.6
82
|
L
 -100.0%
H
0.6
11180
|
L
 -100.0%
H
0.6
16540
|
| SAB Biotherapeutics Inc |
|
279.9
|
3.7
|
L
 1.1%
H
3.5
3.7
|
L
 -7.6%
H
3.5
4.0
|
L
H
3.5
4.1
|
L
 -6.6%
H
3.3
4.6
|
L
 31.2%
H
1.9
6.6
|
L
 320.7%
H
0.4
6.6
|
L
 -63.1%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
882.2
|
3.2
|
L
 -10.7%
H
3.1
3.5
|
L
 -19.3%
H
3.1
4.0
|
L
 12.0%
H
2.9
4.2
|
L
 -8.7%
H
2.6
4.2
|
L
 -26.8%
H
2.6
6.6
|
L
 -45.2%
H
1.3
12
|
L
 -83.1%
H
1.3
26.6
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
52.2
|
1.1
|
L
 -1.8%
H
1.1
1.1
|
L
 -9.2%
H
1.1
1.2
|
L
 -11.5%
H
1.1
1.4
|
L
 -38.6%
H
1.1
1.8
|
L
 -47.8%
H
1.1
5.0
|
L
 -95.0%
H
1.1
42.2
|
L
 -98.7%
H
1.1
146.2
|
L
 -93.1%
H
0.8
146.2
|
| Sunshine Biopharma Inc |
|
3.9
|
1.8
|
L
 -1.6%
H
1.8
1.9
|
L
 -14.5%
H
1.8
2.1
|
L
 -14.5%
H
1.8
2.3
|
L
 -81.9%
H
1.8
23.2
|
L
 -88.0%
H
1.8
24.3
|
L
 -100.0%
H
1.8
12900
|
L
 -100.0%
H
1.8
596000
|
L
 -100.0%
H
1.8
45037037.0
|
| Scilex Holding Co |
|
61.8
|
8.8
|
L
 -4.7%
H
8.7
9.5
|
L
 -4.5%
H
8.5
10.3
|
L
 49.5%
H
5.5
10.4
|
L
 33.4%
H
5.4
12.3
|
L
 25.6%
H
4.2
34.3
|
L
 49.0%
H
0.2
34.3
|
L
 -11.4%
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
44.5
|
4.5
|
L
 -7.3%
H
4.4
4.8
|
L
 -1.8%
H
4.2
5.1
|
L
 9.5%
H
3.7
5.1
|
L
 -46.7%
H
3.7
9.1
|
L
 -26.3%
H
3.7
10.5
|
L
 -79.6%
H
3.7
31.0
|
L
 -91.7%
H
3.7
64.8
|
L
 -97.3%
H
3.7
440.8
|
| Seer Inc (Class A) |
|
118.8
|
2.2
|
L
H
2.2
2.2
|
L
 -1.8%
H
2.1
2.2
|
L
 26.3%
H
1.6
2.3
|
L
 5.4%
H
1.6
2.3
|
L
 1.9%
H
1.6
2.4
|
L
 -54.8%
H
1.5
5.7
|
L
 -93.0%
H
1.5
45.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,289.9
|
8.3
|
L
 -4.0%
H
8.1
8.6
|
L
 -13.9%
H
8.1
9.7
|
L
 -8.0%
H
8.1
11
|
L
 30.6%
H
5.8
11
|
L
 -37.2%
H
5.6
14.6
|
L
 -18.8%
H
5.6
15.6
|
L
 -18.8%
H
5.6
15.6
|
L
 -18.8%
H
5.6
15.6
|
| Shuttle Pharma Holdings Inc |
|
2.1
|
3.6
|
L
 -2.7%
H
3.4
3.7
|
L
 8.2%
H
2.7
5.1
|
L
 -13.0%
H
2.7
6.2
|
L
 244.7%
H
0.4
6.2
|
L
 -9.2%
H
0.4
6.2
|
L
 -98.3%
H
0.4
210
|
L
H
0.4
25252
|
L
H
0.4
25252
|
| SIGA Tech Inc |
|
255.3
|
3.6
|
L
H
3.5
3.7
|
L
 1.7%
H
3.4
3.7
|
L
 -17.2%
H
3.4
4.4
|
L
 -23.3%
H
3.4
4.9
|
L
 -47.5%
H
3.4
9.6
|
L
 -27.8%
H
3.4
12.8
|
L
 -39.5%
H
3.4
27.0
|
L
 88.4%
H
1.9
27.0
|
| SILO Pharma Inc |
|
5.4
|
4.8
|
L
 -2.1%
H
4.8
5
|
L
 -38.2%
H
4.3
6.3
|
L
 -23.5%
H
4.3
8.0
|
L
 837.3%
H
0.3
8.0
|
L
 696.7%
H
0.2
8.0
|
L
 134.3%
H
0.2
8.0
|
L
 -52.2%
H
0.2
496
|
L
 -90.4%
H
0.2
496
|
| Solid Biosciences Inc |
|
891.0
|
9.1
|
L
 -5.9%
H
8.9
9.4
|
L
 -18.8%
H
8.9
11.1
|
L
 28.0%
H
7.1
11.5
|
L
 7.9%
H
6
11.5
|
L
 62.2%
H
3.8
11.5
|
L
 84.3%
H
1.8
15.1
|
L
 -80.5%
H
1.8
51.3
|
L
H
1.8
822.6
|
| Sol-Gel Tech Ltd |
|
255.2
|
78.1
|
L
 1.1%
H
74.6
82.0
|
L
 2.3%
H
72.3
82.0
|
L
 7.2%
H
69.5
82.0
|
L
 3.7%
H
62.5
83.3
|
L
 835.1%
H
8
98.0
|
L
 2485.4%
H
0.3
98.0
|
L
 537.4%
H
0.3
98.0
|
L
H
0.3
98.0
|
| Decoy Therapeutics Inc |
|
3.2
|
6.0
|
L
 -3.1%
H
6.0
6.3
|
L
 -4.3%
H
5.5
6.6
|
L
 1.9%
H
5.5
13.5
|
L
 2.0%
H
4.3
13.5
|
L
 -94.7%
H
4.3
415.8
|
L
 -99.6%
H
4.3
1785.4
|
L
 -100.0%
H
4.3
43200
|
L
 -100.0%
H
4.3
11412000
|
| SELLAS Life Sciences Grp Inc |
|
2,310.4
|
11.8
|
L
 -8.1%
H
11.5
12.7
|
L
 -13.0%
H
11.5
13.7
|
L
 56.0%
H
7.5
15.9
|
L
 138.3%
H
4.2
15.9
|
L
 512.0%
H
1.4
15.9
|
L
 587.1%
H
0.5
15.9
|
L
 41.7%
H
0.5
15.9
|
L
 -99.9%
H
0.5
16764
|
| Summit Therapeutics Inc |
|
10,680.0
|
13.8
|
L
 -8.7%
H
13.5
15.0
|
L
 -11.1%
H
13.5
15.6
|
L
 -0.9%
H
13.5
16.1
|
L
 -43.7%
H
12.6
29.2
|
L
 -51.3%
H
12.6
31.0
|
L
 543.0%
H
1.5
36.9
|
L
 94.4%
H
0.7
36.9
|
L
 82.3%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
2,012.3
|
22.7
|
L
 -3.4%
H
22.7
24.4
|
L
 -8.6%
H
22.3
24.8
|
L
 22.4%
H
18.6
25.2
|
L
 -4.6%
H
16.7
25.2
|
L
 145.5%
H
9.2
25.6
|
L
 7.4%
H
8.6
25.6
|
L
 49.5%
H
8.6
29.9
|
L
 91.0%
H
3.4
29.9
|
| Soligenix Inc |
|
5.3
|
0.4
|
L
 -2.7%
H
0.4
0.4
|
L
 -2.7%
H
0.4
0.4
|
L
 -14.3%
H
0.4
0.4
|
L
 -69.2%
H
0.3
1.4
|
L
 -72.9%
H
0.3
6.2
|
L
 -96.7%
H
0.3
85.3
|
L
 -99.8%
H
0.3
295.2
|
L
 -100.0%
H
0.3
2040.1
|
| Sonoma Pharma Inc |
|
5.8
|
1.2
|
L
H
1.2
1.2
|
L
 -3.2%
H
1.2
1.3
|
L
 10.9%
H
1.0
1.3
|
L
 -44.8%
H
0.9
2.9
|
L
 -66.3%
H
0.9
6.9
|
L
 6.1%
H
0.1
6.9
|
L
 -80.2%
H
0.1
13.4
|
L
 -96.9%
H
0.1
74.2
|
| Sensei Biotherapeutics Inc |
|
668.7
|
25.9
|
L
 -17.6%
H
24.5
31.3
|
L
 -20.3%
H
24.5
37.9
|
L
 78.5%
H
14.0
37.9
|
L
 -11.2%
H
10.8
37.9
|
L
 216.3%
H
6.3
37.9
|
L
 0.5%
H
5
38.8
|
L
 -82.1%
H
5
247.4
|
L
H
5
530
|
| Senti Biosciences Inc |
|
14.3
|
0.5
|
L
 -20.7%
H
0.4
0.6
|
L
 -54%
H
0.4
1.0
|
L
 -50.5%
H
0.4
1.2
|
L
 -52.1%
H
0.4
1.2
|
L
 -76.7%
H
0.4
2.9
|
L
 -93.4%
H
0.4
16.9
|
L
 -53.1%
H
0.4
87.7
|
L
H
0.4
87.7
|
| Spruce Biosciences Inc |
|
121.9
|
44.3
|
L
 -2.6%
H
43.3
45.5
|
L
 -14.4%
H
43.3
52.8
|
L
 -6.0%
H
43.3
57
|
L
 -34.8%
H
43.3
74
|
L
 403.8%
H
7.3
240
|
L
 -71.5%
H
4.3
446.3
|
L
 -94.0%
H
4.3
803.3
|
L
H
4.3
2670
|
| SciSparc Ltd |
|
3.1
|
5.4
|
L
 9.4%
H
4.7
5.4
|
L
 -1.7%
H
4.2
5.4
|
L
 -33.4%
H
4.2
8.1
|
L
 26.4%
H
4.0
15.8
|
L
 -91.9%
H
3.0
80.1
|
L
 -99.8%
H
3.0
2997.5
|
L
H
3.0
41769
|
L
H
3.0
41769
|
| Spero Therapeutics Inc |
|
90.9
|
1.6
|
L
 -7.7%
H
1.5
1.7
|
L
 -25.9%
H
1.5
2.3
|
L
 -43.3%
H
1.5
3.1
|
L
 -41.4%
H
1.5
3.1
|
L
 -36.4%
H
1.5
3.1
|
L
 4.0%
H
0.5
3.2
|
L
 -89.1%
H
0.5
19.9
|
L
H
0.5
23.6
|
| ARS Pharma Inc |
|
740.8
|
7.5
|
L
 -1.2%
H
7.4
7.7
|
L
 -5.3%
H
7.1
8.1
|
L
 -23.1%
H
7.1
10.9
|
L
 -8.8%
H
7.0
10.9
|
L
 -58.3%
H
6.7
18.6
|
L
 9.2%
H
2.6
18.9
|
L
 -75.6%
H
2.6
35.6
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
36.1
|
0.7
|
L
 -7.7%
H
0.7
0.8
|
L
 -21.7%
H
0.6
1.0
|
L
 35.9%
H
0.4
1.8
|
L
 -63.5%
H
0.4
2.4
|
L
 -64.2%
H
0.4
5.3
|
L
 67.4%
H
0.3
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
1,819.1
|
17.2
|
L
 -2.2%
H
17.2
17.8
|
L
 -16.0%
H
17.0
20.5
|
L
 9.2%
H
15.8
20.9
|
L
 -18.6%
H
14.7
23.5
|
L
 -6.3%
H
10.4
25.3
|
L
 -84.0%
H
10.4
173.3
|
L
 -74.3%
H
10.4
173.3
|
L
 -17.4%
H
10.4
181.8
|
| Scholar Rock Holding Corp |
|
6,198.7
|
51.7
|
L
 -4.3%
H
50.8
53.9
|
L
 -10.7%
H
50.8
58.5
|
L
 13.5%
H
45.6
58.5
|
L
 3.5%
H
43.2
58.5
|
L
 25.7%
H
27.1
58.5
|
L
 636.9%
H
5.9
58.5
|
L
 70.2%
H
4.3
58.5
|
L
H
4.3
70
|
| Surrozen Inc |
|
240.9
|
20.8
|
L
 -4.8%
H
20.6
22.4
|
L
 -11.7%
H
20.6
23.7
|
L
 -8.8%
H
20.6
26.8
|
L
 -31.6%
H
20.5
35
|
L
 147.0%
H
8.2
35
|
L
 2704.1%
H
0.3
35
|
L
H
0.3
35
|
L
H
0.3
35
|
| Stoke Therapeutics Inc |
|
1,813.0
|
29.1
|
L
 -2.7%
H
28.5
30.5
|
L
 -11.3%
H
28.4
33.0
|
L
 -0.1%
H
28.4
33.7
|
L
 -17.6%
H
28.0
37.4
|
L
 144.6%
H
11.9
40.2
|
L
 186.8%
H
3.4
40.2
|
L
 -12.7%
H
3.4
40.2
|
L
H
3.4
71.6
|
| Sutro Biopharma Inc |
|
393.2
|
23.7
|
L
 -8.7%
H
23.4
25.8
|
L
 -20.9%
H
23.4
30.1
|
L
 -15.8%
H
23.4
34.1
|
L
 -19.2%
H
23.4
43.9
|
L
 213.5%
H
7.2
43.9
|
L
 -49.8%
H
5.2
61.3
|
L
 -86.4%
H
5.2
237
|
L
H
5.2
283
|
| Shattuck Labs Inc |
|
675.2
|
7.1
|
L
 4.4%
H
6.4
7.2
|
L
 0.6%
H
6.1
7.2
|
L
 63.3%
H
4.4
7.6
|
L
 -3.8%
H
3.3
8.3
|
L
 806.4%
H
0.7
8.3
|
L
 168.8%
H
0.7
11.8
|
L
 -69.3%
H
0.7
24.3
|
L
H
0.7
60.5
|
| Supernus Pharma Inc |
|
2,798.1
|
48.2
|
L
 1.0%
H
47.2
48.3
|
L
 -1.1%
H
46.1
48.8
|
L
 10.6%
H
42.5
51.4
|
L
 -2.1%
H
42.5
53.0
|
L
 43.8%
H
32.2
59.7
|
L
 60.5%
H
22
59.7
|
L
 82.3%
H
22
59.7
|
L
 120.7%
H
13.1
61.3
|
| Savara Inc |
|
1,131.2
|
5.5
|
L
 -5.0%
H
5.5
5.8
|
L
 -12.2%
H
5.5
6.3
|
L
 4.2%
H
5.3
6.5
|
L
 -2.1%
H
4.7
6.5
|
L
 139.0%
H
2.3
7
|
L
 79.2%
H
1.9
7
|
L
 305.9%
H
1.0
7
|
L
 -81.8%
H
0.7
49.6
|
| China SXT Pharma Inc |
|
98.2
|
2.6
|
L
 -0.4%
H
2.4
2.7
|
L
 1.6%
H
2.2
2.7
|
L
 10.8%
H
1.9
2.9
|
L
 33.2%
H
1.4
2.9
|
L
 53.9%
H
0.0
7.0
|
L
 -47.6%
H
0.0
9.4
|
L
 -95.2%
H
0.0
57
|
L
H
0.0
2335
|
| 60 Degrees Pharma Inc |
|
4.0
|
1.5
|
L
 -1.9%
H
1.5
1.6
|
L
 -2.6%
H
1.4
1.6
|
L
 4.1%
H
1.4
1.9
|
L
 -12.1%
H
1.2
1.9
|
L
 -76.8%
H
1.2
8.6
|
L
 -99.8%
H
1.2
912
|
L
H
1.2
2076
|
L
H
1.2
2076
|
| Sanofi (ADR) |
|
105,828.5
|
44.2
|
L
 1.2%
H
43.5
44.2
|
L
 0.7%
H
43.0
44.2
|
L
 0.4%
H
40.9
44.2
|
L
 -7.4%
H
40.9
48.6
|
L
 -8.9%
H
40.9
52.7
|
L
 -16.1%
H
40.9
60.1
|
L
 -15.0%
H
36.9
60.1
|
L
 6.1%
H
36.8
60.1
|